

CRITICAL REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)

Cite this: *Green Chem.*, 2022, **24**, 975

Sustainability in peptide chemistry: current synthesis and purification technologies and future challenges

Lucia Ferrazzano,^a Martina Catani,^b Alberto Cavazzini,^b Giulia Martelli,^a Dario Corbisiero,^a Paolo Cantelmi,^a Tommaso Fantoni,^a Alexia Mattellone,^a Chiara De Luca,^b Simona Felletti,^b Walter Cabri^{*a} and Alessandra Tolomelli^{*a}

Developing greener synthesis processes is an inescapable necessity to transform the industrial landscape, mainly in the pharmaceutical sector, into a long-term, sustainable reality. In this context, the renaissance of peptides as medical treatments, and the enforcement of more stringent sustainability requirements by regulatory agencies, pushed chemists toward the introduction of sustainable processes to prepare highly pure, active pharmaceutical ingredients (APIs). Innovative upstream (synthesis) and downstream (purification) methodologies have been developed during the last 5 years with the introduction and optimization of several technologies in solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), chemo-enzymatic peptide synthesis (CEPS), and chromatographic procedures. These innovations are also moving toward the introduction of continuous processes that represent one of the most important targets for iterative processes. This overview discusses the most recent efforts in making peptide chemistry greener. The extensive studies that were carried out on green solvents, reaction conditions, auxiliary reagents and purification technologies in the peptide segment can be useful to other fields of organic synthesis.

Received 24th November 2021,
Accepted 7th January 2022

DOI: 10.1039/d1gc04387k

rsc.li/greenchem

1. Introduction

In 1990, the scientific community began to pay attention to pollution prevention by enacting the Pollution Prevention Act.¹ Through a collaboration between academia and industry, several initiatives were launched in Europe and USA to solicit the development of new technologies to industrialize environmentally benign processes.² In this context, the paramount role played by chemistry was immediately clear, because reduction or elimination of hazardous or toxic reagents and solvents, together with specific attention to waste and its fate in the environment, represented the first challenge. Following the 12 principles of green chemistry³ and using measurable parameters (*i.e.*, green metrics), excellent research programs have been proposed for designing green synthesis processes and virtuous approaches for scientific development.⁴ Presently, the urgency to protect the environment from pol-

lution, to contain climate change, and to ensure that water and clean energy is available for future generations has transformed green chemistry from an ethical approach to an inescapable necessity. As stated during the US congressional hearing in 2019, green chemistry can be described, according to the U.S. Environmental Protection Agency's (EPA) definition, as "*the design of chemical products and processes that reduce or eliminate the generation of hazardous substances*". It is quite far from the concept of sustainability, which is more connected to the "*improvement of efficiency with which natural resources are used to meet human needs for chemical products and services*".⁵ In this context, companies manufacturing fine-chemical intermediates understood the importance of greener processes early on, both for environmental and economic reasons.⁶ The successful synthesis of structurally challenging molecules for pharmaceutical use has been possible thanks to reliable synthesis strategies. The need to connect the synthesis of active pharmaceutical ingredients (APIs) for clinical development with the timeline required by the market, combined with intellectual-property politics, has often justified the preference for robust methodologies rather than greener approaches. At any rate, difficulties in integrating green chemistry and engineering in the API research and development supply chain is still the challenge of this century.⁷

^aP4i Lab – Peptidomimetics and Peptides Targeting Protein–Protein Interactions, Department of Chemistry "Giacomo Ciamician", Via Selmi 2, 40126 Bologna, Italy. E-mail: walter.cabri@unibo.it, alessandra.tolomelli@unibo.it

^bDepartment of Chemical, Pharmaceutical and Agricultural Science, Via Luigi Borsari 46, 44121 Ferrara, Italy



To bridge the gap, in 2005, the American Chemical Society created a Green Chemistry roundtable to integrate green protocols in the practice of chemical engineering in the pharmaceutical industry (ACS GCI-PR).⁸ As consequence, all of the 26 member-companies, representing a relevant part of the entire industry, have been developing green-by-design processes. Through the identification of sustainable practices in all stages of the manufacturing process, the aim is to reduce their impact on the environment and meet the needs of productive plans, going from preclinical development to commercialization. The use of green metrics, like the process mass intensity (PMI), has become essential for chemists and engineers to categorize processes and guide the selection of greener alternatives, especially in the production of bioactive molecules.⁹ Lately, green processes must also address the issues of cost efficiency, which sometimes generates a complete supply chain revolution. In this context, new chemical entities (NCEs) should be discussed separately from generics. For NCEs, the API cost is not a major influence because the commercialization of a product under patents guarantees a large profit regardless. In contrast, when a product becomes generic, its final price goes down dramatically and API's impact on the cost is a critical consideration. For generics, the market driver is mainly the price. From the industrial point of view, the main barriers to the introduction of green processes are determined by intellectual property and cost position.

Even though the ACS GCI-PR's attention was mainly focused on small molecules initially, more recently, medium-sized molecules have emerged in importance, including peptides. In this context, great attention was paid to peptidomimetic small molecules as modulators and ligands for receptors in several biological processes. This approach was not always convenient due to the reduced potency that peptidomimetics showed when compared to the corresponding reference peptides. Examples include angiotensin II receptor blockers for hypertension, losartan and valsartan, as mimics of the peptide saralasin. In addition, although it is possible to develop small molecules to mimic short peptide sequences,¹⁰ the same approach cannot be applied to mimic longer peptides that are generally developed for protein–protein interference interactions. As recently summarized by Lau and Dunn,¹¹ peptide therapeutics can be divided, according to their sequences, into native, analogs and heterologous forms. Native peptides have the same sequence as natural products but can be obtained through isolation, chemical synthesis, or recombinant technologies. To overcome the limitations that native sequences present in terms of short half-life, proteolytic sensitivity, or low membrane permeability, modifications to the chemical structures can be introduced, improving their pharmacological profiles, and generating a new family of peptide analogues. Finally, when an active peptide sequence is found independently from natural peptides, by library screening or the phage display method, it is classified as a heterologous peptide. Analogues and heterologous peptides generally present a better pharmaceutical profile than the native peptides in term of half-life and membrane permeability. As shown in Fig. 1,

among FDA-approved therapeutic peptides,¹² analogues represent the majority. Some analogues, like liraglutide and semaglutide, take advantage of the integration between recombinant technology to produce long, native sequences, and chemical modifications.¹³ However, for most of the other molecules, chemical synthesis to obtain them is the method of choice. The main industrial target in the last 30 years has been the development of consistent and reliable chemical technologies for peptide production. The scientific achievements in this area, mainly in solid-phase peptide synthesis (SPPS), and the lower attrition rate in peptide development, attracted several pharmaceutical companies to this modality, determining its success.^{11,14} There are three main areas that still need to rapidly evolve. The first is related to product quality, since several regulatory agencies are asking to lower impurity limits to avoid any risk of immunogenicity.¹⁵ In this context, increased efficiency of analytical technologies plays a key role. The second area is related to the introduction of more rigorous Environmental Health & Safety (EHS) policies. The third is due to therapeutic successes in diseases such diabetes and obesity, which require larger production volumes of drugs (>100 kg).¹⁶ During the last six years (2015–2021) several research groups from academia and industry devoted incredible efforts to improve efficacy and greenness of peptide production, as witnessed by the large number of publications and patents on the topic. The bloom of new approaches to upstream and downstream technologies is fragmented. For this reason, the target of this review is a critical evaluation of the latest publications on greening peptide synthesis and purification, to stimulate a proactive approach to the application of these techniques in peptide chemistry.

2. Sustainable peptide synthesis: an inescapable necessity

2.1 Relevance of peptides in the pharmaceutical sector

Recently, the potential of peptides as therapeutics gained particular interest because of their high likelihood of approval (LoA) or probability of success (POS) in clinical trials, compared to small molecules. If the limitations of these “medium-sized” molecules, such as short half-lives and poor oral bioavailability, put a break on enthusiastic peptide drug development, novel synthesis strategies to modulate their pharmacokinetic properties and target-specificity have generated renewed appreciation for this pharmaceutical segment.¹¹ The development of stable techniques for peptide synthesis and purification have made pharmaceutical-grade peptides more accessible, even when they have a high number of amino acids. For these reasons, peptides have received more attention in the last two decades. Today, about 80 peptide-based therapeutics (PbTs) have been approved and launched on the market, with >150 peptides in clinical development and 400–600 peptides in preclinical studies.¹⁷ From a commercial standpoint (excluding insulin), market studies forecast a possible Compound Average Growth Rate (CARG) of 10% per year in the






Fig. 1 Chemical basis of peptide drugs approved by Food & Drug Administration (FDA) from 1952 to 2021. Adapted from ref. 12. Legend: A = Analogs; H = Heterologous; N = Native.




Fig. 2 Revenue in USD million for peptide therapeutic market in the period 2020–2026. Ref. 14.

peptide sector, from \$29 billion to \$51 billion between 2020 and 2026 (Fig. 2).¹⁴ Research into peptide-based drug candidates is attractive because they are smaller than proteins and

can reach extracellular and intracellular targets. This contrasts with proteins, which are large molecules, generally not cell membrane-permeable, and limited to extracellular targets.



Despite their success as pharmacological agents, native peptides cannot be used against many target diseases. Improvement of peptides' pharmaceutical profiles was achieved by structural modifications, like the introduction of unnatural amino acids, cyclization, synthesis of stapled peptides and cyclotides, or conjugation with stabilizing lipids or pegylated chains.¹⁸

Retracing the milestones in the discovery and introduction of peptide-drug therapeutics, the role of peptides as biological mediators is immediately clear, as is the impact of peptides on the pharmaceutical market (Fig. 3). Progress toward a systematic approach to peptides becoming real pharmaceutical entities required the pioneering work of du Vigneaud¹⁹ and Merrifield,²⁰ who are responsible for the total synthesis of oxytocin and vasopressin, and the introduction of SPPS, respectively. Furthermore, the advent of recombinant technologies in the 1980s allowed an enhanced greenness score in peptide production. These important advancements enabled the manufacturing of peptides on larger scales. Examples include production of dulaglutide, liraglutide, octreotide, triptorelin, degarelix, icatibant, abaloparatide, and etelcalcetide. Looking at the frequencies of NCE approvals for peptides and the considerable innovations proposed by synthesis technologies for greener manufacturing (reported below), it is easy to predict further expansion of this pharmaceutical segment.^{17,21}

2.2 Therapeutic areas addressed by peptides

The possibility of exploiting peptide drugs for a wide range of therapeutic indications has been, in the last two decades, the main force pushing pharmaceutical companies towards invest-

ing in peptide candidates for drug discovery and development programs.¹¹ The biggest areas of marketed therapeutic peptides are those targeting protein-protein interactions (PPIs) that regulate several diseases, called interfering peptides (IPs). In this class of drugs, the majority are applied to the treatment of cancer, diabetes and obesity, cardiovascular disease, or gastrointestinal disorders (Fig. 4).²² Recently, the necessity to replace classical antibiotics to address widespread antibiotic resistance led to rapid and continuous production of data on antimicrobial peptides (AMPs).²³ Finally, the recent Covid-19 pandemic pushed forward a search for novel therapeutic peptides against SARS-CoV-2 infection and associated diseases.²⁴

2.3 Green metrics in peptide synthesis

Considering the relevance that peptide pharmaceuticals are gaining from both economic and technological standpoints, to address the greenness of processes for peptide API manufacturing, green metrics must be introduced. Peptide chemical synthesis has some clear limitations compared to small molecules, determined by its specific, iterative nature. In fact, the formation of the peptide bond is always performed by activating the acid moiety of the protected amino acid. Therefore, although Trost's atom economy (AE),²⁵ Wender's step count economy,²⁶ and Baran's ideality factor (IF)²⁷ are inefficient descriptors of peptide synthesis, there is no way to overcome this limitation. Among the different green metrics introduced in the last 25 years,²⁸ the most useful are complete environmental factor (cEF) introduced by Sheldon, and PMI, which, considering all chemicals involved in a synthesis process, comprising water, allow a correct head-to-head comparison for




Fig. 3 Timeline of peptide drug approvals and the top-selling peptide drugs list. Note, the year refers to the first approval. Abbreviations: D = diabetes, obesity; ID = immune diseases; C = cancer; MS = multiple sclerosis; O = osteoporosis; A = acromegaly; CITP = chronic immune thrombocytopenia; IBSC = irritable bowel syndrome with constipation; SBS = short bowel syndrome; MM = multiple myeloma; and H = hyperparathyroidism. Data adapted from ref. 17.






Fig. 4 Application of peptide therapeutics according to the mechanism of action and therapeutic area.

peptide manufacturing technologies. Because the two metrics are easily interconnected, in this review, the PMI will be used.

The techniques commonly adopted in peptide synthesis to build the sequences rely on previously optimized procedures and chemistry, making significant methodological innovations more difficult to achieve.

For example, the synthesis of a model 10-mer peptide through classical Fmoc/*t*Bu orthogonal SPPS consists of (i) a loading step, (ii) 10 Fmoc-deprotections, (iii) 10 couplings, and (iv) final deprotection and cleavage. Of note, each step is followed by (v) several washes, with considerable consumption of solvent. Washes represent 80–90% of the total waste from the process. It has been estimated that, for a peptide with an average molecular mass between 1000 and 5000 Da, a considerable volume of waste is generated, leading to a typical PMI between 3000 and 15 000 kg kg^{−1} of API. Additionally, the use of hazardous solvents and reagents must be added to the calculation (Table 1).⁷

Although techniques other than SPPS can be used in peptide synthesis, the basic chemistry behind each process does not change considerably and the number of synthesis steps cannot be reduced. Moreover, the amount of water needed must be always considered for protocols that require excess removal of side products and reagents by water washes. Only by introducing green solvents and reagents, allowing for efficient and high-purity synthesis of peptides, and by using reagents for couplings and deprotections that are easily recoverable/reusable for a new process, could it be possible to achieve competitive PMI values. However, only one paper in this field reports green-metric evaluations or describes the process in detail.²⁹

2.4 Ranking of solvent selection guides


The selection of a solvent, either as single chemical or a mixture of chemicals for a specific reaction, is strictly connected to its properties.³⁰ In particular for synthesis purposes and the application to peptide chemistry, the solubility of all reaction components is an important parameter to consider when optimizing all steps of the process, including synthesis and purification. Furthermore, physical parameters like the maximum working range between melting and boiling points, chemical and thermal stability, viscosity, density, and heat of vaporization are important toward setting up experiments in both academic laboratories and downstream production plants.³¹ Focusing on the production of therapeutic peptides, target molecules can be synthesized chemically or by recombinant technology. In the first case, different approaches are possible, like solid, liquid, or hybrid-phase synthesis; microwave-assisted technology; or ligation technology. Currently, and likely to still be the case in 2030, peptides are mainly synthesized by chemical methods (as with 80% of peptide API manufacturers in 2020) due to the type of production facility adopted by pharma and related contract development and manufacturing organizations (CDMOs). Among them, liquid-phase and solid-phase synthesis are the most used (39% and 41%, respectively, Fig. 5).³² Concerning purification, the preferred approach relies on reverse-phase, high-performance liquid chromatography (RP-HPLC), which allows, with high efficiency, isolation of the target peptides from by-products (shorter sequences, isomers, and products of side-chain reactions).

These considerations demonstrate the important role played by solvents in making peptide production a greener reality. The solvents' impact on the environment has additional social and economic effects that cost about \$1 billion per year in technologically advanced countries, along with effects on ecosystems and health. For a solvent to be defined as “green”, it needs to conform not only to EHS assessments but also to energy demand evaluations. The latter requirements can be calculated as the net cumulative energy demand (CED) for solvent production, between the energy required to produce it and the recoverable end-of-life energy that can be achieved by incinerating it or recycling it *via* distillation.

Table 1 Analysis of the impact of reagents used in solid-phase peptide synthesis (SPPS) on the Process Mass Intensity (PMI)

PMI impact		Main component
Solvents	80–90%	DMF, NMP, DCM
Base	4–5%	Piperidine
Cleavage blend	4–5%	TFA
Activated amino acid	1%	Fmoc chemistry
Coupling blend	1%	OximaPure/DIC
Resin	0.1%	PS, PEG





Pfizer was the first to develop a list of solvents classified as “preferred”, “usable”, and “undesirable”, accompanied by a list of greener alternatives for those solvents that need to be replaced.³³ Together with the above reported criteria, GlaxoSmithKline’s guide³⁵ considers additional parameters related to physical properties, legislation constraints, and most hazards. The latest version of GSK’s guide includes 110 solvents, and the reported information can be considered according to specific users’ needs. Each solvent is scored from 1 (red, unfavourable) to 10 (green, preferred) considering all the data obtained for each EHS parameter. Combining all the results from each category, a final EHS red flag is attributed to unfavoured solvents. Sanofi’s guide offers, in addition to definitions similar to GSK’s, details for solvent applications in synthesis chemistry and substitution advice (*i.e.*, green for recommended solvents, yellow for substitution advisable, red for

Due to difficulties in finding consensus in the categorisation of solvents, intermediate categories (“recommended or problematic” and “problematic or hazardous”) were intro-

Table 2 Comparison of solvents' greenness scores as reported by common solvent-selection guides

Solvent	Astra Zeneca ^{a,b}	GCI-PR ^{a,c}	GlaxoSmithKline ^{a,d}	Sanofi ^e	Pfizer ^f
Methanol (MeOH)	19	14	14		
Ethanol (EtOH)	16	13	17		
i-Propanol (iPrOH)	16	16	17		
n-Butanol (nBuOH)	17	13	18		
t-Butanol (tBuOH)	20	15	15		
Benzyl alcohol (BnOH)	—	11	20		—
Ethylene glycol (MEG)	—	13	21		
Acetone	21	15	15		
Methyl ethyl ketone (MEK)	21	16	15		
Methyl i-butyl ketone (MIBK)	22	17	15		—
Cyclohexanone (CYC)	—	14	20		—
Methyl acetate (MeOAc)	—	14	14		—
Ethyl acetate (EtOAc)	18	15	16		
i-Propylacetate (iPrOAc, IPA)	18	13	18		
n-Butylacetate (nBuOAc)	13	14	21		—
Diethyl ether (DEE)	27	21	3		
Methyl tert-butyl ether (MTBE)	24	21	4		
Tetrahydrofuran (THF)	23	16	4		
2-Methyl tetrahydrofuran (2-Me-THF)	24	15	11		
1,4-Dioxane	28	21	11		
Anisole (An)	18	13	18		—
Dimethyl ether (DME)	21	23	2		
Diisopropyl ether (DIPE)	—	—	4		
n-Pentane (NPEN)	—	—	7		
n-Hexane (NHEX)	26	21	1		
n-Heptane (NHEP)	21	17	14		
Cyclohexane (Cy)	25	18	14		
Methyl cyclohexane (MeCy)	—	17	16		
Benzene (Bn)	—	21	1		
Toluene (Tol)	22	18	11		
Xylenes (Xy)	19	15	13		
Dichloromethane (DCM)	20	18	5		
Chloroform (CHCl ₃)	—	18	4		
Chlorobenzene (ClBn)	25	16	18		—
Carbon tetrachloride (CCl ₄)	—	19	3		
Dicyclohexyl ether (DCE)	—	19	4		
Acetonitrile (ACN)	24	14	14		
Dimethylformamide (DMF)	20	17	7		
Dimethyl acetate (DMAc)	20	16	4		
N-Methyl pyrrolidone (NMP)	18	16	7		
Dimethyl sulfoxide (DMSO)	8	15	14		
Sulfolane (Sul)	9	13	21		
1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU)	—	—	14		—
Nitromethane	—	—	1		—
Methoxy-ethanol	21	20	3		—
Formic acid (HCOH)	20	15	—		—
Acetic acid (AcOH)	17	15	17		—
Acetic anhydride (Ac ₂ O)	—	16	15		—
Pyridine (Pyr)	26	16	5		—
Triethylamine (TEA)	23	18	3		—
Water	—	—	24		

Sanofi and Pfizer's guides do not use numbers for solvent's greenness evaluation, but only colour codes. ^a Ref. 37b. ^b Arithmetical mean: 20.3. ^c Arithmetical mean: 16.3. ^d Arithmetical mean: 11.5. ^e Ref. 36. ^f Ref. 33; green = recommended; yellow = substitution advisable; red = unfavoured; dark red = banned.

duced, allowing the classification of solvents with ambiguous interpretations (Fig. 6). Generally, the previously reported guides did not consider the source of the solvent as a ranking criterion. Only recently, unconventional bio-based solvents, namely glycerol and Cyrene®, were introduced in two new solvent-selection guides.³⁹ Because both solvents have a boiling point >200 °C, they were red-flagged for experimental reasons related to solvent removal. However, this does not mean these solvents should be defined as environmentally

damaging, considering their low toxicities and their sustainable production.⁴⁰

Solvent selection must always consider the specific reaction or process since it can affect reaction rates, chemical selectivity, temperature control, and efficiency in purification.⁴¹ This aspect makes it fundamental for chemists in academia and industry to use the tools reported above to make the optimization and the scale-up of pharmaceutical manufacturing greener.






Fig. 6 Overall ranking of solvents resulting from the comparison of most common solvent selection guides. Ref. 38.

3. Technologies and synthesis modifications toward “greening” peptide synthesis

The synthesis of peptides can be achieved by different methodologies, namely (i) solid-phase peptide synthesis (SPPS), (ii) liquid-phase peptide synthesis (LPPS), (iii) semi-continuous/continuous peptide synthesis, (iv) chemoenzymatic peptide synthesis (CEPS), (v) mechanochemical peptide synthesis, and (vi) recombinant production *via* fusion proteins. Because the last technique is used only to synthesize long peptides containing natural amino acids, it has a limited scope in modern drug discovery. It is specifically applied to the synthesis of native, pharmaceutically active peptides or to the semi-synthesis of analogues, in which the native sequence is sufficiently long (*e.g.*, liraglutide or semaglutide). In this section, we focus on the five other synthesis technologies, reporting on the most recent improvements toward enhancing the greenness of synthesis processes for peptide production.

The final goal of peptide synthesis, independent from the applied technique, is to achieve the target product with the least amount of impurities, in order to reduce downstream purification phases and impact the PMI of the whole process. For this reason, particular attention is paid to monitoring the most commonly occurring side reactions observed in peptide synthesis: racemization, diketopiperazine and aspartimide formation, arginine lactamization, *etc.* (see Fig. 7). Moreover, the deprotection and coupling efficiency must be always guaranteed, being critical to avoid redundant amino acid incorporation or sequence deletion.⁴² Accordingly, whenever a new synthesis methodology is studied, or a new solvent or reagent is introduced, the standard procedures include an evaluation of the tendency of the peptide model sequences to produce the

above-mentioned impurities. Therefore, this study represents the key, common determinants in assessing the feasibility of a new protocol.

3.1. Green solid-phase peptide synthesis (GSPPS)

SPPS technology has been optimized over more than half a century around the use of *N,N*-dimethylformamide (DMF) as a solvent. Currently, this technology allows for the synthesis of long peptide sequences with a high throughput in purity and yield, with any kind of amino acid. SPPS is based on stepwise growth of a peptide sequence on a polymer-based, insoluble, solid support. Once the first amino acid, protected at the amino group, is anchored on the resin *via* the acidic terminal end, the peptide sequence is built-up by an iterative reaction sequence, consisting of amino deprotection–wash–coupling–wash steps. Then, the peptide is cleaved from the solid support and isolated by precipitation with an anti-solvent. The Fmoc/*t*Bu orthogonal strategy^{42b} is routinely exploited, in which the growing α -amino terminus is protected with a temporary Fmoc group that is removed at each deprotection step under basic conditions. Conversely, the amino acid side chains are protected with acid-sensitive groups, which can be removed, if required, together with the cleavage of the peptide from the resin.⁴³ During the SPPS cycle, purification steps are not necessary because the excess of reagents or by-products are eliminated from the solid support by simple filtrations. This is not only an advantage in terms of yield, but it also saves time and introduces the possibility of automating the process. However, this approach has a high environmental impact due to the huge volume of solvents required for the synthesis protocol, and super-stoichiometric amounts of reagents introduced to push the reaction to completion and minimize the formation of impurities. In addition, when the






Fig. 7 Common side reactions in peptide synthesis occurring on resin (a and b) or during Fmoc-amino acid activation (c and d).

access to the growing peptide attached to the resin is particularly hampered the procedure requires a double coupling. Peptide PMIs⁴⁴ are estimated about 100 times higher than those for other synthesis procedures, justifying the great need for new, eco-friendly protocols.⁴⁵

3.1.1. Solvents. In selecting a solvent for SPPS, a series of requirements related to the swelling of the solid support, the ability to dissolve amino acids and coupling reagents, and the capacity to accomplish both coupling and deprotection steps have to be simultaneously satisfied. Contextually, physical features strictly associated with the chemical nature of the solvent should be considered, *i.e.*, appropriate values of polarity and viscosity for optimal SPPS process performance.

Only very recently, prompted by the increasing interest in the GSPPS field by both academia and the pharmaceutical industry, the technical requirements that a solvent should fulfil in a green API manufacturing industrial setting were clearly defined as follows:^{6b,46}

- Melting point ≤ 10 °C;
- Viscosity < 4 mPa s;
- Reagents' and by-products' solubilities ≥ 0.25 M;
- Starting resin's swelling: $4\text{--}7$ mL g⁻¹;
- Coupling time: 60–90 min;
- Fmoc-removal time: 30–40 min;
- Loading of the first amino acid on the resin < 120 min;
- Stability and inertia along the SPPS cycle;
- Low levels of epimerization or other side-reactions.

All of these features are required in order to obtain the best product output while reducing possible technical issues in production plants. A single candidate that can simultaneously produce optimal results in all steps may be difficult to find. For this reason, a great number of green solvents have been excluded from the reported studies over the years.

N,N-Dimethylformamide (DMF) and, to a lesser extent, *N*-methyl-2-pyrrolidone (NMP) and dichloromethane (DCM), are currently the solvents of choice in SPPS. These solvents match every characteristic defined above together with low cost. However, as reported in Table 2, these solvents are classi-

fied by the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation as substances of very high concern (SVHC) because of their carcinogenic, mutagenic, or reproductive-toxin (CMR) properties,⁴⁷ and need to be urgently replaced.⁴⁸ This is emphasized when considering that, for SPPS, a solvent's impact on waste production represents $>80\%$ of the total, justifying attempts to replace the hazardous, reproductively toxic solvents, DMF and NMP, with more benign and environmentally friendly alternatives. These attempts go together with introducing methods for recycling solvents or minimizing their impact.

As several green innovations for SPPS have been introduced for single steps of the process (swelling, coupling, or washing), for this report on green solvents, only cases in which all steps of the SPPS cycle were evaluated simultaneously were considered, because a green solvent (or mixture) should be successful in the whole process to have a chance to be industrially applicable. Only a brief mention of green solvents for cleavage and precipitation steps is included, because they are outside of the repeating steps of the SPPS cycle. Finally, due to the importance of PMIs in the evaluation of synthesis and productive processes, recent methodologies on solvent reduction or recycling after SPPS are described.

Generally, SPPS protocols are performed at room temperature and the majority of green innovations introduced along the years, concerning reagents and solvents, have been applied under these conditions. Anyway, the easiest way to accelerate the synthesis process reducing its impact on the productivity programs (and on the costs associated) would be increasing the operative temperatures. In this context, the most important implementation has been the introduction of microwaves (MW) as an alternative to conventional heating.⁴⁹

MW-assisted peptide synthesis has been largely used at lab scale, and only recently has the development of the technology reached a semi-industrial scale. The main technological contributions in this field came from CEM⁵⁰ and CS Bio⁵¹ companies, who developed efficient MW-assisted automatic peptide synthesizers, largely employed both in small- and kilogram-



Another systematic study was conducted by Lopez and co-workers from Novartis, in which 37 non-hazardous solvents were evaluated step-by-step for their resin-swelling capacities, SPPS reagent solubility, coupling efficiency, and Fmoc removal ability.⁶⁸ At the end of the selection process, only a few solvents were compatible with all of the steps and were further investigated using full SPPS protocols, namely dimethyl sulfoxide (DMSO), 1,3-dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone (DMPU), 1,3-dimethyl-2-imidazolidinone (DMI), *N*-ethylpyrrolidone (NEP) and *N*-butylpyrrolidone (NBP) (Table 3, entries 11–15). Among them, NBP had the best results in terms of peptide purity,

Table 3 Alternative solvents for SPPS (timeframe 2015–2021)

Entry	Solvent ^a	Full SPPS: peptide	Resin	Coupling reagent	HPLC crude purity (%)	Group ^b (ref.)	Year
1	THF	Aib-Enkephalin-NH ₂	Fmoc-	DIC/OP	93.6 (DMF/DCM 53)	Albericio ^d (57)	2015
2		Aib-ACP	RA-AM-PEG		69.8 (DMF/DCM 37.8)		
3	ACN	Aib-Enkephalin-NH ₂	Fmoc-	DIC/OP	91.8 (DMF/DCM 53)		
4		Aib-ACP	RA-AM-PEG		49.6 (DMF/DCM 37.8)		
5	2-MeTHF	Aib-Enkephalin-NH ₂	CM	DIC/OP	95 (DMF/DCM 53); 91.9 (EtOAc in deprot. steps)	Albericio ^d (54)	2016
6		Aib-ACP			37.3 (DMF/DCM 37.8); 87.1 (with coupl/depr at 40 °C)		
7		Aib-Enkephalin-NH ₂	Fmoc-		41.6 (DMF/DCM 71.8); 88.6 (with coupl/depr at 40 °C)		
8	PC	Bradykinin	HMPB-CM	HBTU/HOBt/DIPEA	77 (DMF 79)	North ^d (67)	2017
9	NFM	Aib-ACP	Fmoc-	DIC/OP	54 (DMF/DCM 93.8)	Albericio ^d (54)	
10	GVL		RA-AM-PS		52 (DMF/DCM 93.8)		
11	NBP	linear octreotide	AMRES	DIC/HOBt	80 (DMF 86)	Novartis (68)	2018
12	TMU				78		
13	DMI				78		
14	DMSO				52		
15	DMPU				51		
16	GVL (Microwave)	Jung-Redemann ACP, ABC peptide, Thymosin	RA-CM	DIC/OP	68	Albericio ^d (55)	
17			RA-CM	DIC/OP	Not reported, comparable to DMF		
18	EtOAc/DMSO 9 : 1	Aib-ACP	RA-AM-PS	DIC/OP	76	PolyPeptide (29c)	2019
19	NBP/EtOAc 1 : 1	Ac-Nle-DHFRWK-NH ₂	Fmoc-RMG-AMS	DIC/OP	90	PolyPeptide (78)	
20	Anisole/DMC 7 : 3	Aib-Enkephalin	Fmoc-RMG-AMS	DIC/OP	72.1 (DMF 53)	Tolomelli/Cabri ^d (80)	
21	DEC/Cyr 7 : 3		RA-CM		72.0 ^c (DMF 85.8)		
22	DEC/Sul 7 : 3		PS-Wang		62.0 (RA-CM), 72.8 (PS-Wang)		
23	Anisole/DMC 7 : 3	Aib-ACP	RA-CM		31.0 (DMF 37.8)		
24	DEC/Sul 7 : 3		RA-CM		10.0 (DMF 37.8)		
25	Anisole/DMC 7 : 3	linear Octreotide	PS-Trt-Cl		64.6 (DMF 88.0)		
26 ^e	2-MeTHF, 2-MeTHF/MeOH 1 : 1	Leu-Enkephalin-NH ₂	RA-AM-PS	DIC/HOBt	82.3 (with Cys ⁷ coupl at 40 °C)	Schütznerová (110a)	
27 ^e	2-MeTHF, 2-MeTHF/MeOH 1 : 1	Triptorelin	RA-PS	DIC/HOBt	99 (DMF 99)	Schütznerová (110b)	2020
28	NBP	AKDGYI-NH ₂	RA-AM-PS	DIC/OP	72 (DMF 96)	Albericio ^d (69b)	
29	DMSO/EtOAc 4 : 6	Aib-Enkephalin	RA-AM-PS	DIC/OP	>99 (DMF 92) at 45 °C	Bachem/NovoNordisk ^d (46)	2021
30		Jung-Redemann			44 (DMF 69)		
31		Thymosin-α1			52 (DMF 57)		
32		Dasiglucagon amide			41 (DMF 52)		
33	DMSO/2-MeTHF 3 : 7	Aib-Enkephalin	RA-AM-PS		49 (DMF 59)		
34		Jung-Redemann			75		
35		Thymosin-α1			53		
36		Dasiglucagon amide			47		
37		Bivalirudin	2-CTC		50		
38	DMSO/DOL 3 : 7	Aib-Enkephalin	RA-AM-PS		70.7 (DMF 73.8)		
39		Jung-Redemann			59		
40		Thymosin-α1			52		
41		Dasiglucagon amide			42		
42		Bivalirudin	2-CTC		53		
43	NBP/DOL 4 : 6	Bivalirudin	2-CTC		72.7		
44	NOP/DMC 8 : 2	Aib-Enkephalin, linear Octreotide	PS Wang	DIC/OP	62.7	Aib-Enk: 97.5 (Wang); Octreotide: >99 (Trt-Cl) (DMF >99)	Tolomelli/Cabri ^d (29a)
45	NOP	Aib-Enkephalin, linear Octreotide	PS Wang		Aib-Enk: 97.7 (Wang), 97.4 (Trt-Cl); Octreotide: >99 (Trt-Cl)		
46	NBP	Aib-Enkephalin	PS Wang		Aib-Enk: 91.1 (Wang), 91.6 (Trt-Cl); Octreotide: >99 (Trt-Cl)		
47	NCP	Aib-Enkephalin	PS Wang		Aib-Enk: 88.5 (Wang, DMF 85.8); Aib-Enk: 89.9 (Trt-Cl, DMF 81.1)		
48	ACN	H-YIGFLYIGFL-NH ₂	RA-CM	DIEA/T3P/OP	Not reported	Albericio (136)	
49	PolarClean	Leu-Enkephalin-NH ₂ , AKDGYI-NH ₂ , KTTKS-NH ₂	RA-AM-PS	DIC/OP	Not reported, comparable to DMF	Albericio ^d (64)	
50	H ₂ O/PolarClean 4 : 1	Leu-Enkephalin-NH ₂	RMG-TG-S	TCFH/collidine	86	PolyPeptide (65)	
51 ^f	Anisole/EtOH/DMSO	Leu-Enkephalin-NH ₂	RA-PS	DIC/OP	99 (DMF 99)	Schütznerová (110c)	
52 ^f	Anisole/EtOH/DMSO	Leu-Enkephalin-OH	PS-Wang	DIC/HOBt	93 (DMF 95)		
53 ^f	Anisole/EtOH/DMSO	Aib-Enkephalin-NH ₂	RA-PS	DIC/HOBt	28 (DMF 26)		

^a Only solvents effective for all steps of SPPS and authors' best conditions are reported. ^b Corresponding author or company is listed. ^c Double loading was performed. ^d Piperidine was used as deprotecting agent for the selected entries. ^e 2-MeTHF/MeOH = 1 : 1 was used for deprotections, while 2-MeTHF was used for couplings. ^f An/DMSO = 4 : 1 for couplings, An/EtOH = 1 : 1 for deprotection. RA = Rink Amide; CM = ChemMatrix; AM = amino methyl; Trt = trityl; CTC = chlorotriyl; RMG = Ramage; AMS = aminomethylstyrene; TG S = TentaGel S; AMRES = aminomethylresin; HMPB = 4-(4-hydroxymethyl-3-methoxyphenoxy)-butanoyl amide; OP = OxymaPure.



proving to be a strong candidate to replace DMF.⁶⁸ NBP is a high-boiling, polar, aprotic solvent. More importantly, it is non-mutagenic, non-reprotoxic, and biodegradable, in contrast to its structurally related analogue, NMP. Accordingly, it was further exploited because it limited many common SPPS side reactions, such as Arg intramolecular δ -lactamization, racemization, and aspartimide formation (see Fig. 7).⁶⁹ In these cases, the lower polarity of NBP strongly outperformed DMF in racemization-prone Cys-, His-, and Ser-containing sequences, and in suppressing aspartimide formation (Table 3, entry 28).^{69b} After NBP was validated in full SPPS processes, the class of *N*-alkyl pyrrolidones was further explored by Tolomelli and Cabri^{29a,b} after having tested their promising results in green cross-coupling reactions.⁷⁰ While retaining the main characteristics of the parent compound, NMP, they displayed a completely different metabolic profile in an *in vitro* metabolic investigation, being nontoxic and not reprotoxic. The high boiling and flash points of the above solvents represent industrially relevant features for recovery by distillation.

After first screening for swelling, solubility tests, Fmoc deprotection, and coupling efficiency, *N*-octylpyrrolidone (NOP) emerged as the best candidate that efficiently accomplished all of these steps. In addition, it is commonly employed as a surfactant and in cosmetic formulations, guaranteeing a safety profile and a competitive cost (approximately \$1–2 per kg). A full SPPS using NOP, NBP, and *N*-cyclohexylpyrrolidone (NCP) showed that they outperform DMF (Table 3, entries 45 and 46), with NOP displaying the best performance (Table 3, entry 45).^{29a}

Although these issues are far from being explored *versus* other key steps of SPPS, there has also been little work in recent years investigating the greenness potential of cleavage and precipitation steps. However, it is important to highlight that the attempts to upgrade the environmental profile of the whole SPPS process and to obtain greener downstream purification processes are required to guarantee prioritizing the quality and the purity of the crude peptides. Concerning cleavage steps, there is still no effective way to replace trifluoroacetic acid (TFA) in the SPPS Fmoc/*t*Bu strategy.⁷¹ However, cleavage of side chain-protected peptides from 2-chlorotrityl chloride (CTC) resins requires a low amount of TFA (1–3%) mixed with an organic solvent. Despite DCM being routinely used to do this, recent studies reported the possibility of replacing it with green solvents. Anisole and 1,3-dimethoxybenzene emerged as excellent candidates, also allowing for better manipulation due to their higher boiling points.⁷² Concerning using scavengers in peptide cleavage, only a single report thus far has described the use of greener options in a cleavage cocktail, obtained by the introduction of 1,4-benzenedimethanethiol (1,4-BDMT) as a scavenger for global deprotection of exenatide from the resin. This novel thiol, besides being non-malodorous and UV detectable (contrary to standard aliphatic thiol reagents), was effective in reducing the content of critical cleavage-induced peptide impurities.⁷³

Other studies have focused on solvents that could replace standard ethers for post-cleavage peptide precipitation. The

commonly employed diethyl, diisopropyl, and *tert*-butyl methyl ethers (DEE, DIE, TBME, respectively) are indeed considered hazardous due to their low flash and boiling points and the tendency to form peroxides. In addition, TBME was found to induce undesired *tert*-butylation of peptides during precipitation⁷⁴ and is considered carcinogenic for its toxic metabolites.^{35b,37b} The replacement of these ethers is therefore recommended, and, consequently, other anti-solvents were proposed in the last few years. In this context, CPME⁷⁵ and 2-MeTHF⁷⁶ may be alternatives. CPME has favourable EHS features, specifically a high boiling point and higher flash point, together with a low propensity to form peroxides. Both solvents naturally display a good stability under acidic conditions⁷⁷ and were tested in the precipitation of 5mer to 28mer peptides. Recovery and purity of the resulting crude products were in line with those obtained with standard DEE and methyl *tert*butyl ether (MTBE). Interestingly, after these and previously described results, 2-MeTHF was shown to be suitable as a single solvent in all the steps of SPPS, with the advantage of minimizing morphological damage to the resin.⁵⁹ Lastly, the Polypeptide group proposed 4-methyltetrahydropyran (MTHP) as anti-solvent for crude peptide precipitation, yielding good performance if used in a 1:4 mixture with *n*-heptane.⁷⁸

In 2019, the Rasmussen,^{29c,78} North,⁷⁹ and Tolomelli and Cabri⁸⁰ groups simultaneously reported the use of green binary mixtures for SPPS, opening a revolutionary possibility for new solvents to successfully accomplish all steps of SPPS. Fine-tuning the chemical/physical features of solvents by using a binary mixture is a valuable instrument for obtaining the appropriate polarity and/or viscosity for successful resin swelling and reagent solubilization,⁸¹ as highlighted in the guidelines for a perfect SPPS solvent.⁴⁶ The influence of different solvent mixtures on swelling was first described by the North group, who developed a computational model outlining, for the first time, that resin swelling did not correlate linearly with solvent composition. More importantly, they showed that a binary mixture could be better at achieving swelling than neat solvents; mimicking the properties of traditional, polar, aprotic solvents; and replacing them. In particular, the authors identified that mixtures of EtOAc/PC and EtOAc/2,2,5,5-tetramethyloxolane (TMO) could swell PS resins more efficiently than each solvent separately.⁷⁹ The paramount importance of resin swelling is highlighted by the number of publications focused on investigating this step in green solvents,⁸² despite traditional solvents (DMF, NMP and DCM) maintaining the highest swelling values overall.⁸³

The concept of binary mixtures was then expanded to other SPPS steps. The Pawlas and Rasmussen group proposed a two-dimensional, green approach, where the first dimension involves a full SPPS and the second describes examples of on-resin derivatization in neat, green solvents or in a 1:1 EtOAc/MeCN mixture (*i.e.*, selective removal of acid-labile protecting groups and on-resin cyclization).⁷⁸ Specifically, the full synthesis of model APIs was performed in 1:1 EtOAc/NBP (Table 3, entry 19)⁷⁸ or 9:1 EtOAc/DMSO (but minimizing the



amount of DMSO in the wash steps to 49:1, Table 3, entry 18).^{29c} Of note, the 1:1 EtOAc/MeCN mixture was also successfully tested as a DCM-replacing solvent for cleavage from CTC resins.⁷⁸

As mentioned previously, Rasmussen's group also reported the use of PolarClean as an efficient water co-solvent for the first reported Fmoc/*t*Bu SPPS in aqueous conditions.⁶⁵ The solubility of standard Fmoc-AAs was achieved by the addition of 20% PolarClean.⁸⁴ In this way the full GSPPS of a model peptide was obtained with the same purity as with DMF (Table 3, entry 50), achieving a new aqueous Fmoc/*t*Bu peptide synthesis method with minimized amounts of inexpensive and non-hazardous solvents.

The only recent innovation in this field was published in 2020. It described a so-called aqueous solid phase peptide synthesis (ASPPS), made possible by the introduction of the water-compatible 2,7-disulfo-9-fluorenylmethoxycarbonyl (Smoc) protecting group that combines a fluorenyl moiety with negatively charged sulfonic substituents. The *N* α -Smoc-protected amino acids are water soluble and compatible with the lack of side chain protecting groups. Moreover, they are fluorescent, which enables real-time detection of both coupling and deprotection steps. The applicability of ASPPS was demonstrated through the synthesis of 22 biologically active peptides using water-compatible activating additives for the coupling steps.⁸⁵

In 2019, Tolomelli and Cabri's group also paved the way for green solvent mixtures, when they analysed new alternatives by mixing CyreneTM (Cyr), sulfolane (Sul), or anisole (An) with DMC or diethyl carbonate (DEC) in different ratios. After an extensive study of the selected mixtures on the ability to swell different kinds of resins, three binary mixtures (7:3 DEC/Cyr, 7:3 DEC/Sul, and 3:7 DMC/An) were further explored in a full SPPS protocol with promising results (Table 3, entries 20–25).⁸⁰ Moreover, with their newly proposed *N*-octylpyrrolidone, they enlarged the available pattern of green solvent candidates. To overcome the issue of its viscosity (6.6 mPa s at 25 °C) to an acceptable value (<4 mPa s) for automated processes, low-viscosity DMC was added to obtain a green mixture of 8:2 NOP/DMC, which was successfully tested both in manual and automatic SPPSs of linear octreotide, obtaining excellent crude purities (Table 3, entry 44).^{29a}

Recently, alternative solvent mixtures with a low viscosity for automated synthesis have been also explored by NovoNordisk and Bachem.^{46,86} Identification of the solvents' key physical parameters allowed for the prediction of a set of potential green binary solvent mixtures that could surpass DMF's performance in the large-scale SPPS of industrially relevant peptides. The authors focused on the composition of the binary mixtures, demonstrating how single steps of SPPS could be easily customized by varying the ratio of the selected solvents. This hypothesis was first validated by assessing reagent solubility, resin swelling, and by controlling coupling and deprotection reactions in a series of sustainable neat solvents or binary combinations.⁴⁶ Moreover, mixtures were investigated for minimization of frequently occurring SPPS side reactions.⁸⁶ Accordingly, they confirmed how solvent viscosity and polarity

are the physiochemical features that mainly affect SPPS steps and therefore need to be optimized when planning a GSPPS. Mixtures of DMSO with dioxolane (DOL), 2-MeTHF, or EtOAc resulted in efficient Fmoc-removal steps (promoted by polar solvents). Couplings could instead be addressed using NFM/DOL or NBP/DOL (promoted by non-polar solvents). After these preliminary results, the authors moved onto a full GSPPS with binary mixtures (Table 3, entries 29–43). Considering all aspects, 3:7 DMSO/DOL (Table 3, entries 38–42) and 3:7 DMSO/2-MeTHF (Table 3, entries 33–37) provided the best results when compared to DMF, while 4:6 NBP/DOL gave slightly worse results (Table 3, entry 43).⁴⁶

3.1.1.2. Solvent recycling and reduction. The benchmark concept of solvent recycling in SPPS was only introduced in 2019.^{29c} It is still not as well-considered as other aspects of SPPS, mentioned only as an encouraging possibility in most papers on green alternatives. Given the urgent demand for peptides in the pharmaceutical sector and the extensive amount of solvents being discarded as waste, applying the circular economy (CE) concept to SPPS is dutiful.⁸⁷ CE sets as its priorities eliminating waste, recycling products, and saving resources and the environment.⁸⁸

A short-term objective is lessening the amount of solvent, namely DMF, in SPPS processes. Minimization of solvent consumption could be achieved by introducing real-time monitoring techniques. Among the developed process analytical tools (PATs), continuous refractive index (RI) measurement of coupling, deprotection and wash solutions was recently validated as a successful technique for online monitoring of all SPPS steps. Besides providing information on the kinetics of the process, RI monitoring avoids sampling, interruption of the process, and extra-analytical procedures. In this way, the consumption of reagents and solvents, together with time and costs, could be strongly minimized, favouring automation of the process, and decreasing the waste impact (Fig. 8).⁸⁹

Similarly, in 2019 Polypeptide developed an automated synthesis reactor that allows real-time monitoring of the SPPS process by means of solvent percolation.⁹⁰ In this context, the




Fig. 8 Schematic representation of SPPS real-time monitoring by refractive index.



“tea bag” approach could also respond to CE features by lessening the amount of solvent required for SPPS. In fact, the main idea of this strategy is to perform parallel multi-syntheses of long peptides, each separately in a tea-bag (propylene bag microreactors containing the growing peptide-resin), exploiting the same solution bottles for Fmoc removal and wash steps where the bags are simultaneously immersed. In this way, washes and base solutions are re-utilized in further steps along the SPPS, allowing 25–30% less DMF volume to be used without affecting the quality of the target peptides.⁹¹ A more ambitious objective is to establish green solvents or mixtures in full SPPS protocols, which must be accompanied by a related recycling strategy in order to reduce their costs. For this long-term objective, physical features of all reagents and solvents involved in the process need to be carefully evaluated.

The ReGreen protocol proposed by Pawlas and Rasmussen^{29c} aimed to recover reagents and solvents from the waste stream to be re-used in subsequent syntheses (Fig. 9). In particular, they focused on solvent recycling (9:1 EtOAc/DMSO) and the coupling additive (OxymaPure®), and evaluating DIC and base for Fmoc-removal (4-methylpiperidine; 4-MP), the last too reactive to be recovered as such. Then, an easy protocol was developed to distill-off the most volatile component from the waste stream, playing on the different boiling points of the various species and, hence, different temperatures/pressures of the distillation process. The recycled EtOAc, DMSO and OxymaPure® were then re-employed in a full GSPPS without affecting the results when compared to virgin materials. Importantly, the authors also evaluated the solvents from the life cycle standpoint, considering the impact of waste disposal.

From a deep analysis, it emerged, unsurprisingly, how much cEF and process costs could be greatly decreased after recovery. A different recycling method was recently disclosed by the same authors, who combined the concepts of CE and water-based SPPS. After the synthesis of Leu-Enkephalin amide in 4:1 H₂O/PolarClean,⁶⁵ (Table 3, entry 50), they developed a protocol for recycling the waste by filtration through a mixed ion-exchange resin (cation exchange plus anion exchange resins). They were able to capture both acid and basic species present in the waste streams (Fig. 9). The H₂O/PolarClean mixture obtained was re-utilized in a full Leu-Enkephalin amide SPPS, without affecting the quality of the crude peptide by the recovered solvents.

Inspired by these concepts, Tolomelli and Cabri's group also investigated a distillation protocol for recovering NOP or a NOP/DMC mixture after the full SPPS of linear octreotide (Table 3, entries 44 and 45). For the first time, a high recovery of all liquid components (85–95% solvent recovery yields) was also considered and successfully obtained, including bases for Fmoc removal (piperidine^{29a} or DEAPA^{29b} with 92–95% recovery yields) (Fig. 9). Of note, coupling and deprotection waste streams were distilled separately in order to prevent base consumption by Fmoc-amino acids, which were used in excess in the coupling steps. In all cases the PMI of the process after recycling was decreased by more than 60%.

3.1.1.3. Solvents: general remarks. Several alternative solvents for SPPS have been proposed in recent years, and others are expected to be reported soon. Considering all aspects of SPPS, a single solvent is unlikely to replace the touchstone DMF. For comparison, the most important characteristics to consider in comparing the most successful green solvents for SPPS are summarized in Table 4. The use of mixtures will




Fig. 9 Schematic representation of solvent and reagent recovery from SPPS waste streams. Specifically, solvents coming from SPPS waste (grey arrows) can be recovered by filtration through ion exchange resin (left side), or can be distilled to separate OxymaPure from liquid components (base/solvents; right side). In both cases, recycled solvents can be reused in a new SPPS process (green arrows).



Table 4 Summary of the most relevant characteristics of best-performing solvents proposed for full GSPPS

Solvent	Availability	Viscosity	Flash point	Peroxide formation	Side-reaction induction	Toxicology	Biodegradation	Biomasses origin	Used alone	Used in mixtures
MeCN										
THF										
2-MeTHF										
EtOAc					—				—	
GVL										
NBP										
DMSO					—				—	
DMC					—				—	
Anisole					—				—	
NOP										
PolarClean					—					

“—” stands for data not reported.

drive GSPPS, matching of all the properties of DMF that are otherwise impossible to achieve with neat solvents. As recently highlighted by Albericio,⁴⁶ there is probably not one single mixture that will work for every peptide's synthesis.


However, there are several hurdles to overcome to use green solvent mixtures for industrial production. These hurdles are mainly related to practical and economic considerations. In fact, by using solvent mixtures, plant supply chains will be more complex, as will the management of waste disposal. Furthermore, DMF, used in a volume exceeding 400 000 tons yearly, is a very cheap solvent, but using alternative mixtures will increase production costs. In fact, the price of most of the proposed green alternatives (mixtures or not) is higher than DMF. Only if the green alternatives are universally accepted and applied industrially will the increased market demand boost volume and decrease market prices. Furthermore, regulatory authorities' reluctance in changing synthesis protocols for already-established processes needs to be addressed.

3.1.2. Alternative bases. The role of bases in SPPS is a subtle balance between ensuring complete removal of temporary *N*-protecting groups and minimizing any eventual base-induced side reactions involving the growing sequences. The Fmoc group is largely employed for these purposes and its first

appearance dates to Carpino's work in 1970.⁹² However, its widespread application in SPPS started in the early 1980s, when the orthogonal Fmoc/*t*Bu strategy was independently reported by the Sheppard⁹³ and Meienhofer groups.⁹⁴ The timeline for the introduction of new bases for Fmoc removal is described in Fig. 10.

Fmoc groups can be cleaved under mild basic conditions via an E1cB β -elimination mechanism. The reaction is more efficient with bases with a high pK_a and low steric hindrance in polar solvents like DMF. Being that piperidine is very efficient in both steps, the standard procedure for Fmoc removal is based on exposure of the protected peptide during SPPS or LPPS to a 20% piperidine solution in DMF, at room temperature for a few minutes.⁹⁵ According to the mechanism, dibenzofulvene (DBF) is formed in the first step (Fig. 11). It is a highly reactive electrophile that could be attacked by the newly formed free α -amino group on the growing, anchored peptide or undergo polymerization.⁹⁶

Unfortunately, the use of piperidine is highly regulated, being a precursor in the illicit preparation of phencyclidine (PCP, also referred to as “angel dust”).⁹⁷ This issue underlines the need for new bases amenable for use in the manufacturing of peptides without any usage restrictions,⁹⁸ considering that

**Fig. 10** Timeline of bases introduced for Fmoc removal in SPPS.




Fig. 11 Mechanism of base-DBF adduct formation.

the base impacts the PMI of the entire process. Besides Fmoc removal efficiency, other criteria should be used for base selection, namely EHS parameters, solubility, boiling point, recovery, and handling. This was clearly highlighted in GSK's acid and base selection guide.⁹⁹

Analogous to piperidine, several secondary amines, namely piperazine,¹⁰⁰ morpholine,^{95a,101} methyl-piperidines, 4-methyl-piperazine,¹⁰² and pyrrolidine¹⁰³ have been described to efficiently remove the Fmoc moiety, taking advantage of both basicity for the first step and nucleophilicity for DBF trapping (see Fig. 11). However, efficient deprotection has also been described using 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU),¹⁰⁴ *tert*-butyl amine (TBA),¹⁰⁵ and 3-diethylaminopropylamine (DEAPA).^{29b} These bases do not efficiently react with DBF, therefore the addition of good nucleophiles like piperidine,¹⁰⁶ piperazine,¹⁰⁷ or thiols¹⁰⁸ is generally required to scavenge the reactive DBF.

Piperidine was largely used in green solvent protocols for SPSS (see footnote *d* in Table 3) and peptide-anchored LPPS (see the corresponding paragraph in 3.2). Fine-tuning of alternative bases to piperidine has been carried out over the years, taking into consideration the potential impact on formation of impurities as described in Fig. 7. In Table 5, the introduction of bases is reported according to publication sequence, reaction solvents, the length of the target peptide, and its purity.

4-Methylpiperidine (4-MP) emerged as one of the most popular alternative bases to DMF (Table 5, entries 5–8 and 17)¹⁰⁹ and it was the first to be used in a green solvent setup.⁶⁸ In fact, in 2018, Lopez and coworkers combined the use of 4-MP with several green solvents (Table 5, entry 9), with NBP giving the best results.⁶⁸ Rasmussen *et al.* successfully extended the use of 4-MP to green solvents mixtures (Table 5, entries 14, 15, 28 and 34).^{29c,65,78} The Tolomelli and Cabri group described the use of TBA and DEAPA in green solvents like NOP and NOP/DMC (Table 5, entries 29 and 30).^{29b} TBA was also able to avoid the formation of the hydantoin (Hyd) impurity as rearrangement of the dihydroorotic (Hor) moiety during degarelix synthesis (Table 5, entry 16), but it was less efficient as a general base for Fmoc removal.¹⁰⁵ Later, Novo

Nordisk-Bachem reported the use of pyrrolidine in green solvent mixtures with low viscosity (Table 5, entries 18–27).¹⁰³

Considering only the organic bases, the protocols generally developed in DMF can be easily transferred to green solvents. However, it is important to consider that side-products, like isomerization, aspartimide and diketopiperazine (Fig. 7), are generally determined by the pK_a and the nucleophilicity of the considered base. As an example, pyrrolidine, which is less sterically demanding than piperidine, generates a higher amount of aspartimide and diketopiperazine side-products.¹⁰³ In addition, less-polar solvents or solvent mixtures were efficient in reducing side-reactions. For example, the aspartimide by-product generated by piperidine or DEAPA is consistently lower in NBP and NOP than in DMF, with DEAPA giving the best results.^{29b}

For the development of a potential industrial process, the same solvent or solvent combinations should be used for the entire synthesis to simplify their recovery. In this context, the only exception reported in Table 5 is the use of NaOH (entries 12, 13 and 33), which was introduced in protocols requiring different co-solvents according to the synthesis step (coupling or deprotection). Furthermore, NaOH is not compatible with SPSS, in which the peptide is linked with an ester. The use of alcohols to favour NaOH solubility affects resin swelling and performance.¹¹⁰

3.1.2.1. Bases: general remarks. To be a credible alternative to piperidine for Fmoc removal, a base should fulfil several features. In addition to possessing similar physicochemical properties (*i.e.*, pK_a and nucleophilicity), it should not be a controlled substance, it should have a robust supply chain, it should be low cost,¹⁰³ and it should have a good green score.⁹⁹ However, since the cost is strictly related to production volumes, the final considerations are limited to its green score and chemical performance. In fact, as summarized in Table 6, piperidine is by far the base with the highest production volume and, therefore, the cheapest. Among the potential alternatives, 4-MP has been the most investigated. Unfortunately, there are no toxicological data available for it.¹¹¹ However, one can assume that piperidine and 4-MP are comparable in terms of toxicity and greenness score with their basicity and nucleophilicity almost identical. Among the other bases, DBU and DEAPA perform well and display a better greenness score than piperidine. However, with these bases, the use of a DBF-trapping reagent is advisable. Finally, concerning NaOH, it is not compatible with several resins and substrates. In addition, NaOH requires the presence of an alcohol to be sufficiently soluble in organic media. These mixtures cannot be applied to the coupling step, resulting in increased complexity of the logistic and waste management.

3.1.3. Coupling reagents. The development of green methods for the formation of amide bonds has received increasing interest in recent years, for as long as it has been included as one of the 10 key, green chemistry research areas by the ACS Green Chemistry Institute Pharmaceutical Roundtable (GCIPR).⁴⁸ Nevertheless, because there are not yet universally accepted solutions for the green construction of



Table 5 Bases for Fmoc-removal in full SPPS (timeframe 2016–2021)

Entry	Base (pK _a)	Amount	Solvent	Full SPPS peptide	HPLC crude purity (%)	Group ^a (ref.)	Year
1	Piperazine (9.8)	10% w/v	DMF/EtOH 9 : 1 (microwave)	H-FISEAIIHVLHSR-NH ₂	57.7 (Pip 43.6)	Albericio (109b)	2016
2				H-TLEEFSAKL-NH ₂	74.8 (Pip 83.0)		
3				H-KKWRWWLKALAKK-NH ₂	55.6 (Pip 59.1)		
4				H-VAPIAKYLATALAKWALKQGFAKLKS-NH ₂	21.4 (Pip 29.0)		
5	4-(Me) piperidine (10.8)	20% v/v	DMF	H-FISEAIIHVLHSR-NH ₂	47.6 (Pip 43.6)		
6				H-TLEEFSAKL-NH ₂	65.1 (Pip 83.0)		
7				H-KKWRWWLKALAKK-NH ₂	50.4 (Pip 59.1)		
8				H-VAPIAKYLATALAKWALKQGFAKLKS-NH ₂	20.6 (Pip 29.0)		
9	4-(Me) piperidine (10.8)	20% v/v	Polar aprotic solvents	linear Octreotide	86 (DMF) 80 (NBP) 78 (TMU) 78 (DMI) 52 (DMSO) 51 (DMPI)	Novartis (68)	2018
10	Morpholine (8.4)	50% v/v	2-MeTHF	—	—	Schütznerová (110a)	2019
11	DBU (13.5)	0.5% v/v	2-MeTHF	—	—		
12	NaOH (15.74)	0.2 M	2-MeTHF/MeOH 1 : 1 or 3 : 1 ^b	Leu-Enkephaline-NH ₂	99 (Pip 99)	Schütznerová (110b)	
13				Triptorelin	57–72 (Pip/DMF 96)	Polypeptide (78)	
14	4-(Me) piperidine (10.8)	5% v/v	NBP/EtOAc 1 : 1	Ac-Nle-DHFRWK-NH ₂	90		
15	4-(Me) piperidine (10.8)	1–5% v/v	EtOAc/DMSO 9 : 1	Aib-ACP	76	Polypeptide (29c)	
16	TBA (10.7)	30% v/v	DMF	Degarelix	87.5 (Pip 83.99)	Fresenius Kabi (105b)	2020
17	4-(Me) piperidine (10.8)	2.5% v/v	DMF	KKWQWK-Ahx-RLLRLLR	99	Garcia (109c)	2020
18	Pyrrolidine (11.3)	20% v/v	EtOAc/DMSO 9 : 1	Aib-Enkephalin	96 (Pip/DMF 69)	Bachem/NovoNordisk (103)	2021
19				Jung-Redemann	59 (Pip/DMF 57)		
20				Thymosin-α1	56 (Pip/DMF 52)		
21				Dasiglucagon amide	58 (Pip/DMF 59)		
22				Bivalirudin	67 (Pip/DMF 78)		
23			NBP/DOL 4 : 6	Aib-Enkephalin	97		
24				Jung-Redemann	67		
25				Thymosin-α1	54		
26				Dasiglucagon amide	55		
27				Bivalirudin	69		
28	4-(Me) piperidine (10.8)	5%v/v	H ₂ O/ PolarClean 4 : 1	Leu-Enkephalin amide	86	Polypeptide (65)	
29	TBA (10.7)	20% v/v	NOP	Aib-Enkephalin	97.9 (Pip 97.8)	Tolomelli/Cabri (29b)	
30	DEAPA (10.5)	5% v/v	NOP NOP/ DMC 8 : 2	Aib-Enkephalin, linear Octreotide	Aib-Enk: 97.1–97.5 (Pip 97.8) linear Octreotide: >99 (Pip >99)		
31	Morpholine (8.4)	50% v/v	Anisole ^c (microwave)	Leu-Enkephalin (OH or NH ₂) Aib-enkephalin-NH ₂	Leu-Enk-NH ₂ : 94 (Pip /DMF 99)	Schütznerová (110c)	
32	DBU (13.5)	5% v/v	Anisole ^c		Leu-Enk-NH ₂ : 98–99 (Pip/DMF 99) Leu-Enk-OH: 93 (Pip/DMF 95) Aib-Enk-NH ₂ : 28 (Pip/DMF 26)		
33	NaOH (15.7)	0.2 M	An/EtOH 1 : 1 ^c		Leu-Enk-NH ₂ : 92 (Pip/DMF 99)		
34	4-(Me) piperidine (10.8)	20% v/v	ACN	H-YIGFLYIGFL-NH ₂	Not reported	Albericio (136)	

^a Corresponding author or company is listed. ^b The mixture was replaced by 2-MeTHF only for coupling steps. ^c The mixture was replaced by An/DMSO = 4 : 1 for coupling steps.



Table 6 Summary of characteristics of bases applied in SPPS

Base	EHS ^a	Clean chemistry ^a	Greenness ^a	DBF scavenging	Side-reaction induction	pK _a ^a	Comments ^{a,b}
Piperidine	5	9	6.9			11.2	R11; R24
4-Methylpiperidine	n.r.	n.r.	n.r.			11.2	n.r.
Piperazine	n.r.	n.r.	n.r.			9.7	n.r.
Pyrrolidine	n.r.	n.r.	n.r.			11.3	n.r.
DBU	7	8	7.3			12.5	R35
Morpholine	7	9	7.5			8.5	—
DEAPA	7	9	7.5			10.5	—
TBA	5	9	6.5			10.6	R11/R25/R35
NaOH	7	9	8.0			15.7	R35

^a Data were extracted from GSK base selection guide (ref. 99); n.r.: not reported. ^b Risk phrases: R11: highly flammable; R24/R25: toxic; R35: causes severe burns.

amide bonds during peptide synthesis,¹¹² the vast majority of peptide coupling reactions are still performed with a wide range of conventional additives.¹¹³ This fact translates into the absence of general criteria for defining a “green coupling reagent”. Therefore, sustainable properties of these reagents have almost never been investigated,¹¹² despite hazardous features or disadvantages that have emerged in recent decades, limiting their applicability for a green process.

To date, extensive reviews have summarized the interchanging series of additives/coupling reagents actually present on the market (Fig. 12),^{113,114} but very few examples can be described as green reagents. The current state of the art for peptide bond formation in SPPS almost exclusively uses the carbodiimide/additive methodology,^{114c} mainly based on DIC. Concerning additives for carbodiimides in couplings, the

main options are benzotriazoles or oximes. Despite the family of benzotriazoles being the first coupling reagents introduced for SPPS (HOBt, HOAt, HBTU are prime examples, see Fig. 12), these additives have a risk of explosion and are accordingly regulated under the “Class 1 explosive category”.¹¹⁵ Moreover, they could induce skin sensitization after long-term exposure.¹¹⁶ This classification also includes all derivatives introduced as stand-alone coupling reagents, despite showing enhanced stability, a higher coupling efficiency, and a lower racemization tendency (see Fig. 12 for examples).¹¹⁷

Concerning oximes, in 2009, Albericio and coworkers were the pioneers in introducing this class of additives,¹¹⁸ focusing on OxymaPure® (ethyl 2-cyano-2-(hydroxyimino)acetate)¹¹⁹ for its excellent properties regarding yields, low racemization levels, and increased safety compared to hydroxybenzotriazole-




Fig. 12 Timeline of introducing coupling reagents and additives in SPPS and relative structures. Reagents written in green or red are classified according to their thermal stability as reported in the coupling reagents selection guide by Sperry *et al.* (ref. 137).



based coupling additives.^{114b} From then onwards, OxymaPure® became the “first-in-class” of the category, gaining constant traction in manual, automated, and MW-assisted SPPS protocols.¹²⁰ Many other analogue derivatives have flourished in recent years, with several modifications along the skeleton, namely K-Oxyma,¹²¹ COMU,¹²² PyOxyma,¹²³ Oxyma B,¹²⁴ TOMBU,¹²⁵ COMBU,¹²⁵ and Oxyma T,¹²⁶ to mention some examples (see Fig. 12). Although these compounds did not possess industrial potency or applicability to green chemistry, COMU is an exception and shows great coupling efficiency accompanied by less epimerization and broad solubility in several solvents. It was recently used in liquid-phase amidations in EtOAc, 2-MeTHF, and DMC,¹²⁷ and remarkably has applications in water-based SPPS. On the other hand, COMU exhibits a very low stability in DMF,¹²⁸ and this, of course, limits its application in SPPS. However, in recent studies, COMU showed stability in GVL and ACN, therefore becoming an attractive coupling reagent for GSPPS.¹²⁹

Notably, among the wide series of coupling reagents available for amide bond formation, DIC/OxymaPure® has undoubtedly become a benchmark in peptide synthesis due to its excellent efficacy, safety, and thermal stability,^{114c} together with low cost and good solubility of the diisopropylurea (DIU) by-product in organic solvents. Accordingly, this reagent combination is now the coupling system of choice, and only a few protocols still involve the use of benzotriazole derivatives (see Table 3 for a comparison of coupling reagents used in GSPPS in recent years). Compatibility of DIC/OxymaPure® in the studied green solvents for SPPS is notably an established property, as demonstrated for the first time by Albericio's group in 2015 in a coupling reaction in 2-MeTHF and ACN.⁵⁷

Recently, scientists from Eli Lilly pointed out a major issue with using this protocol for couplings, detecting the formation of HCN during amino acid activation.¹³⁰ After deeper investigations, it was proposed that HCN was coming from the adduct formed between DIC and OxymaPure® that can hydrolyse, leading back to OxymaPure®, or undergo a nucleophilic, *N*-driven intramolecular cyclization on the activated C–N bond to form the intermediate oxadiazole with consequent release of HCN (Fig. 13). This report raised awareness on the need to warrant a careful evaluation of possible EHS consequences when using DIC/OxymaPure® in SPPS and in amide bond for-

mation in general. Even if the generation of HCN was not reported in the presence of the amino counterpart, which is a reality in peptide synthesis,¹³¹ other research groups have focused their efforts on deeper investigation of this side reaction. In 2020, the Pawlas and Rasmussen group reported that HCN formation increases over time and with higher amounts of DIC.¹³² Interestingly, this side reaction was found to be solvent-dependent, and among several tested green alternatives, the 4 : 1 EtOAc/NBP mixture performed the best in less HCN formation. Also, the addition of dimethyltrisulfide (DMTS) as an HCN scavenger¹³³ proved feasible for minimizing HCN development without affecting coupling performance.

Albericio's group evaluated the effect of carbodiimides on HCN generation when coupled with OxymaPure® in SPPS protocols. Together with the most commonly used reagents, DCC, DIC, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), *N,N'*-di-*sec*-butylcarbodiimide (DSBC), *N,N'*-di-*tert*-butylcarbodiimide (DTBC) and *N-tert*-butyl-*N'*-ethylcarbodiimide (TBEC) were tested in solution phase in the presence of OxymaPure®. The steric hindrance of their *N*-substituents affected the formation of the linear carbodiimide/OxymaPure® adduct and consequently HCN release. The primary carbodiimide, EDC, and hybrid, TBEC, outperformed the other reagents with less adduct formation.¹³⁴ In addition, it was discovered very recently by the same research group how the generation of HCN could be reduced or suppressed according to the sequence of adding reagents. The optimal conditions call for pre-activation of the Fmoc-amino acid with DIC, subsequent addition of the mixture onto the resin, followed by insertion of OxymaPure® directly on the resin.¹³¹

In 2019 Isidro-Llobet and coworkers introduced tetramethylfluoroformamidinium hexafluorophosphate (TFFH) and propylphosphonic anhydride (T3P®) as the most sustainable coupling reagents (Fig. 12),¹¹² despite the fact that they are very rarely used in SPPS.

However, TFFH and tetramethylchloroformamidinium hexafluorophosphate (TCFH) have been recently tested in the water/PolarClean-based SPPS proposed by Rasmussen, with TCFH performing the best.⁶⁵ However, T3P® is a cyclic reagent that maintains a discrete stability in organic solvents. It is well known for promoting amidations in liquid phase with high efficiency and no epimerization.¹³⁵ Moreover, its related by-product after activation is water-soluble. Albericio's group¹³⁶




Fig. 13 Schematic representation of reactions involving DIC and OxymaPure® to form a linear adduct and consequent possible formation of HCN. Note: DIU = diisopropyl urea.



3.2.1. Molecular Hiving™ technology. Taking advantage of Tamiaki's seminal work,^{144d} Chiba at Tokyo University of Technology and Agriculture, in collaboration with Jitsubo, described the synthesis of peptides using the Molecular Hiving™ technology (MHT). Later, the patents covering MHT

Table 7 Comparison between LPPS and SPPS, with highlight on advantages of both techniques

Parameters	LPPS	SPPS
Reaction medium	Solution	Gel (swollen insoluble polymer)
Synthesis strategy	Convergent or stepwise	Stepwise
Temporary protecting group	Typically Boc or Z	Typically Fmoc
Rapidity of synthesis	Slow	Fast
Consumption of amino acid derivatives	Moderate	Medium to high
Consumption of organic solvents	Moderate to high	High
In-process control	Direct monitoring applicable (e.g. HPLC)	Typically indirect monitoring applied (e.g. resin colour tests)
Isolation of intermediates	Typically isolated by precipitation	No isolation of intermediates

Bold was used for the positive aspects of the technique from a greenness stand point.




Fig. 14 Examples of anchors developed by Jitsubo (Anchor 1: Molecular Hiving™ anchors), Ajinomoto Bio Pharma Services (Anchor 2: AJINOMOTO anchors), researchers from Eli Lilly and Exactmer (Anchor 3: PEPSTAR anchors), GAPPeptides and Northwestern Polytechnical University, China (Anchor 4: GAP anchors and SAP anchors, respectively); * Anchor 4 (MHT) is a general representation of amine anchors and some of these are more stable than the corresponding HBA under acidic conditions (TFA).

have been licenced to Neuland and Bachem. In this application, the first amino acid was linked *via* the acid terminus to a lipophilic organic molecule and the peptide was built using the Fmoc chemistry (Fig. 14, anchor 1). The tag-anchored peptides are mainly soluble in less-polar solvents like cyclohexane, THF, DCM, or CHCl_3 , and polar solvents, like ACN or MeOH, were used as antisolvents for precipitation of intermediates. The precipitation was carried out at each step of the reaction sequence. Upon completion of the peptide, the cleavage step was performed by the same reagents commonly used in SPPS (*i.e.*, TFA), because the tags generally polymerize in strong acidic conditions, facilitating their removal by filtration. At the same time, the peptide was solubilized by TFA solutions and

was filtered-off. Importantly, this technology is compatible with the use of Boc chemistry using anchors, such as anchor 2 shown in Fig. 14. In fact, HCl in toluene/dioxane is suitable for the removal of the Boc moiety.¹⁴⁹

The technology was later optimized to also produce terminal amide peptides¹⁵⁰ (Table 8) and to improve the efficiency of the reaction sequence of the Fmoc technology, avoiding the precipitation at each reaction step. After the coupling step, the excess activated amino acid was quenched by adding a nucleophilic amine, such as propyl amine. Only after Fmoc removal with DBU/piperidine as bases was the anchored peptide precipitated as shown in Fig. 15.¹⁵¹ Propyl amine selectively reacts with the activated amino acid avoiding unwanted reactivity of the



Table 8 Synthesis of peptides by anchored peptide LPPS as reported by Chiba and coworkers

Entry	Peptide or PNA	No of aa/ bases	Yield ^a (%)	Ref.	Year
1	Antagonist of TNF- α	15	70	149a	2010
2	Somatostatin	14	50	150b	2011
3	Somatostatin ^b	14	57	150c	2012
4	Leuprolide	9	40	149b	2013
5	Bivalirudin ^c	20	44		
6	h-Ghrelin ^c	28	8		
7	Mahafacyclin B	7	39	150d	2013
8	a-Conotoxin MII	16	43	150e	2013
9	Elastin	10	41	150f	2014
10	ABT-510	9	66	150g	2015
11	iA β 5	5	63	150h	2015
12	Angiotensin III selective antagonist ^d	7	73	149c	2017
13	Oligomer ^e	9	56	150j	2018
14	Icatibant acetate ^f	10	57	151	2019
15	Stellarin E	7	29	150k	2021

^a The yield does not include the reaction step for the synthesis of TAG.

^b Disulfide bond obtained by electrochemical reaction. ^c Convergent synthesis. ^d (H-RVYIHPI-OH). ^e H-AGTCAGTC-Lys-OH. ^f Including the purification process, the yield is 37% with purity >99%.

deprotected amine moiety. Of note, the reaction was performed in 9 : 1 THF/DMF. Most recently, through a collaboration with Jitsubo (as of 2008),¹⁵² Bachem claimed the industrialization of technology that avoids intermediate precipitation. The semicontinuous process was performed using aqueous washes for reagent and side product removal. In several webinars, Bachem researchers claimed a ~60% reduced use of solvents with respect to the corresponding SPPS, without disclosing the target peptide length, the quality achieved or the final procedure.


3.2.2. Ajiphase® method. Ajinomoto technology was derived from a Tamiaki anchor publication.^{144d} Beginning 2005, the Ajinomoto Group started developing a practical manufacturing process for peptides, named AJIPHASE®.¹⁵³ In parallel with Chiba/Jitsubo, Ajinomoto developed the first generation of anchors mimicking the steric hindrance of trityl groups¹⁵⁴ and Rink Amide linkers.¹⁵⁵ The technology was consistently improved by the introduction of branched side-chains

instead of the standard linear ones, which consistently increased the solubility of the anchored peptides in organic solvent (Fig. 14, anchor 2).¹⁵⁶

These second-generation anchors were tested in different solvents such as CHCl₃ and toluene, as well in the greener solvents, EtOAc and CPME. Interestingly, the solubilities of these new branched-chain anchors in various organic solvents consistently increases. As an example, the solubility of the linear anchor in ethyl acetate increases 100-fold, from 0.2 to >25 weight%. The protocol used Fmoc-protected natural and unnatural amino acids in slight excess (1.1–1.3 eq.), and EDC-HCl/HOBt as a coupling mixture. After brine washing, Fmoc removal was performed in the presence of thiomalic acid and DBU (Fig. 15). The addition of thiomalic acid as scavenger was necessary to convert the dibenzofulvene, coming from Fmoc removal, into a water-soluble species, allowing the elimination of reagents and side products of the deprotection step by a simple wash with a mixture of aqueous sodium carbonate and DMF. The organic layer was subjected to the next coupling reaction without concentration or drying. No impurities derived from thiomalic acid or fulvene were observed in the subsequent coupling reaction. The fully protected, full-length peptides demonstrated satisfactory solubility in the organic layer, and phase separation was easily accomplished. The final anchored peptide was then precipitated by ACN addition, and the cleavage was carried out using standard methods. It is worth noting that the syntheses of two generic peptides (20-mer, Bivalirudin, anchor 5; and 10-mer, Degarelix, anchor 6), using CHCl₃ as solvent, have been achieved with an HPLC purity of 84% and 89%, respectively.

The real value and greenness of AJIPHASE® technology cannot be judged using the available publications. The possibility to use alternative greener solvents, like esters, was highlighted by the solubility of the anchor with branched chains, and the large body of literature that describes ethyl acetate as an efficient solvent for peptide synthesis.

3.2.3. PEPSTAR® technology. More than 10 years ago, preliminary studies on the use of membranes for the removal of reagents and side products were the basis of the membrane enhanced-peptide-synthesis (MEPS). This variation of the LPPS

**Fig. 15** General pathway for peptide synthesis by PA-LPPS.

was achieved using simple PEG esters and DMF/DCM as the solvent.¹⁵⁷ The MEPS concept was proved by the synthesis of short peptides; however, the technology was limited by the poor loading of the anchor, the use of DMF, and the PMI being consistently higher than the corresponding SPPS synthesis. In order to improve MEPS, Livingston and co-workers moved to the use of anchors, namely liquid-phase peptide synthesis *via* one-pot nanostar-sieving (PEPSTAR, Fig. 16).^{29d} The technology is based on the use of a three-armed, star-shaped, monodisperse anchor, or nanostar anchors, mimicking Wang and Rink-amide resins (Fig. 14, anchor 3). With respect to the MHT/Ajiphase technologies, the anchor is bigger (i) to avoid

losses during the organic-solvent-nanofiltration (OSN), a critical step to eliminate low molecular weight impurities, and (ii) to increase loading using multiple arms. In fact, the loading capacities of OH-Wang-nanostar and H-Rink-nanostar anchors were 2–3 times higher than the corresponding SPPS resins. After screening various membranes, the polybenzimidazole (PBI) asymmetric membrane, cross-linked with α,α' -*p*-dibromoxylene (DBX) and modified with a polymer brush Jeffamine® M-2005 (denoted as PBI_2005(1)),¹⁵⁸ was selected because of its balance between a good separation factor and higher permeability. The PEPSTAR process was applied to Leu-Enkephalin (H-Tyr-Ser-Ser-Phe-Leu-NH₂) and octreotate amide




Fig. 16 Representation of the PEPSTAR synthesizer. At the top, the scheme and photos of the instrument are shown (open access from ref. 29d); at the bottom, a general reaction scheme of the process is described (adapted from ref. 29d).



Table 9 PMI of linear ocreotide acetate (1 mol) synthesized by MEPS, PEPSTAR and SPPS

g mol ⁻¹	MEPS	PEPSTAR	SPPS
Anchor	5000	707	2000
Amino acid	6788	5770	10 182
Solvent	9 190 000	2 800 000	1 510 000
Yield %	80	80	75
Target peptide	940.8	940.8	882
PMI	9783	2983	1726

Adapted from ref. 29d.

using a 35:65 THF/NMP mixture, working in the 30–35 °C temperature range with an automatic synthesizer, and employing the H-Rink-nanostar anchor. In Fig. 16, a schematic representation of the synthesizer is shown.

Cleavage was performed using a TFA/TIS/H₂O mixture, affording the crude pentapeptide H-Tyr-Ser-Ser-Phe-Leu-NH₂ and the linear octreotate amide with 94% and 90% purity, respectively. PEPSTAR was a consistent improvement of the MEPS technology. However, there are still several drawbacks to be addressed. For example, the OH-Wang-nanostar, that opens the way to the synthesis of peptides with acid termini, did not perform well. In particular, the protocol requires the use of toxic NMP in mixture with THF, as the organic solvent nanofiltration (OSN) was time-demanding, and consistently decreased the productivity and increased the PMI. In fact, the impact of the OSN on the PMI was surprising. In Table 9, a comparison of the different technologies highlights the better performance of SPPS. Based on the authors' data, SPPS outperformed MEPS and PEPSTAR, with the PMI being 5.6- and 1.7-times lower, respectively.

3.2.4. GAP and SAP technologies. In 2016, Seifert *et al.* from GAPeptides introduced another anchor to perform a process similar to the one described by the other PA-LPPS.¹⁵⁹ The use of anchors was based on their experience on group-assisted-purification (GAP).

The anchor is a very simple organic compound ((4-hydroxy-methyl)phenyl)diphenylphosphine oxide, HOBndpp (Fig. 14, anchor 4). After the first amino acid is attached, the reaction sequence is performed in DCM and, after Fmoc deprotection with 30% piperidine and washes with a NH₄Cl solution, the subsequent amino acid coupling is promoted by TBTU/DIPEA. After several washes, the DCM solution is evaporated, and the residue dissolved in ethyl acetate and precipitated by adding petroleum ether. The process is reiterated, and the crude peptide is isolated *via* a two-step process: TFA/DCM/water followed by palladium-catalysed hydrogenation. Despite this being the technology described in peer reviewed publications, several issues are associated with the use of DCM as solvent, explosive TBTU as coupling reagent, and the final cleavage that is performed in 2 steps comprising hydrogenation. Still, the technology efficiency was verified by synthesizing the pentapeptide thymopentin.

On the company's website, several documents are reported, claiming the use of sustainable alternative solvents, like 2-MeTHF as a reaction solvent and cyclopentyl methyl ether for the intermediate's precipitation. However, these two solvents are classified

as problematic in several guides. The synthesis of the 20mer, Bivaluridin, obtained with an 88% purity, was also claimed on the website to be competitive in terms of PMI with respect to the corresponding SPPS process.¹⁶⁰ However, it is not possible to make an evaluation of the technology since no raw data are available.

In 2020, Qin and coworkers focused their attention on the PA-LPPS, developing a series of novel anchors based on phosphorous derivatives: tri(4-benzoylphenyl) phosphate (TBP), tri(4-formylphenyl)phosphonate (TFP), diphenylphosphonyloxyl diphenyl ketone (DDK), and tri(4'-diphenylphosphonyloxyl benzoyl-phenyl)phosphate (TDPBP) (in Fig. 14 only TDPBP was described).¹⁶¹ The supported-assisted-precipitation technology (SAP) used DCM as a solvent. The precipitation was performed at any step by adding EtOAc in a mixture with hexane, petroleum ether, or acetonitrile, depending on the anchor used. The technology can be performed using Fmoc or Boc amino acids. In this case, there is also a major issue related to the use of DCM and of the counter solvent mixtures reported above.

3.2.5. PA-LPPS: general remarks. Several anchors and process strategies have been developed during the last 5 years in the PA-LPPS segment. However, the information available in peer reviewed journals, most of the time, does not allow a full and detailed evaluation of the technologies. In this context, intellectual property and trade secrets play a major role. In fact, the most interesting technologies will be not available for a long time to the rest of the scientific and industrial community. An analytical comparison between Molecular Hiving™, Ajiphase, PEPSTAR and GAP/SAP strategies is summarised in Table 10.

From a scientific perspective this area is absolutely interesting; however, additional efforts are necessary to prove that the technology can be sustainable and suitable to deliver the same complex peptide currently produced using SPPS (Table 10).

The greatest advantage that all these techniques have in common is, undoubtedly, the possibility of considerably reducing the amount of solvent and coupling reagents needed to carry out the reactions.

However, few examples have been reported on synthesis processes involving the use of green solvents or reagents with a reduced impact on operator health, plant safety, or effect on the environment. Furthermore, evaluating the use of anchors for peptide synthesis makes it immediately clear that the possibility of obtaining good processes in terms of atom economy is already *a priori* excluded. However, through a relative evaluation of the process, by comparing it with SPPS, it appears that the impact of the technique is extremely limited. It is also clear that PA-SPPS techniques are poised for implementing the basic processes needed for greener solutions. Proven and successful application toward the synthesis of API peptides, therefore, creates optimal starting conditions to proceed towards a large-scale transfer of these synthesis procedures to obtain a more sustainable production chain.

3.3. Semi-continuous/continuous peptide synthesis

This section is dedicated to technologies that are based on semi-continuous/continuous processes, avoiding the use of anchors for the acid terminus, or being an evolution of the



Table 10 Evaluation of pros/cons of PA-LPPS technique

Technique	Pros	Cons
Molecular Hiving™ Technology	<ul style="list-style-type: none"> - High yield and purity of products - Speed 	<ul style="list-style-type: none"> - Use of DCM and DMF for synthesis of both anchor and peptide sequence
AjIPHASE®	<ul style="list-style-type: none"> - Intellectual property - Synthesis up to 10mer peptide - High yield and purity of products - Intellectual property 	<ul style="list-style-type: none"> - Coupling reagents and advisable of replacement (DMM-TM and COMU) - Use of CHCl₃ for peptide synthesis and DMG in some water washes. The use of more green solvents has been claimed but not disclosed
PEPSTAR	<ul style="list-style-type: none"> - Synthesis up to 20mer peptide - High yield and purity of products - Synthesis up to 8mer peptide 	<ul style="list-style-type: none"> - Coupling reagents are advisable of replacement (EDC/HOBt), - Use of NMP in peptide synthesis
GAP	<ul style="list-style-type: none"> - High yield and purity of products - Synthesis up to 5mer peptide - The anchor can be recovered. 	<ul style="list-style-type: none"> - Coupling reagents advisable of replacement (HBTU) - PMI higher than SPPS - Use of DCM for peptide synthesis – use of coupling reagents advisable of replacement (TBTU, EDC/HOBt, EDC/DMAP, DEA)

classical SPPS. The main targets of these protocols are to decrease solvent consumption and increase process efficiency and speed. Diosynth Rapid Solution Synthesis of Peptides (DioRaSSP®) by Aspen and μ LOT® by SB3000 are examined, highlighting the pros and cons based on the available information, and painting a precise picture of the possible direction that continuous techniques can take for industrial synthesis of API peptides.¹⁶²

3.3.1. Diosynth Rapid Solution Synthesis of Peptides (DioRaSSP®) method. DioRaSSP® is a method patented by Aspen Oss company and developed by Eggen and co-workers in the early 2000s for the large-scale manufacture of peptides in solution.^{162a,163} Interestingly, no new information has been reported by Aspen since 2005. DioRaSSP® keeps all the advantages of classical solution-phase peptide synthesis (CSPS), introducing a number of implementations to make it reproducible in an automated setup. Essentially, in the DioRaSSP® approach, the growing peptide is kept in an organic phase, typically EtOAc, by using a simple hydrophobic C-terminal ester, generally a *tert*-butyl group.¹⁶⁴ As shown in Fig. 17, a DioRaSSP® cycle comprises three key steps: the coupling, generally performed using EDC/HOBt and a benzyloxycarbonyl-protected amino acid (30–60 min); the quenching of residual activated carboxylic compound using β -alanine benzyl ester; and the deprotection of the N-terminus of growing peptide and by-products *via* palladium-catalysed hydrogenolysis, using 3–4 equivalents of formate (30–60 min). Interestingly, all excess reagents and side products are removed by simple aqueous washes at different pH. Moreover, as a consequence of the aqueous washes, the coupling agents must be compatible with the presence of moisture. However, the use of the hydrogenolysis to remove the amino protecting group eliminates the necessity to use a large excess of base (*e.g.*, in Fmoc removal) (Fig. 17). With this strategy, Eggen and co-workers managed to simultaneously deprotect the amino group of the growing peptides and all the β -alanine by-products. Following this protocol, functional groups on amino acids' side-chains are protected not only to avoid side-reactions but also to

increase the hydrophobicity of the growing peptide, thus limiting losses in the water washes.¹⁶⁵ According to this quenching strategy, DioRaSSP® accounts for the absolute absence of truncation or unwanted elongation of the sequences. From a sustainability point of view, it is impossible to measure the effect on the PMI, since the volume of the aqueous washes is not reported, even though there is a clear advantage from the reduced use of organic waste.^{162a} It is worth noting that the DioSynth technology uses real-time reaction monitoring to follow and optimize every reaction step, thanks to the absence of resin and anchors. Using to this protocol, Eggen and co-workers have synthesized a considerable number of protected peptides, varying from tripeptides to dodecapeptides, including leuprolide, buserelin, deslorelin, goserelin, histrelin and triptorelin. Purities are generally high (95.3–97.6%) and average yields >95% are typically obtained for each chemical conversion in fast, first-trial syntheses.¹⁶⁶ Unfortunately, it is difficult to evaluate product purities since the analytical method's resolution and the impurities are not described. However, according to the company's website, Aspen has been able to commercialize desmopressin (9mer), gonadorelin (10mer), leuprolide (9mer), and oxytocin (9mer) by employing the DioRaSSP® protocol.¹⁶⁷

Finally, it is reasonable to assume that Aspen Oss improved the technology during the last 20 years, even though it seems to be industrially limited to the production of short peptides (<10mer).

3.3.2. Continuous manufacturing technology: μ LOT®. μ LOT® is a continuous manufacturing technology based on hybrid solid/liquid-phase chemistry, developed by 3000 Swedish Biomimetics® (SB3000®). As such, μ LOT® can be applied not only to peptide synthesis but also to the preparation of oligonucleotides, carbohydrates, small molecules, and antibody–drug conjugates. At present, the μ LOT® process is claimed to be applicable to 80% of the marketed products for which solid phase synthesis can be performed.^{162b} The μ LOT® platform was inspired by Houghten's tea bag methodology¹⁶⁸ in which the main idea is to perform a parallel multi-synthesis of long peptides, each separated in a propylene bag microreactor containing the growing peptide-resin. In this way,





Unfortunately, the efficiency of μ LOT $^{\text{®}}$ claimed by SB3000 $^{\text{®}}$ concerning production quality, reliability, and PMI reductions is not supported by data. In fact, there are no patents or publications that allow a real evaluation of the technology. All available information has been collected from the company's website and conference presentations.¹⁶⁹ At the TeknoScience online event on peptides held in March 2021, 90% reduced use of DMF using μ LOT $^{\text{®}}$ compared to SPPS was claimed. Considering the technology potential, monitoring the evolution of μ LOT $^{\text{®}}$ will certainly offer interesting information.

The efficiency of these synthesis techniques in producing API peptides is evident from their proven application in industry and their subsequent intellectual property protection. Maintaining very strong similarities, the two techniques are configured as valid green alternatives to the well-established methods for peptide synthesis (Table 11). Even if it is a currently unpracticable flow design for these methodologies, it is noteworthy that the “continuous” feature allows a complete synthesis (including monitoring) to be performed, avoiding the isolation or precipitation steps that are necessary in other heterogeneous strategies that were previously mentioned. Allowing a satisfactory reduction of waste and PMI, in combination with the possibility of being integrated with green solvents, these technologies represent the most promising sustainable alternatives to produce API peptides, as evidenced by the initiation of industrial production by the companies involved. However, the lack of access to fundamental information regarding the type of coupling and deprotection reagents used, due to intellectual property issues, does not allow a full judgment to be made on the greenness of the process. Moreover, the issue of long synthesis times must be resolved to make these methodologies further implementable. This is particularly important for μ LOT® technology, whose main challenges rely on the different relative speeds of the ribbon flow in each syn-




Fig. 18 Schematic representation of μ LOT® technology (ref. 162b).

Table 11 Summary of pros and cons of DioRaSSP and μ LOT® technologies

Technique	Pros	Cons
DioRaSSP (Aspen)	<ul style="list-style-type: none"> - Applicability to industrial scale - Automated process - Use of green solvent without organic waste 	<ul style="list-style-type: none"> - Absence of recent undisclosed information - Suitable for short peptide sequence. - Hydrogenolysis deprotection (Pd metal and hydrogen formation) - Unclear necessity of specific apparatus for hydrogen evolution
μ LOT® (SB3000®)	<ul style="list-style-type: none"> - Absence of intermediate isolation - Use of aqueous work-up to remove side products - Detection of low amount of epimers, insertion or truncated sequences - Real time monitoring <p>The lack of data does not allow a critical evaluation of the technology</p>	

thesis step, and on the ribbon/sachet length, thus affecting productivity. In fact, couplings and deprotections have different reaction speeds, with the former being considerably slower than the latter. Yet, the ribbon speed must be constant for a smooth and efficient process and therefore should be set based on the slower reaction step. This increases the possibility of base-dependent side-products being formed. Finally, the ribbon/sachet length necessary to avoid mechanical ruptures and charge 1 kg of resin is still unknown, according to accessible data.

3.4. Chemoenzymatic peptide synthesis (CEPS)

Alongside synthesis methods, biocatalysis can be considered one of the pillars of sustainable chemistry, with wide application in different industrial segments, including drug manufacturing. In chemo-enzymatic peptide synthesis (CEPS), several classes of enzymes are used in the synthesis of pharmaceutical intermediates.¹⁷⁰ Thanks to the evolution of sophisticated

technologies to adapt the enzyme for a specific use, enzymatic catalysis for peptide and protein ligations has recently emerged as a potentially sustainable alternative to chemical ligation.¹⁷¹ In particular, four classes of enzymes have been widely investigated: butelase, sortase, trypsiligase, and subtiligase variants, owing to their capability to generate a specific peptide bond in water.¹⁷¹ However, the enzymatic steps need to be fully integrated with other technologies such as GSPPS and PA-LPPS. As described in the following paragraphs, CEPS can be useful in synthesizing a wide range of linear and cyclic peptides and protein conjugates, including highly complex substrates.

3.4.1. Engineered enzymes for efficient coupling steps. The use of a biocatalyst to form the peptide bond ensures several advantages over synthesis strategies, because of its excellent regio- and chemoselectivity, mild reaction conditions, and elimination of highly reactive and toxic stoichiometric amount of coupling reagents.



In the last few years, extensive research has been performed by several teams worldwide that led to the creation of engineered enzyme platforms with broad substrate scope, improved activity, and stability.

3.4.1.1. Sortases. A well-established enzyme for peptide ligation is Sortase A (SrtA), a natural enzyme that catalyses the adhesion of surface proteins to the cell wall of prokaryotes, whose use is hampered by a low catalytic efficiency. Sortase A recognises the LPXTG (where X is any amino acid) sequence on the C-terminal peptide fragment. It cleaves the glycine and generates a thioacyl-enzyme intermediate with threonine, susceptible to nucleophilic attack by the N-terminal fragment to create the peptide bond (Fig. 19).¹⁷²

The use of sortase for peptide ligation, defined as *sortagging*, is possible when the identification motif LPXT is included in the acyl-donor fragment, while a Gly is required at the N-terminus of the acyl acceptor.¹⁷³ In other words, the LPXTG recognition sequence is fixed and must be part of the target peptide. In addition the reversibility of the reaction leads to low yields.

Some engineering variants have been developed to broaden the substrate scope of the reaction, but only in a few cases has the activity been improved.^{174,175} Interestingly, Zou *et al.* were able to increase the enzyme stability by the formation of a cyclized mutant of Sortase A, namely CyM6, with improved

thermal stability and a good resistance against denaturing agents, such as urea.¹⁷⁶

In summary, sortagging has a limited scope in CEPS because of the LPTXG motif sequence that must be present in the target peptide (there are no commercial peptides with that sequence) and the large amount of enzyme necessary to get good conversions.

3.4.1.2. Asparaginyl endopeptidases (AEPs). Another suitable solution for enzymatic peptide ligation is offered by asparaginyl endopeptidases (AEPs). Butelase 1, one of the most important enzymes of this class, was isolated from *Clitoria ternatea*,¹⁷⁷ a tropical plant in which this enzyme naturally catalyzes a head-to-tail cyclization in the biosynthesis of cyclotides.¹⁷⁸ For this reason it was classified as a ligase rather than a protease. Butelase 1 catalyses the peptide bond *via* the same thioester acyl-enzyme intermediate of Sortase A (disrupted by an amine on the N-terminal fragment, affording the ligation product). It recognises a shorter motif on acyl-donor fragment, namely NHV (Fig. 19).¹⁷⁷ In this case, only an Asp residue is retained in the ligated sequences, differently from the longer motif of Sortase A-catalyzed ligations. Concerning the N terminal, the reaction takes place with any amino acid in the first position except Pro, Asp and Glu, and there is less tolerance for the second position, where only Ile, Leu, Val or Cys are compatible. From a green perspective, the major advantages of




Fig. 19 Schematic representation of catalytic mechanisms of Cys-dependent enzymes, like sortases and asparaginyl endopeptidases (butelase-1), peptilgases, and recognition pockets of omniligase-1 (adapted from ref. 193b).



this enzyme are its high catalytic efficiency (0.005 molar eq. of enzyme are required) and the high yields, with cyclization preferred on intermolecular ligation. Moreover, the competitive reaction between the cleaved HV-dipeptide and the thioacyl enzyme complex is a critical aspect. Several solutions to this problem have been proposed. In linear ligation, the use of thiodipeptide as acyl-donor was tested successfully by Tam's group, which significantly contributed to the development and improvement of sortase applications; the thioester leaving group was not recognized by the Butelase-1, allowing high yields for the coupling steps.¹⁷⁹ After several unsuccessful attempts, Tam and coworkers were able to successfully produce the recombinant enzyme, thus opening the possibility to produce a butelase-1 with an activity identical to the natural enzyme.¹⁸⁰ The potential of this enzyme attracted the attention of several research groups that investigated, in parallel, the active site and the possibility of producing additional variants *via* recombinant technologies.¹⁸¹ Recently, Hemu and coworkers reported an engineered variant of butelase-2 able to work as peptide ligase.¹⁸²

Other AEPs have also been identified, namely OaAEP1b/3/4,¹⁸³ HeAEP3¹⁸⁴ and VyPAL2¹⁸⁵ with similar attributes for cyclization reactions. In particular, OaAEP1 was crystallized and several variants inspired by the natural enzyme were produced by recombinant methodologies.¹⁸⁶ From a technological perspective, the immobilization of butelase-1 and VyPAL2 was recently explored, with satisfactory outcomes for non-covalent immobilization of butelase-1 (39% of immobilization yield, 50% of recovered activity). Interestingly, the operational stability was substantially retained over 100 runs (>90%).¹⁸⁷ The loss of enzymatic activity after immobilization is expected, but an improvement in immobilization yield could make this technique more convenient. In summary, AEPs are interesting because of their short recognition motif and the efficiency in macrocyclization reactions. In particular, butelase-1 variants appear to be the most efficient class of AEPs enzymes thus far. The recent breakthroughs in the availability of the active site's crystal structure and recombinant production of several nature-inspired AEP enzymes open up the path to rapid optimization and evolution towards more efficient macrocyclization/ligation reactions and industrial applications.¹⁸⁸

3.4.1.3. Subtilisin variants. Subtilisin protease was subjected to extensive modification by genetic engineering during the past few decades, generating an incredible amount of variants. This journey started with the chemical modification of the catalytic site in subtilisin protease. The Ser²²¹ in the catalytic triad Asp-His-Ser was converted into a cysteine, increasing the ligation activity over hydrolysis (Fig. 19).¹⁸⁹ Unfortunately, the introduction of a thiol group generated steric crowding of the catalytic site, thus a further mutation was introduced in the 1990s leading to the double mutant S221C/P225A subtiligase.^{171a,190} This catalyst still had some limitations, such as the necessity of high nucleophile excess (10 eq.) and a poor stability. Then peptiligase, a new variant of the Ca²⁺-independent subtilisin BPN', including the previously mentioned mutations, was introduced by Toplak and coworkers.¹⁹¹ The

impact of reagents was significantly lowered due to the theoretical 100% conversion rate with almost equimolar amount of substrates, and the side-products were minimized thanks to the high efficiency of the ligation process over hydrolysis. Despite the efforts made to reach an effective chemoenzymatic ligation, peptiligase had a narrow substrate scope, limiting its application as general peptide bond-forming catalyst. Subsequent work reported further mutations, which led to a very efficient enzyme, called omniligase-1. Thanks to engineering, the substrate scope was broadened, with two major limitations at the P₄ position, where only hydrophobic or slightly polar amino acids are tolerated, and on the P₁ position, where proline is not accepted. On the acyl acceptor fragment at the P₁' position, almost all amino acids except proline are tolerated, while proline and charged residues are not recommended at the P₂' position (Fig. 19).¹⁹² Furthermore, the subtiligase variants require the use of activated esters on the C-terminal fragment, usually carboxyamidomethyl (OCam) ester, improving kinetic control of the reaction.

Omniligase-1 has been applied in the synthesis of the pharmaceutical peptide exenatide. In this approach, the acyl-donor (H-1-21-O-Cam-L-NH₂) and the acyl acceptor (H-22-39-NH₂) fragments, produced by standard SPPS, were ligated under different conditions, in both crude and purified form, with very efficient catalytic activity. In particular, comparing the well established SPPS method with the CEPS approach, the latter proved to have a good impact on the PMI (more than halved), avoiding difficult SPPS steps, and reducing byproduct formation, thus simplifying the purification process of the target peptide. Interestingly, the ligation of purified fragments produced exenatide using only 1.1 eq. of the acyl acceptor with a very low amount of biocatalyst (0.0008 mol eq.).¹⁹³ A further study on subtiligase variants demonstrated that it is possible to tailor the enzyme to a specific substrate, improving the reaction conditions and process yield compared to standard synthesis. This was the case of thymoligase, successfully applied in the synthesis of the API thymosin- α_1 , doubling the yields with respect to a full SPPS approach.¹⁹⁴ Peptiligase variants are also used in the cyclization of peptides due to their high ligation efficiency (conversion >90%) in reactions involving peptides with more than 12 residues. Furthermore, they are based on a very interesting methodology since the insertion of recognition motifs in the substrates is not necessary, enabling a traceless ligation.¹⁹⁵ More recently, the determination of the X-ray crystal structures of omniligase mutants, and the creation of computational models of the peptide binding mode, allowed a broadened substrate scope, making this class of enzymes more attractive for CEPS.¹⁹² In this context, the subtilisin variants developed by Enzyep have been used for the synthesis of at least two therapeutic peptides, namely exenatide and thymosin- α .^{193,194}

3.4.1.4. Trypsin variants. Native trypsin and its variants have been known for decades. Bordusa and coworkers described a variant of trypsin, termed trypsiligase, for the site-specific labeling of both N- and C-termini of target peptides or proteins. Thanks to four mutations, K60E, N143H, E151H and



D189 K, which conserved serine in the catalytic site, these variants can mediate ligation reactions after the activation of the enzyme by Y-RH-containing substrates.¹⁹⁶ Trypsiligase is in equilibrium between an inactive zymogen-like conformation and an active conformation, which occurs in the presence of the YRH recognition motif and Zn^{2+} . When the ligation occurs between a peptide or protein carrying the Y-RH motif at the C-terminus and a nucleophilic RH-peptide or protein, the competition between the RH leaving group and the RH-peptide or protein reduces the ligation efficiency and, following the Le Chatelier principle, an excess of nucleophile substrate is required.¹⁹⁶ Trypsiligase has a good catalytic activity when only 0.1 eq. of enzyme is used, and the reaction is usually complete in a few minutes.¹⁹⁷ The main use of tryptiligase is protein labelling even if the Y-RH recognition motif is not very common in natural proteins.¹⁹⁷ Notably, these enzymes are not used for the CEPS approach to polypeptides (Table 12).

3.5. Mechanochemistry applied to peptide synthesis

Mechanochemical reactions, defined as chemical transformations which involve the use of mechanochemical energy to facilitate and induce reactivity, have attracted the attention of both the academic and the industrial communities.^{198,199} The increasing popularity and success of ball-milling techniques is due to the fact that the protocols can be carried out under solvent-free conditions or only in the presence of minimum volumes of organic solvents,²⁰⁰ thereby drastically reducing waste.²⁰¹ Moreover, other features have led mechanochemistry to be considered as a state of art technique by the scientific community, such as fast reaction time, high efficiency protocols, stoichiometry control and unique reactivity, opening the way to the synthesis of several compounds not attainable by other synthesis techniques.^{202,203} Regarding peptide synthesis, the mechanochemical approach is normally limited to the use of Boc protected amino acids and only to the coupling process. In addition, there are only a few papers describing the synthesis of amino acid sequences that goes beyond dipeptides.

The pioneering work in the area was reported by Lamaty and coworkers²⁰⁴ in 2009, who demonstrated the successful use of mechanochemical solvent-free strategies in peptide synthesis using activated urethane-protected α -amino acid *N*-carboxyanhydride (UNCA) derivatives. This work set the basis for the development of a mechanochemical protocol for the synthesis of Leu-Enkephalin, using a liquid-assisted-grinding (LAG) technique. The addition of EtOAc as liquid additive

was critical in order to enhance the yield and the reactivity of the coupling.²⁰⁵

However, early developments of ball-milling peptide synthesis were based on the utilization of activated *N*-protected α -amino esters, but the low commercial availability of these chemicals limited the scope of the approach.^{204–206}

For this reason, the further development of mechanochemistry has been focused on the use of commercially available amino acids and more classical coupling agents such as carbo-diimides, benzotriazoles and oximes, mainly for the synthesis of dipeptides with low level of epimerization, <1%.²⁰⁷ Unfortunately, some of these protocols still suffer from some drawbacks, such as the use of harmful additives like DMAP, DCM, MeNO_2 , HOBt, cyanuric chloride and PPh_3 . In addition, most of the time the workup comprised the use of organic solvents, and the deprotection of the amino group, necessary for the potential elongation, was performed using gaseous HCl or was not described.

More recently, Lamaty and coworkers developed a more environmentally friendly mechanosynthesis protocol of a wide range of dipeptides, tripeptides and tetrapeptides.^{208–210} The optimized strategy was then utilized in the synthesis of the tetrapeptide VVIA. The coupling steps were performed by ball-milling amino ester salts (*p*-toluenesulfonate or hydrochloride) with Boc-AA-OH in the presence of EDC, Oxyme, NaH_2PO_4 as base and small amounts of EtOAc as the liquid grinding assistant. Conventional workup based on acid/basic extractions and washings was performed to achieve the desired coupling products in yields ranging from 78 to 89% (Fig. 20).

In this case the removal of the Boc group under mechanochemical conditions was attempted, obtaining the Boc-VVIA-OBn peptide with an overall yield of 59%. In 2020, Anselmi *et al.*²¹¹ utilized nanocrystalline hydroxyapatite as a bio-compatible, reusable inorganic base to promote the mechanochemical solvent-free coupling synthesis of the tetrapeptide YPWF, using conventional coupling reagents and the Boc strategy already described. Furthermore, the base could be reused for several times, after a simple regeneration, with only a partial loss in activity.

As reported above, chemoenzymatic catalysis has been widely used in solution and solid-phase peptide chemistry due to the mild reaction conditions required, lower use of toxic chemicals, higher yields, minimal side-chain protections, and to the possibility to strictly control the stereoselectivity of the peptide.²¹²

Table 12 Summary of pros and cons of CEPS

Pros	Cons
<ul style="list-style-type: none"> - Reduced excess of reagent - Complete conversions - Absence of epimerization - Use of water as reaction medium - Effective under mild conditions - Effective for peptide cyclization - Possibility to reuse the enzyme after recovery (immobilization) - Absence of protecting groups 	<ul style="list-style-type: none"> - Necessity to introduce specific recognition motifs (short substrate scope) - Modification of C-terminal motif to generate activated ester - Necessity to work in combination with sustainable technologies for the chemical synthesis of fragments






Fig. 20 Approaches for mechanochemical synthesis of peptides.

These observations quickly led to the development of mechanochemical enzymatic reactions and recently the compatibility between enzymes and mechanochemical ball-milling has been reported. In 2017 Hernández *et al.* developed a mechanochemical chemoenzymatic peptide and amide bond formation catalysed by papain, a cysteine protease found in papaya latex (*Carica papaya*).²¹³ Despite the high energy inside the ball mill, the biocatalyst proved to be stable and highly efficient to catalyze the formation of α,α and α,β -dipeptides in good-to-high yields using $\text{Na}_2\text{CO}_3 \cdot 10\text{H}_2\text{O}$ as base.

3.5.1 Mechano-peptide synthesis: general remarks. Mechanochemical techniques have been successfully applied to the synthesis of short peptides and shown to be stable under mechanical stress, through fast and selective reactions under solvent-free conditions. Despite its advantages, this technique still needs time to be fully optimized since there are variables that cannot be directly controlled, such as temperature and mass transfer, that can affect the outcome of the reaction. In addition, the evaluation in terms of greenness of a full iterative process for the synthesis of therapeutic peptides cannot be done, since it has still not been described in the literature. In our opinion, mechanochemistry in peptide synthesis should be further explored to prove suitability to the synthesis of longer peptides, affording pharmaceutical-quality products. However, the possibility to have a fast procedure, avoiding the use of nasty chemicals, can find application in the production of short cosmetic peptides.

4. Peptide purification improvements

The interconnection between synthesis and purification is a normal practice in organic chemistry. Moving to peptide man-

ufacturing, the complexity of the mixtures and the presence of impurities, structurally related to the main drug, determines that the upstream and downstream co-development, guided by a reliable analytical method, is the critical factor to achieve the target quality attributes. In the synthesis of any API peptide, regardless of the technique chosen, it is inevitable that a reaction crude will be characterized by the presence of various impurities, which would become increasingly significant in number as the length of the peptide increases. Regulatory agencies increased consistently their requirements by lowering the level of impurities and requesting a very sophisticated characterization of their immunogenicity and influence on product aggregation.¹²

A preliminary evaluation on the purification method must establish the process-related impurities that cannot be eliminated by chromatography and that must be tackled in the upstream process by a fine tuning of the stoichiometry, the reaction conditions or by a change of synthesis strategy.

A possible change in strategy is the use of a hybrid SPPS/LPPS approach for the synthesis of particularly long peptides, which consists of assembling shorter sequences, optionally purified, instead of linear peptide sequences. An explicative example has been recently reported by researchers from Eli Lilly for the synthesis of the 39mer Tirzepatide. Shorter peptide fragments obtained in high purity (>97%) *via* SPPS and completely characterized were kept protected and then coupled *via* LPPS to afford the target peptide with good yield and purity (>55% and >80%, respectively) using a semi continuous approach in green solvents.²¹⁴

The hybrid approach, in addition to a simplification of the chromatographic purification of the final peptide, can decrease the industrial risk and potentially generate intellectual property.^{215,216} Indeed, experimental conditions, such as



the eluent flow rate, the temperature and, especially, the combination of stationary and mobile phase, must be adjusted case by case. In addition, it is possible to choose whether to maintain the eluent composition constant along time (isocratic mode) or to operate in gradient conditions, which most of the time is necessary when dealing with complex peptide mixtures.

Despite several benefits, including high productivity, chromatography also has some drawbacks, such as high operating costs and large solvent volumes.²¹⁷ A single chromatographic step is not usually enough to achieve the desired product purity, and therefore the downstream processing usually represents the bottleneck of the entire production workflow in terms of time. This issue is the most concerning aspect related to the greenness of chromatography, since large volumes of non eco-friendly solvents, with potential risks towards environment, human health, and safety, are required.

Besides the 12 principles of green chemistry, green analytical chemistry (GAC) promotes also three Rs, that are *Reduce*, *Replace* and *Recycle*.³ In the past, it was believed that the only way to increase sustainability of analytical processes was through the *replacement* of not eco-friendly materials (such as solvents or modifiers) with greener ones, but in the last few years *reduction* of solvent demand has also become a viable choice thanks to the establishment of innovative continuous chromatographic techniques. These approaches, indeed, allow for internal *recycling* of impure fractions in the system, permitting not only to reduce wastes but also to decrease the solvent consumption.

In the following sections, current trends to increase sustainability of downstream processing of peptides are thoroughly discussed. Perspectives and pitfalls in the search for greener materials and techniques are also presented.

4.1 Greener materials

The first approach that can be pursued to increase the sustainability of purification processes is the replacement of toxic materials with more eco-friendly ones. Polar biomolecules, such as some peptides, are usually purified under ion-pair reversed-phase liquid chromatographic (RPLC) conditions by using acetonitrile/water mixtures as mobile phases, to which an ion pairing reagent is added. Its role is to mask the charge of polar biomolecules, allowing for their retention on hydrophobic adsorbents.²¹⁸

4.1.1 Green mobile phases. ACN has been the preferred organic solvent for RPLC for a long time due to its low viscosity, excellent elution strength, UV-transparency, and good miscibility with water. Nevertheless, since it has been classified as advisable for substitution, its replacement with alternative solvents is a priority. In this framework, alcohols (methanol, ethanol, 2-propanol, *etc.*) represent the most promising alternatives to ACN for the purification of peptides. Although methanol (MeOH) cannot be considered a 100% green compound, it is one of the most employed organic solvents for RPLC. Its toxicity is lower with respect to ACN, and it is more biodegradable. MeOH/water mixtures show similar elution

strength to that of ACN/water ones, but higher viscosities which impose the use of lower flow rates.²¹⁹

A greener option is ethanol (EtOH), which has several advantages over MeOH including lower toxicity, generation from biomasses and fast biodegradation besides slightly lower costs. EtOH has also higher elution strength with respect to MeOH, meaning that less EtOH is required for the elution of the target at comparable retention times. Disadvantages of the use of EtOH are related to its higher viscosity and, most importantly, to its lower vapor pressure with respect to MeOH (and ACN).²²⁰ This last condition is particularly disadvantageous in preparative chromatography because the solvent contained in the collected samples needs to be evaporated, but EtOH is particularly difficult to remove.

The employment of other alcohols, such as 2-propanol or *n*-butanol, is limited by their higher viscosities and boiling points in comparison with MeOH. Another trend, promoted by modern GAC and in general by green chemistry, is to shift from the use of sources coming from fossil fuels to bio-based ones, obtainable from renewable origins including agricultural wastes, forestry and wood processing, and marine biomasses.²²¹ Except ethanol, the other bio-solvents have never, or barely ever, been applied as solvents for liquid chromatography so far. Their use is limited by the fact that a deep physico-chemical characterization of the bio-solvent/water mixture (in terms of solubility, viscosity, UV transparency, inertness, *etc.*) is needed before considering them suitable alternatives. Unfortunately, there are no data available on efficient purification of peptides carried out using alternative solvents, and ACN it still the most efficient one.

4.1.2 Green ion pairing reagents. As mentioned at the beginning of section 4.1, ion-pairing reagents are largely used for the chromatographic separation of peptides. Trifluoroacetic acid (TFA) represents the most widely used mobile phase additive since its introduction, more than 20 years ago,²²² and it is employed not only for purification but also for the cleavage of the peptide after synthesis. Therefore, cationic peptides are obtained as trifluoroacetate salts, and since the most used counterions for peptide drugs are chlorides and acetates, an ion exchange step must be carried out prior to lyophilization using ion exchange or reverse phase chromatography. However, TFA represents a possible breakdown product of more than one million of chemicals, including pharmaceuticals, with potentially hazardous and toxic consequences for the environment. Indeed, TFA salts are stable and tend to accumulate in water basins such as sea coasts, salt lakes, and oceans.²²³ In addition, TFA may interfere not only with physical-chemical characteristics of the peptide, but also in biological experiments, for which it is thought to have a negative impact in terms of toxicity.²²⁴ For the reasons mentioned above, there is an increasing trend aiming at replacing TFA with other ion-pairing reagents.

The most accepted alternatives are formic and acetic acids, which are ranked in a relatively high position in terms of sustainability.⁹⁹ The use of these chemicals is considered to be acceptable from the environmental point of view, and acetic



acid is particularly advantageous since most drugs and peptide-based therapeutics are provided as acetate salts, therefore no additional steps of counterion exchange would be needed.²²⁵

Other alternatives that are increasingly used as additive in mobile phase are quaternary ammonium salts, usually with phosphate counterion. These ion pairing reagents are characterized by UV transparency, allowing to achieve high resolution, loading and recovery yields. In addition, they are compatible with further *in vitro* and *in vivo* analysis once organic solvent has been evaporated.²²⁶

4.1.3. From extraction to catch-release (c&r) methods for pre-RP-HPLC treatments. Most of the time, one or more extraction steps are required for peptide sample pre-treatment. The principal objective of extraction processes is to maximize the yield of the target-compound without modification of its physical-chemical properties, while also minimizing the extraction of undesirable compounds. The most common approach used to extract peptides from a solvent-based sample is liquid-liquid extraction (LLE), which, however, requires the use of large volumes of solvent per sample, usually volatile organic compounds (VOCs). This is obviously not acceptable from the point of view of sustainability of the process, with the consequent necessity to reduce solvent consumption. The ideal extraction method makes use of minimal amounts of solvent, and water should be the ideal one to be used, even if for many systems its properties are not appropriate.

More recently the University of Berlin in collaboration with Belyntic described a chemical approach useful to pre-purify crude peptides and simplify the RP-HPLC process, identified as the “catch&release” (c&r) method.²²⁷ Other methods have been reported in the literature,²²⁸ but this appears to be the most efficient one. This approach was typically connected with the introduction at each step of the SPPS process of a capping step. The capped fragments did not react at the N terminal with the base-labile cleavable linkers, introduced in the last coupling as a catch tag to be recognized by the oxime-based and hydrazone-based ligation chemistry (Fig. 21).

The TFA cleavage released the peptide from the resin, removing at the same time the BOC protecting group on the oxime. The peptide was then treated with aldehyde-modified agarose beads at pH 4.5, to generate the oxime, that was extensively washed to eliminate the capped peptide fragments. The final peptide was then typically released by treatment with ethanolamine. This pre-purification process was applied to several peptides, comprising liraglutide. The elimination of some impurities should, in principle, facilitate the final purification. However, it is difficult to understand the impact on the PMI. In fact, the critical impurities, that affect the loading or the number of sequential column purification required to get the correct quality, are mainly diastereoisomers close to the main peak.

4.2 Greener technologies

Besides the replacement of non eco-friendly chemicals with greener ones, the other possible choice to improve the sustainability of the downstream processing is to move towards greener purification techniques.

In batch liquid chromatography, the sample injected is completely eluted before the next injection is performed, and between two consecutive injections the column is cleaned and regenerated. The amount of sample injected is chosen to overload the column until a compromise between purity, yield and productivity is achieved. An excessive overloading of the column leads to a worsening from the point of view of the resolution between the target peak and the close-eluting species, and therefore this behavior has a direct repercussion on the product's purity. Actually, in preparative single-column chromatography, it is not uncommon to run into a purity-yield trade-off: some impurities are chemically very similar to the target product and, in consequence, their chromatographic behavior is also analogous.²²⁹ This causes their resolution to be insufficient, their peaks' baseline not being separated, and this effect worsens at increasing loadings. The front and/or the tail of the main peak, therefore, overlap with close-eluting impurities' peaks, and for this reason they are usually not col-




Fig. 21 Scheme of catch-and-release method.



lected in the collecting pool, which must fulfill very strict purity requirements. Excluding the overlapping windows causes the recovery to decrease unavoidably. On the other side, widening the collecting window would be beneficial for the recovery, to the detriment of the purity. In this kind of situation, purity and yield cannot be both high at the same time, and this represents a limit intrinsic to single-column chromatography often referred to as “purity–yield trade-off” (see Fig. 22).^{215,229} To alleviate this trade-off, it is possible to decrease the sample volume loaded or to use less steep gradients, but this would come at the cost of lower productivity and higher solvent consumption.²³⁰ This is why the downstream processing represents the manufacturing bottleneck for many biopharmaceuticals.²³¹ Continuous chromatographic techniques can help to overcome this issue thanks to the countercurrent movement of the stationary phase with respect to the mobile phase, as will be explained in the next section. These techniques lead to a *reduction* in the solvent usage. Moreover, the perspectives related to the use of Supercritical Fluid Chromatography (SFC), a technique barely explored for preparative purposes but with great potential, will be illustrated. In this case, the organic solvent is *replaced* with an eco-friendlier one, namely carbon dioxide.

4.2.1 Continuous and semicontinuous chromatography.

The overlapping regions causing the yield–purity trade-off just illustrated can be either discarded, but this implies a consistent and unjustified waste of expensive product, or recycled, meaning reprocessed and purified again. The volume of product overlapped with impurities is reprocessed either manually by the operator, or automatically, through a commuting recycling valve that can direct the eluent flow again inside the same column, as happens in closed-loop steady-state recycling chromatography (SSR).^{217e,232}

In the first case, the fractions containing impure product, overlapped with close-eluting impurities, are reinjected by the operator into the same column, either with or without addition of some fresh feed. If no fresh feed is added, this two-step batch process leads to very low productivity, since the same portion of feed is reprocessed twice. On the other hand, in closed-loop the SSR fresh sample is injected into the interior of the circulating chromatographic profile, at a specific

moment. Since a single column is employed (see Fig. 23),^{232a} the injection of the feed into the instrument is not performed continuously and, therefore, SSR cannot be considered a continuous process.

4-Zone Simulated Moving Bed (SMB), patented in early 1960s,²³³ follows the same concepts as SSR but works continuously, since four or more columns are used to form a circuit with two inlets and two outlets.^{217e,234} SMB is based on the principle of countercurrent chromatography, according to which the stationary phase moves virtually in the opposite direction with respect to the mobile phase.²³⁵ For technical reasons, the packed bed cannot be truly moved into the system or into the chromatographic column; in fact, a system of columns and valves simulates this movement. As a consequence, the faster eluting compound (more similar to the mobile phase) and the slower eluting compound (more similar




Fig. 23 Schematic diagram of a closed-loop recycling system. Abbreviations: MP, mobile phase pump; C, column; D, detector; CVM, collection valve manifold; C1, C2, C3, C4, fraction collection valves; W, waste valve; RV, recycle valve; SR, sample reservoir; MR, mobile phase reservoir; SV, three-way selection valve. Reproduced with permission from ref. 232a.




Fig. 22 Purity–yield trade-off scheme. (A) Front and/or tail of the main peak are discarded, affecting the yield. (B) Front and/or tail of the main peak are included in the collected fractions, affecting the overall purity. Reproduced with permission from ref. 215.






Fig. 24 Schematic diagram of binary SMB system. Modified with permission from ref. 236b.

to the stationary phase) can be separated in two streams, the raffinate and the extract, respectively (see Fig. 24).²³⁶ Clearly, this feature makes this technique particularly appealing for the purification of binary mixtures such as racemates. This chromatographic mode allows one to increase the stationary phase utilization and therefore achieves a much higher throughput than the batch and, furthermore, can save up to 90% of the mobile phase, which is a great result from the point of view of green chemistry, especially at commercial scale.²³⁷

The main disadvantage of SMB is the initial investment required, since the equipment is much more expensive than batch LC systems with similar production capacity.

At large commercial scale, the saving in solvent consumption and the increase in productivity obtained with SMB justify the significant initial cost, whereas at lab scale other solutions are often preferred. On the other hand, closed-loop SSR equipment is a preparative chromatograph for liquid chromatography, connected to a recycling valve (needed to recycle the unresolved portion) and an injection valve (to inject fresh feed at the suitable point in the profile).^{232a} Therefore, the capital cost that must be faced for a SSR unit is not much higher than that for a traditional preparative system and is considerably lower with respect to SMB.

During the purification of industrially obtained complex peptide mixtures, the most typical situation is the so-called “center-cut (or ternary) separation”, where the target elutes as intermediate between two other groups of impurities.²³⁸ Also, SSR and SMB can only perform isocratic or step gradient elution, whereas to purify complex peptide mixtures generally a linear solvent gradient is required in order to modulate the separation, since the retention of biomolecules is greatly affected by the mobile phase composition.²³⁹

Continuous chromatography has been implemented to manage ternary separations, allowing remarkable reductions in solvent consumption during peptide purification.²⁴⁰ As for other chromatographic techniques based on the automatic recycling of impure fractions, and for the case of continuous ternary separations, the special feature is not the continuous nature but the countercurrent movement of the stationary phase with respect to the mobile phase.²³⁵ Two or more columns are connected in series and the positions of inlet and outlet streams are moved between the columns at precise time intervals. The switching of the valves allows one to collect suitably pure product windows, to recycle impure fractions and to discard impurities, as will be explained later.

In fact, over the years the 4-zone SMB process has been extended from binary to ternary separations, for example connecting two SMB units in series. This set-up is called “tandem SMB”. In this case, one of the streams eluting from the first SMB contains a single solute, while the other outlet stream contains two different species, that are separated into the second SMB unit. For example, this technology has been employed to separate insulin from protein aggregates and zinc chloride salt. Aggregates were removed into the first SMB unit, while insulin and salt were sent to the second SMB unit to be further separated.^{234,241}

Using tandem SMB allowed an increase in productivity of more than 5 times and a reduction of solvent consumption of more than 3 times, while achieving high yield (99%) at steady-state. However, the compound of interest is just one, whereas the impurities to be removed are dozens, depending on the peptide size and on the number of steps performed in the upstream processing. For example, if the target peptide is produced through SPPS, the complexity of the synthesis increases with peptide length and the purity of the crude mixture decreases proportionally. Therefore, the techniques just described are not suitable for these purifications, where the use of a linear solvent gradient is of utmost necessity to increase the resolution.

To fill the gap between batch separations under solvent gradient conditions and continuous chromatography in the field of ternary mixtures, a process was developed in around 2006, called Multicolumn Countercurrent Solvent Gradient Purification (MCSGP).^{230,242} The working principle of MCSGP has been extensively described elsewhere.^{218,229,231a,243}

During the purification in batch conditions, the overlap between the peptide of interest and other groups of impurities worsens, due to large injected volumes, slow mass transfer and low selectivity, from which the already mentioned yield–purity trade-off derives. The obtained batch chromatogram resembles the scheme depicted in Fig. 25: in zone 1 the feed is loaded, then the gradient starts and 4 elution zones can be identified (from 2 to 5) and, last, the column is stripped and equilibrated in zone 6. Zones 3 and 5 represent the overlapping regions that need to be recycled within the MCSGP process, whereas zone 4 is the collecting window, and in zones 2 and 6 the eluting impurities go to waste.^{243d} The idea is to use a system of columns working either interconnected or disconnected, to






Fig. 25 Schematic representation of a MCSGP in batch. Abbreviations: W = weak impurities, P = product, S = strong impurities. Reproduced with permission from ref. 243c.

recycle the impure product, collect the pure product and elute the product-free waste streams.²³⁰

In MCSGP, from two up to six columns can be used. The version of MCSGP using six columns is the oldest and the most complex one from the point of view of the fluidics; in this case, the chromatographic process can be said to be *continuous* since the feed is continuously injected into the system, either in one column or in another.^{239c,244} In the case where the columns employed are only two, as in the most recent version of MCSGP, the system is much simpler and works cyclically and continuously.^{229,231b,245} The sample cannot be injected continuously into the unit since technical times are required in order to recover the purified product and discard the impurities window. Therefore, twin-column MCSGP is a *semicontinuous* process.

The possibility to internally recycle the impure sections of the chromatogram into the unit allows for three remarkable advantages. The first one is the automation of the whole process, which permits one to decrease the time necessary for the purification and to avoid potential errors caused by the operators.²⁴⁶ The second one is to overcome the yield–purity trade-off typical of the batch process, thanks to the fact that the mass of target peptide only leaves the unit when it has been purified. Finally, a net reduction in solvent consumption is achieved since the solvent eluting in the overlapping regions (and containing impure product) remains in circulation through the system.

MCSGP is a process particularly suitable for challenging purifications of several classes of biomolecule: peptides, proteins, monoclonal antibodies and, lately, also oligonucleotides and cannabinoids. In many cases, it gave successful results from the point of view of yield–purity trade-off, productivity and solvent consumption.

In the literature, some examples of MCSGP employed for peptide mixtures can be found. For instance, a comparison between batch and MCSGP processes for a peptide purification has been described.²²⁹ At a final purity of almost 99%, yield was improved by 4 times, a tenfold increase in productivity was achieved and solvent consumption decreased by 70%,

from 3.5 to 1 L of solvent per gram of purified product using 3-column MCSGP. Another polypeptide, purified by MCSGP by means of reversed-phase chromatography, had an improvement of 25 times in productivity and a 60% reduction in solvent consumption.^{243b} Recently, very good results were obtained in the purification of icatibant with MCSGP: at a purity greater than 99%, recovery and productivity increased by almost 7- and almost 6-fold, respectively, whereas the buffer consumption was reduced by more than 80% with respect to the corresponding batch set-up.^{231a}

Ströhlein *et al.*²⁴⁷ demonstrated, through a process modeling formerly developed^{242c} for a particularly challenging polypeptide purification conducted in reversed-phase conditions, that the batch process with no recycling led to a solvent consumption equal to 3000 L g^{−1} (because of the scarce yield), the batch process with ideal recycling²⁴⁷ to 80 L g^{−1} and the MCSGP to only 8 L g^{−1}, which corresponds to an improvement of 10 times with respect to the typical process employed, corresponding to batch with recycling protocol.

The remarkable improvements obtained in productivity and solvent consumption lead undoubtedly to benefits both in the economics and in the greenness of the process. Of course, MCSGP processes are more challenging to design and operate, but Müller-Späth and Bavand²⁴⁸ evaluated that MCSGP would allow around 40% cost savings in the downstream processing compared to the batch chromatography scenarios, for a peptide production plant generating around 10 kg of product per year. Most of the costs in downstream processing performed in batch are indeed attributable to solvents and plant operating costs, followed by stationary phase costs and quality assurance/quality control costs. Equipment costs give the smallest contribution. This means that investing money once to implement purification systems for continuous chromatography can lead to great savings and to a decrease in the payback period, which is estimated to be around 6–18 months. Also, for the MCSGP case, stationary phase costs are negligible, since significantly smaller columns are used. Recently, the first industrial purification system based on MCSGP was installed by one of the leading companies in the peptide business, namely Bachem.²⁴⁹

4.2.2 Preparative supercritical fluid chromatography (SFC). Although liquid chromatography often represents the best option in the field of peptide separations, it nevertheless presents some limitations. For example, large volumes of organic solvents are required, as already stated above, and, besides, usually more than one purification step is necessary. To make the whole process greener and more environmentally friendly, purifications through Supercritical Fluid Chromatography (SFC) could represent a possible solution, since the main component of the mobile phase is supercritical CO₂, which is considered a green solvent with low environmental impact, non-toxic, cheap, non-flammable, non-corrosive and safe to use.²⁵⁰ The use of supercritical CO₂, thanks to its mild critical temperature (31 °C), makes SFC particularly suitable for thermally labile compounds. In addition to carbon dioxide, the eco-friendly ethanol can replace acetonitrile or methanol. CO₂ is



also easy to remove because it evaporates right after the separation process: a direct consequence is that much less energy is required for the treatment of the purified sample, *e.g.*, during its evaporation or lyophilization.²⁵¹ Otherwise, the eluting CO₂ could be collected, recycled, and re-employed²⁵² in the perspective of circular reuse of chemicals, even though this practice is far from being systematically applied.

Another advantage of preparative SFC over preparative LC is an improvement in productivity, thanks to higher used flow rates.²⁵³ In fact, supercritical fluids exhibit higher diffusivities and lower viscosities with respect to liquids, with very similar properties to gases. This translates in 3- to 4-fold higher velocity for maximum efficiency with respect to HPLC, with clear advantages in terms of time and productivity.^{250a}

SFC is a separation technique orthogonal to RPLC, since the supercritical CO₂ is rather apolar. Typical stationary phases applied in reverse and normal phase chromatography can be easily used under SFC conditions, making it a very flexible technique. The separation of a wide range of samples with different solubilities is then possible, from non-polar to polar ones. The separation and purification of highly polar compounds is also possible with the addition of water as an additive in the polar co-solvent of the mobile phase (usually 1 to 5%).²⁵⁴

SFC has been extensively employed in the past for the purification of chiral compounds, including chiral APIs in the pharmaceutical industry,^{253,255} but lately it has been used also in the field of peptides' separations for analytical purposes, as proved by a rich literature.²⁵⁶ Stationary phases commonly employed are amine or cyanopropyl-bonded silica or copolymer of styrene and divinylbenzene.^{250a}

On the other hand, very few studies report the feasibility of SFC large-scale purification of biomolecules like peptides and proteins, because this technique has started being studied only recently for this kind of preparative application.²⁵⁴ Schiavone *et al.*,²⁵⁷ for instance, managed to purify some peptides and proteins, among which were bradykinin, insulin, ubiquitin, cytochrome C and myoglobin, through preparative SFC using a mixture of methanol, ACN, water, TFA and CO₂ as mobile phase. Recently, Ventura proposed a mobile phase made of methanol and two additives (TFA and ammonia) to separate crude synthetic therapeutic peptides using a cross-linked diol Luna® HILIC column, a stationary phase with unique selectivity properties. This separation was performed in analytical conditions but represents a good starting point for the scale-up to preparative conditions.²⁵⁸ Lately, Govender and coworkers demonstrated, with a proof-of-concept, that it is possible to purify, through semi-preparative SFC, samples of human insulin analogues, biosynthesized *via* recombinant DNA technology. Also, in that case, the organic modifier contained methanol with 5% water (added to improve peak shape) and 0.2% TFA. The biological activity of insulin was studied *in vitro* after the SFC purification, and it was assessed that it was not affected by the purification process.^{251a}

On the other hand, the conformations of peptides and proteins purified and tested by Schiavone *et al.*, except for insulin,

were not preserved after the purification through SFC.²⁵⁷ According to Kasche *et al.*²⁵⁹ and Zagrobelny *et al.*,²⁶⁰ denaturation of some proteins (such as trypsin and α -chymotrypsin) occurs both during compression and depressurization steps. This could be a serious issue for proteins and long peptides employed as APIs, highlighting the need for a method to verify if the tridimensional structure of the compound has been irreversibly affected, and therefore if SFC is suitable for the purification under study.²⁵⁷

In addition, SFC also carries other drawbacks, such as the difficulty in the process scale-up from analytical to preparative conditions because of the compressibility of the mobile phase.²⁵³

In conclusion, even though the potential of SFC in the preparative purification of peptides and proteins is indisputable and promising, further knowledge of the fundamentals, such as adsorption properties and the physical-chemical behavior of supercritical fluids under nonlinear and gradient conditions, should be further explored. Therefore, supplementary developments in the applications are needed for SFC to overcome HPLC performance.²⁶¹

5. Conclusions

Peptides' synthesis represents one of the most serious challenges in green chemistry. During the last 5 years, several new protocols have been developed by academic and industrial laboratories in order to increase the sustainability of the chemical iterative synthesis of peptide sequences. This systematic investigation allowed optimization of several pieces of the puzzle following an approach that can be extended to other fields of organic chemistry to decrease their environmental impact.

Greening SPPS was one of the main subjects and, from all the overviewed data, it clearly emerges that, for the Fmoc/tBu-based approach, there is not a single combination of solvent (s)/base able to replace the DMF/piperidine one. As a result, in agreement with Albericio's observation, the reported data suggest that the specific substrate dictates the protocol of choice. From an industrial stand point, the use of greener solvents' mixtures is hampered by the increased solvent costs and supply chain complexity. In addition, regulatory agencies apply stricter regulations to peptides with respect to small molecules, in terms of process change requirements. For all these reasons, the DMF/piperidine system continues to be applied in SPPS for the synthesis of API peptides, limiting the space for the introduction of the reported greener alternatives.

Moving to LPPS, Tamiaki's 2001 publication opened the way to the development of PA-LPPS, but despite several anchors that have been introduced, only recently has the protocol reached a good level of maturity. The developed technologies are characterized by the use of different coupling reagents, Fmoc deprotection systems and procedures to eliminate side-products, ranging from precipitation of the anchored peptides to the use of membranes or water washings. Unfortunately, in order to protect their technology, in addition



to the patent filing, most of the companies kept their own data as trade secrets, describing the peptide synthesis only in general terms. The direct consequence is that the available information is not sufficient to calculate the upstream PMI, needed to make an unequivocal assessment on the greenness of the process. In addition, even if the solubility in organic solvents is increased by the presence of lipophilic anchors, the technology appears to be currently able to deliver only short peptide sequences.

An important innovation for both SPPS and PA-LPPS is the use of in-line analysis, that can decrease the amount of solvents, chemicals and process time. In upstream technology the main target is, indeed, to generate crude peptide with the highest possible purity, to facilitate the chromatographic purification. On the other hand, the downstream target is to decrease the number of chromatographic steps, introduce automation and increase the downstream yield. The use of semi-continuous chromatography, that immediately recycles the mixed fractions in the following column, allows one to decrease the amount of ACN/water that are still the main used eluents. Moving to cyclic peptides, the use of enzyme-catalysed macrocyclizations appears to be the technique of choice.

Considering all the overviewed literature, our impression is that the integration between different synthesis technologies, like SPPS, PA-LPPS, enzymatic catalysis, microwave-assisted synthesis, and continuous protocols, with innovative semi-continuous chromatographic separations is the way forward to decrease the PMI of chemical peptide synthesis. The stairway to ideal green peptide synthesis has probably still to be completed, but matching all the knowledge achieved to date in different areas may bring research closer to the goal.

Author contributions

LF, WC, AT, have been responsible for conceptualization, supervision, writing, review and editing the paper. AC, MC, GM, DC, PC, AM, TF, SF, CDL have been responsible for data collection and writing of the original draft. The manuscript was written in collaboration with all authors, who have given approval for the final version.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We kindly acknowledge Alma Mater Studiorum University of Bologna for financial support. Fondazione CarisBo is gratefully acknowledged for the funding of the project #18668 "Tecnologie Avanzate per il Controllo e lo Sviluppo di Molecole Innovative per la Salute". Fondazione del Monte di Bologna e Ravenna is kindly acknowledged for financial support (Prot. N°702bis/2019).

Notes and references

- 1 Pollution Prevention Act 1990.42 U.S.C., sections 1310113109.
- 2 S. G. Koenig, D. K. Leahy and A. S. Wells, *Org. Process Res. Dev.*, 2018, **22**, 1344.
- 3 P. T. Anastas and J. C. Warner, *Green Chemistry: Theory and Practice*. Oxford University Press, New York, 1998.
- 4 EPA-United States Environmental Protection Agency <https://www.epa.gov/greenchemistry/information-about-green-chemistry-challenge>.
- 5 D. J. Constable, *ACS Sustainable Chem. Eng.*, 2020, **8**, 14675.
- 6 (a) K. Alfonsi, J. Colberg, P. J. Dunn, T. Fevig, S. Jennings, T. A. Johnson, H. P. Kleine, C. Knight, M. A. Nagy, D. A. Perry and M. Stefaniak, *Green Chem.*, 2008, **10**, 31; (b) V. Martin, P. H. G. Egelund, H. Johansson, S. Thordal Le Quement, F. Wojcik and D. S. Pedersen, *RSC Adv.*, 2020, **10**, 42457.
- 7 S. G. Koenig, C. Bee, A. Borovika, C. Briddell, J. Colberg, G. R. Humphrey, M. E. Kopach, I. Martinez, S. Nambiar, S. V. Plummer, S. D. Ribe, F. Roschangar, J. P. Scott and H. F. Sneddon, *ACS Sustainable Chem. Eng.*, 2019, **7**, 16937.
- 8 M. G. Braun, A. Diaz-Rodriguez, L. Diorazio, Z. Fei, K. Fraunhoffer, J. Hayler, M. Hickey, M. McLaws, P. Richardson, G. D. Roiban, A. T. Parsons, A. Steven, J. Terrett, T. White and J. Yin, *Org. Process Res. Dev.*, 2019, **23**, 1118.
- 9 (a) C. Jiménez-González, P. Poehlauer, Q. B. Broxterman, B. S. Yang, D. Am Ende, J. Baird, C. Bertsch, R. E. Hannah, P. Dell'Orco, H. Noorman, S. Yee, R. Reintjens, A. Wells, V. Massonneau and J. Manley, *Org. Process Res. Dev.*, 2011, **15**, 900; (b) K. Budzinski, M. Blewis, P. Dahlin, D. D'Aquila, J. Esparza, J. Gavin, S. V. Ho, C. Hutchens, D. Kahn, S. G. Koenig, R. Kottmeier, J. Millard, M. Snyder, B. Standard and L. Sun, *New Biotechnol.*, 2019, **49**, 37; (c) A. Borovika, J. Albrecht, J. Li, A. S. Wells, C. Briddell, B. R. Dillon, L. J. Diorazio, J. R. Gage, F. Gallou, S. G. Koenig, M. E. Kopach, D. K. Leahy, I. Martinez, M. Olbrich, J. L. Piper, F. Roschangar, E. C. Sherer and M. D. Eastgate, *Nat. Sustain.*, 2019, **2**, 1034.
- 10 (a) A. Tolomelli, L. Gentilucci, E. Mosconi, A. Viola, S. D. Dattoli, M. Baiula, S. Spampinato, L. Belvisi and M. Civera, *ChemMedChem*, 2011, **6**, 2264; (b) A. Tolomelli, M. Baiula, L. Belvisi, A. Viola, L. Gentilucci, S. Troisi, S. D. Dattoli, S. Spampinato, M. Civera, E. Juaristi and M. Escudero, *Eur. J. Med. Chem.*, 2013, **66**, 258; (c) A. Tolomelli, M. Baiula, A. Viola, L. Ferrazzano, L. Gentilucci, S. D. Dattoli, S. Spampinato, E. Juaristi and M. Escudero, *ACS Med. Chem. Lett.*, 2015, **6**, 701; (d) L. Ferrazzano, D. Corbisiero, E. Potenza, M. Baiula, S. D. Dattoli, S. Spampinato, L. Belvisi, M. Civera and A. Tolomelli, *Sci. Rep.*, 2020, **10**, 7410.
- 11 J. L. Lau and M. K. Dunn, *Bioorg. Med. Chem.*, 2017, **26**, 2700.



- 12 <https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products> (accessed on November 10th, 2021).
- 13 (a) M. M. Goldenberg, Pharmaceutical approval update, *P T*, 2010, **35**, 216; (b) K. L. Bjerre and L. Jasper, *Front. Endocrinol.*, 2019, **10**, 155.
- 14 Mordor Intelligence. *Peptide Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021–2026)*. <https://www.mordorintelligence.com/industry-reports/peptide-therapeutics-market> (accessed on November 10th, 2021).
- 15 L. Wu, *Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls*, ed. V. Srivastava, RSC publishing, Cambridge, 2013, p. 1.
- 16 Y. Gao, X. Yuan, Z. Zhu, D. Wang, Q. Liu and W. Gu, *Exp. Ther. Med.*, 2020, **20**, 234.
- 17 M. Muttenthaler, G. F. King, D. J. Adams and P. F. Alewood, *Nat. Rev. Drug Discovery*, 2021, **20**, 309.
- 18 (a) E. Valeur, S. M. Guert, H. Adihou, R. Gopalakrishnan, M. Lemurell, H. Waldmann, T. N. Grossmann and A. T. Plowright, *Angew. Chem., Int. Ed.*, 2017, **56**, 10294; (b) A. M. Vargason, A. C. Anselmo and S. Mitragotri, *Nat. Biomed. Eng.*, 2021, **5**, 951.
- 19 V. du Vigneaud, C. Ressler, J. M. Swan, C. W. Roberts and P. G. Katsoyannis, *J. Am. Chem. Soc.*, 1954, **76**, 3115.
- 20 R. B. Merrifield, *J. Am. Chem. Soc.*, 1963, **85**, 2149.
- 21 J. Henninot, J. C. Collins and J. M. Nuss, *J. Med. Chem.*, 2018, **61**, 1382.
- 22 (a) W. Cabri, P. Cantelmi, D. Corbisiero, T. Fantoni, L. Ferrazzano, G. Martelli, A. Mattellone and A. Tolomelli, *Front. Mol. Biosci.*, 2021, **8**, 697586; (b) A. C. L. Lee, J. L. Harris, K. K. Khanna and J. H. Hong, *Int. J. Mol. Sci.*, 2019, **20**, 2383.
- 23 Y. Huan, Q. Kong, H. Mou and H. Yi, *Front. Microbiol.*, 2020, **11**, 582559.
- 24 V. Khavinson, N. Linkova, A. Dyatlova, B. Kuznik and R. Umnov, *Molecules*, 2020, **25**, 4389; K. S. Bhullar, S. J. Drews and J. Wu, *Eur. J. Pharmacol.*, 2021, **890**, 173661.
- 25 B. M. Trost, *Science*, 1991, **254**, 1471.
- 26 P. A. Wender, V. A. Verma, T. J. Paxton and T. H. Pillow, *Acc. Chem. Res.*, 2008, **41**, 40.
- 27 T. Gain and P. S. Baran, *J. Org. Chem.*, 2010, **75**, 4657.
- 28 (a) R. A. Sheldon, *Green Chem.*, 2017, **19**, 18; (b) F. Roschangar, A. Sheldon and C. H. Senanayake, *Green Chem.*, 2015, **17**, 752.
- 29 (a) G. Martelli, P. Cantelmi, A. Tolomelli, D. Corbisiero, A. Mattellone, A. Ricci, T. Fantoni, W. Cabri, F. Vacondio, F. Ferlenghi, M. Mor and L. Ferrazzano, *Green Chem.*, 2021, **23**, 4095; (b) G. Martelli, P. Cantelmi, C. Palladino, A. Mattellone, D. Corbisiero, T. Fantoni, A. Tolomelli, M. Macis, A. Ricci, W. Cabri and L. Ferrazzano, *Green Chem.*, 2021, **23**, 8096; (c) J. Pawlas and J. H. Rasmussen, *Green Chem.*, 2019, **21**, 5990; (d) J. Yeo, L. Peeva, S. Chung, P. Gaffney, D. Kim, C. Luciani, S. Tsukanov, K. Seibert, M. Kopach, F. Albericio and A. Livingston, *Angew. Chem., Int. Ed.*, 2021, **60**, 7786; (e) O. Maurin, P. Verdié, G. Subra, F. Lamaty, J. Martinez and T. X. Métro, *Beilstein J. Org. Chem.*, 2017, **13**, 2087.
- 30 R. Gani, *Comput. Chem. Eng.*, 2004, **28**, 2441.
- 31 D. K. Babi, K. Kulajanpeng, A. Tongrod, A. Kammafoo, K. Lourvanij and R. Gani, *A Systematic Approach to Green Solvent Selection, Design, and Verification. The Application of Green Solvents in Separation Processes*, Elsevier, 2017, p. 57.
- 32 Roots Analysis research report. *Peptide Therapeutics: contract API manufacturing market, 2020–2030*.
- 33 F. P. Byrne, S. Jin, G. Paggiola, T. H. M. Petchey, J. H. Clark, T. J. Farmer, A. J. Hunt, C. R. McElroy and J. Sherwood, *Sustainable Chem. Processes*, 2016, **4**, 7.
- 34 L. Cseri, M. Razali, P. Pogany and G. Szekely, *Organic Solvents in Sustainable Synthesis and Engineering. Green Chemistry - An inclusive approach*, Elsevier, 2018, 513.
- 35 (a) R. K. Henderson, C. Jimenez-Gonzalez, D. J. C. Constable, S. R. Alston, G. G. A. Inglis, G. Fisher, J. Sherwood, S. P. Binksa and A. D. Curzons, *Green Chem.*, 2011, **13**, 854; (b) C. M. Alder, D. Hayler, R. K. Henderson, A. M. Redman, L. Shukla, L. E. Shuster and H. F. Sneddon, *Green Chem.*, 2016, **18**, 3879; (c) C. Jimenez-Gonzalez, A. D. Curzons, D. J. C. Constable and V. L. Cunningham, *Clean Technol. Environ. Policy*, 2004, **7**, 42.
- 36 D. Prat, O. Pardigon, H. W. Flemming, S. Letestu, V. Ducandas, P. Isnard, E. Guntrum, T. Senac, S. Ruisseau, P. Cruciani and P. Hosek, *Org. Process Res. Dev.*, 2013, **17**, 1517.
- 37 (a) L. J. Diorazio, D. R. J. Hose and N. K. Adlington, *Org. Process Res. Dev.*, 2016, **20**, 760; (b) D. Prat, J. Hayler and A. Wells, *Green Chem.*, 2014, **16**, 4546.
- 38 D. Prat, A. Wells, J. Hayler, H. Sneddon, C. R. McElroy, S. A. Shehada and P. J. Dunn, *Green Chem.*, 2016, **18**, 288.
- 39 M. Tobiszewski, S. Tsakovski, V. Simeonov, J. Namiesnik and F. Pena-Pereira, *Green Chem.*, 2015, **17**, 4773.
- 40 (a) J. Sherwood, M. De bruyn, A. Constantinou, L. Moity, C. R. McElroy, T. J. Farmer, T. Duncan, W. Raverty, A. J. Hunt and J. H. Clark, *Chem. Commun.*, 2014, **50**, 9650; (b) H. J. Salavagione, J. Sherwood, M. De bruyn, V. L. Budarin, G. J. Ellis, J. H. Clark and P. S. Shuttleworth, *Green Chem.*, 2017, **19**, 2550.
- 41 (a) F. M. Kerton and R. Marriott, *Alternative solvents for green chemistry*, RSC publishing, Cambridge, 2nd edn, 2013; (b) C. Reichardt and T. Welton, *Solvents and solvent effects in organic chemistry*, Wiley-VCH, Weinheim, 4th edn, 2011; (c) A. S. Matlack, *Introduction to green chemistry*, Marcel Dekker, New York, 2001, p. 201.
- 42 (a) Y. Yang, *Side reactions in peptide synthesis*, Tsinghua University Press Limited, Published by Elsevier Inc, 2016; (b) O. Al Musaimi, B. G. de la Torre and F. Albericio, *Green Chem.*, 2020, **22**, 996.
- 43 J. M. Palomo, *RSC Adv.*, 2014, **4**, 32658.
- 44 R. A. Sheldon, *Green Chem.*, 2007, **9**, 1273.



- 45 K. Hojo, A. Hara, H. Kitai, *et al.*, *Chem. Cent. J.*, 2011, **5**, 49.
- 46 V. Martin, S. Jadhav, P. H. G. Egelund, R. Liffert, H. J. Castro, T. Krüger, K. F. Haselmann, S. Thordal Le Quement, F. Albericio, F. Dettner, C. Lechner, R. Schönleber and D. S. Pedersen, *Green Chem.*, 2021, **23**, 3295.
- 47 Data for each solvent retrieved at <https://echa.europa.eu/it/candidate-list-table> (accessed on November 10th, 2021).
- 48 M. C. Bryan, P. J. Dunn, D. Entwistle, F. Gallou, S. G. Koenig, J. D. Hayler, M. R. Hickey, S. Hughes, M. E. Kopach, G. Moine, P. Richardson, F. Roschangar, A. Steven and F. J. Weiberth, *Green Chem.*, 2018, **20**, 5082.
- 49 J. M. Collins, *Microwaves in Organic Synthesis*, Wiley-VCH Verlag GmbH & Co. KGaA, 3rd edn, 2012.
- 50 <http://www.cem.com> (accessed on November 10th, 2021).
- 51 <http://www.csbio.com> (accessed on November 10th, 2021).
- 52 G. Sabatino, A. D'Ercole, L. Pacini, M. Zini, A. Ribecai, A. Paio, P. Rovero and A. M. Papini, *Org. Process Res. Dev.*, 2021, **25**, 552.
- 53 <https://www.ambiopharm.com/news-press/cem-corporation-and-ambiopharm-form-u-s-partnership-for-gmp-peptide-production/> (accessed on November 10th, 2021).
- 54 A. Kumar, Y. E. Jad, J. M. Collins, F. Albericio and B. G. de la Torre, *ACS Sustainable Chem. Eng.*, 2018, **6**, 8034.
- 55 A. Kumar, Y. E. Jad, A. El-Faham, B. G. de la Torre and F. Albericio, *Tetrahedron Lett.*, 2017, **58**, 2986.
- 56 G. A. Acosta, M. del Fresno, M. Paradis-Bas, M. Rigau-DeLlobet, S. Cote, M. Royo and F. Albericio, *J. Pept. Sci.*, 2009, **15**, 629.
- 57 Y. E. Jad, G. A. Acosta, S. N. Khattab, B. G. de la Torre, T. Govender, H. G. Kruger, A. El-Faham and F. Albericio, *Org. Biomol. Chem.*, 2015, **13**, 2393.
- 58 V. Pace, P. Hoyos, L. Castoldi, P. Domínguez de María and A. R. Alcántara, *ChemSusChem*, 2012, **5**, 1369.
- 59 Y. E. Jad, G. A. Acosta, S. N. Khattab, B. G. de la Torre, T. Govender, H. G. Kruger, A. El-Faham and F. Albericio, *Amino Acids*, 2016, **48**, 419.
- 60 Y. E. Jad, G. A. Acosta, T. Govender, H. G. Kruger, A. El-Faham, B. G. de la Torre and F. Albericio, *ACS Sustainable Chem. Eng.*, 2016, **4**, 6809.
- 61 T. Govender, H. G. Kruger, A. El-Faham, B. de la Torre and F. Albericio, *Org. Proc. Res. Dev.*, 2017, **21**, 365.
- 62 (a) A. Kumar, A. Sharma, B. G. de la Torre and F. Albericio, *Molecules*, 2019, **24**, 4004; (b) A. Kumar, A. Niyi, K. P. Nandhini, J. M. Collins, F. Albericio and B. G. de la Torre, *Org. Process Res. Dev.*, 2019, **23**, 1096.
- 63 <https://www.solvay.com/en/brands/rhodiastolv-polarclean> (accessed on November 10th, 2021).
- 64 A. Kumar, A. Sharma, B. G. de la Torre and F. Albericio, *Green Chem. Lett. Rev.*, 2021, **14**, 544.
- 65 J. Pawlas and J. H. Rasmussen, *ChemSusChem*, 2021, **14**, 3231.
- 66 S. Lawrenson, M. North, F. Peigneguy and A. Routledge, *Green Chem.*, 2017, **19**, 952.
- 67 S. B. Lawrenson, R. Arav and M. North, *Green Chem.*, 2017, **19**, 1685.
- 68 J. Lopez, S. Pletscher, A. Aemissegger, C. Bucher and F. Gallou, *Org. Process Res. Dev.*, 2018, **22**, 494.
- 69 (a) B. G. de la Torre, A. Kumar, M. Alhassan, C. Bucher, F. Albericio and J. Lopez, *Green Chem.*, 2020, **22**, 3162; (b) A. Kumar, M. Alhassan, J. Lopez, F. Albericio and B. G. de la Torre, *ChemSusChem*, 2020, **13**, 5288.
- 70 (a) L. Ferrazzano, G. Martelli, T. Fantoni, A. Daka, D. Corbisiero, A. Viola, A. Ricci, W. Cabri and A. Tolomelli, *Org. Lett.*, 2020, **22**, 3969; (b) T. Fantoni, S. Bernardoni, Al. Mattellone, G. Martelli, L. Ferrazzano, P. Cantelmi, D. Corbisiero, A. Tolomelli, W. Cabri, F. Vacondio, F. Ferlenghi, M. Mor and A. Ricci, *ChemSusChem*, 2021, **14**, 2591.
- 71 P. Palladino and D. A. Stetsenko, *Org. Lett.*, 2012, **14**, 6346.
- 72 M. Alhassan, O. Al Musaimi, J. M. Collins, F. Albericio and B. G. de la Torre, *Green Chem.*, 2020, **22**, 2840.
- 73 J. Pawlas, T. Svensson and J. H. Rasmussen, *RSC Adv.*, 2019, **9**, 38928.
- 74 B. G. de La Torre and D. Andreu, *J. Pept. Sci.*, 2008, **14**, 360.
- 75 O. Al Musaimi, Y. E. Jad, A. Kumar, J. M. Collins, A. Basso, B. G. de la Torre and F. Albericio, *Curr. Opin. Green Sustain. Chem.*, 2018, **11**, 99.
- 76 O. Al Musaimi, Y. E. Jad, A. Kumar, A. El-Faham, J. M. Collins, A. Basso, B. G. de la Torre and F. Albericio, *Org. Process Res. Dev.*, 2018, **22**, 1809.
- 77 K. Watanabe, N. Yamagiwa and Y. Torisawa, *Org. Process Res. Dev.*, 2007, **11**, 251.
- 78 J. Pawlas, B. Antonic, M. Lundqvist, T. Svensson, J. Finnman and J. H. Rasmussen, *Green Chem.*, 2019, **21**, 2594.
- 79 Y. Ran, F. Byrne, I. D. V. Ingram and M. North, *Chem. – Eur. J.*, 2019, **25**, 4951.
- 80 L. Ferrazzano, D. Corbisiero, G. Martelli, A. Tolomelli, A. Viola, A. Ricci and W. Cabri, *ACS Sustainable Chem. Eng.*, 2019, **7**, 12867.
- 81 Y. Marcus, *Solvent mixtures-Properties and selective solvation*, Marcel Dekker, New York/Besel, 2002.
- 82 (a) C. Amadi-Kamalu, H. Clarke, M. McRobie, J. Mortimer, M. North, Y. Ran, A. Routledge, D. Sibbald, M. Tickias, K. Tse and H. Willway, *ChemistryOpen*, 2020, **9**, 431; (b) Data available at <https://www.webofscience.com/wos/woscc/analyze-results/5a129d4c-2318-4366-9f89-f39db566beac-0d2e7594> using as key words “resin swelling green solvent” (accessed on November 10th, 2021).
- 83 J. K. Magtaan, M. Devocelle and F. Kelleher, *J. Pept. Sci.*, 2020, **26**, e3250.
- 84 A. Randová, L. Bartovská, P. Morávek, P. Matějka, M. Novotná, S. Matějková, E. Drioli, A. Figoli, M. Lanč and K. Friess, *J. Mol. Liq.*, 2016, **224**, 1163.
- 85 S. Knauer, N. Koch, C. Uth, R. Meusinger, O. Avrutina and H. Kolmar, *Angew. Chem., Int. Ed.*, 2020, **59**, 12984.
- 86 S. Jadhav, V. Martin, P. H. G. Egelund, H. Johansson Castro, T. Krüger, F. Richner, S. Thordal Le Quement, F. Albericio, F. Dettner, C. Lechner, R. Schönleber and D. S. Pedersen, *Green Chem.*, 2021, **23**, 3312.



- 87 O. Al Musaimi, D. Al Shaer, B. G. de la Torre and F. Albericio, *Chem. Today*, 2021, **39**, 18.
- 88 K. Kümmerer, J. H. Clark and V. G. Zuin, *Science*, 2020, **367**, 369.
- 89 B. G. de la Torre, S. Ramkisson, F. Albericio and J. Lopez, *Org. Process Res. Dev.*, 2021, **25**, 1047.
- 90 O. Ludemann-Hombourger, I. Martinuzzi, C. Bobier and E. Francomme, *Patent application* WO2019/211531A1, 2019.
- 91 F. Guzmán, A. Gauna, O. Luna, T. Román, C. Álvarez, C. Pareja-Barrueto and L. Mercado, *Molecules*, 2021, **26**, 5035.
- 92 L. A. Carpino and G. Y. Han, *J. Am. Chem. Soc.*, 1970, **92**, 5748.
- 93 E. Atherton, H. Fox, D. Harkiss, C. J. Logan, R. C. Sheppard and B. J. Williams, *J. Chem. Soc., Chem. Commun.*, 1978, 537.
- 94 C.-D. Chang and J. Meienhofer, *Int. J. Pept. Protein Res.*, 1978, **11**, 246.
- 95 (a) G. B. Fields, *Methods in Molecular Biology, in Peptide Synthesis Protocol*, 1995, vol. 35, p. 17; (b) W. Li, N. M. O'Brien-Simpson, M. A. Hossain and J. D. Wade, *Aust. J. Chem.*, 2020, **73**, 271; (c) A. El-Faham and F. Albericio, *Pept. Sci.*, 2020, **112**, e24164.
- 96 L. A. Carpino, *Acc. Chem. Res.*, 1987, **20**, 401.
- 97 M. S. Sonders, J. F. W. Keana and E. Weber, *Trends Neurosci.*, 1988, **11**, 37.
- 98 Red List of the International Narcotics Control Board available at https://www.incb.org/incb/en/precursors/Red_Forms/red-list.html, 18th edn, 2021 (accessed on November 10th, 2021).
- 99 R. K. Henderson, A. P. Hill, A. M. Redman and H. F. Sneddon, *Green Chem.*, 2015, **17**, 945.
- 100 J. D. Wade, M. N. Mathieu, M. Macris and G. W. Tregear, *Lett. Pept. Sci.*, 2000, **7**, 107.
- 101 O. Seitz, F. Bergmann and D. Heindl, *Angew. Chem., Int. Ed.*, 1999, **38**, 2203.
- 102 J. Hachmann and M. Lebl, *J. Comb. Chem.*, 2006, **8**, 149.
- 103 P. H. G. Egelund, S. Jadhav, V. Martin, H. Johansson Castro, F. Richner, S. T. Le Quement, F. Dettner, C. Lechner, R. Schoenleber and D. S. Pedersen, *ACS Sustainable Chem. Eng.*, 2021, **9**, 14202.
- 104 (a) A. K. Tickler, C. J. Barrow and J. D. Wade, *J. Pept. Sci.*, 2001, **7**, 488; (b) J. D. Wade, J. Bedford, R. C. Sheppard and G. W. Tregear, *Pept. Res.*, 1991, **4**, 194.
- 105 (a) I. Guryanov, A. Orlandin, A. Viola, B. Biondi, D. Badocco, F. Formaggio, A. Ricci and W. Cabri, *Org. Process Res. Dev.*, 2019, **23**, 2746; (b) I. Guryanov, A. Orlandin, A. Viola, B. Biondi, F. Formaggio, A. Ricci and W. Cabri, *Org. Process Res. Dev.*, 2020, **24**, 274.
- 106 S. A. Kates, N. A. Sole, M. Beyermann, G. Barany and F. Albericio, *Pept. Res.*, 1996, **9**, 106.
- 107 K. Ralhan, V. G. KrishnaKumar and S. Gupta, *RSC Adv.*, 2015, **5**, 104417.
- 108 J. E. Sheppeck, H. Kar and H. Hong, *Tetrahedron Lett.*, 2000, **41**, 5329.
- 109 (a) C. F. Vergel Galeano, Z. J. Rivera Monroy, J. E. Rosas Pérez and J. E. García Castañeda, *J. Mex. Chem. Soc.*, 2014, **58**, 386; (b) O. F. Luna, J. Gomez, C. Cárdenas, F. Albericio, S. H. Marshall and F. Guzmán, *Molecules*, 2016, **21**, 1542; (c) V. Rodríguez, H. Pineda, N. Ardila, D. Insuasty, K. Cárdenas, J. Román, M. Urrea, D. Ramírez, R. Fierro, Z. Rivera and J. García, *Int. J. Pept. Res. Ther.*, 2020, **26**, 585.
- 110 (a) A. Přibylka, V. Krchňák and E. Schütznerová, *Green Chem.*, 2019, **21**, 775; (b) A. Přibylka, V. Krchňák and E. Schütznerová, *J. Org. Chem.*, 2020, **85**, 8798; (c) A. Přibylka, M. Pastorek, M. Grepl and E. Schütznerová, *Tetrahedron*, 2021, **99**, 132452.
- 111 The European Chemicals Agency (ECHA) Brief Profile for 4-methylpiperidine: <https://echa.europa.eu/it/brief-profile/-/briefprofile/100.009.959> (accessed on November 10th, 2021).
- 112 A. Isidro-Llobet, M. N. Kenworthy, S. Mukherjee, M. E. Kopach, K. Wegner, F. Gallou, A. G. Smith and F. Roschangar, *J. Org. Chem.*, 2019, **84**, 4615.
- 113 A. El-Faham and F. Albericio, *Chem. Rev.*, 2011, **111**, 6557.
- 114 (a) S. R. Manne, B. G. de la Torre, A. El-Faham and F. Albericio, *Synthesis*, 2020, 3189; (b) R. Subirós-Funosas, S. N. Khattab, L. Nieto-Rodríguez, A. El-Faham and F. Albericio, *Aldrichimica Acta*, 2013, **46**, 21; (c) F. Albericio and A. El-Faham, *Org. Process Res. Dev.*, 2018, **22**, 760.
- 115 (a) W. König and R. Geiger, *Chem. Ber.*, 1970, **103**, 788; (b) L. A. Carpino, *J. Am. Chem. Soc.*, 1993, **115**, 4397; (c) A. El-Faham and F. Albericio, *Org. Lett.*, 2007, **9**, 4475.
- 116 K. J. McKnelly, W. Sokol and J. S. J. Nowick, *J. Org. Chem.*, 2020, **85**, 1764.
- 117 (a) R. Knorr, A. Trzeciak, W. Bannwarth and D. Gillessen, *Tetrahedron Lett.*, 1989, **30**, 1927; (b) V. Dourtoglou, J.-C. Ziegler and B. Gross, *Tetrahedron Lett.*, 1978, **19**, 1269; (c) L. A. Carpino, A. El-Faham and F. Albericio, *Tetrahedron Lett.*, 1994, **35**, 2279; (d) L. A. Carpino, A. El-Faham, C. A. Minor and F. Albericio, *J. Chem. Soc., Chem. Commun.*, 1994, 201; (e) O. Marder, Y. Shvo and F. Albericio, *Chimica Oggi*, 2002, **20**, 37; (f) J. Coste, D. Le-Nguyen, G. Evin and B. Castro, *Tetrahedron Lett.*, 1990, **31**, 205; (g) R. Subirós-Funosas, J. A. Moreno, N. Bayo-Puxan, K. Abu-Rabeah, A. Ewenson, D. Atias, R. S. Marks and F. Albericio, *Chimica Oggi*, 2008, **26**, 10; (h) F. Albericio, M. Cases, J. Alsina, S. A. Triolo, L. A. Carpino and S. A. Kates, *Tetrahedron Lett.*, 1997, **38**, 4853; (i) L. A. Carpino, A. El-Faham, C. A. Minor and F. Albericio, *J. Chem. Soc., Chem. Commun.*, 1994, 201.
- 118 A. El-Faham and F. Albericio, *Eur. J. Org. Chem.*, 2009, 1499.
- 119 R. Subirós-Funosas, R. Prohens, R. Barbas, A. El-Faham and F. Albericio, *Chem. – Eur. J.*, 2009, **15**, 9394.
- 120 J. M. Collins, S. K. Singh and G. S. Vanier, *Chem. Today*, 2012, **30**, 2.
- 121 P. Cherkupally, G. A. Acosta, L. Nieto-Rodríguez, J. Spengler, H. Rodríguez, S. N. Khattab, A. El-Faham,



- M. Shamis, Y. Luxembourg, R. Prohens, R. Subiros-Funosas and F. Albericio, *Eur. J. Org. Chem.*, 2013, 6372.
- 122 (a) A. El-Faham, R. Subirós-Funosas, R. Prohens and F. Albericio, *Chem. – Eur. J.*, 2009, 15, 9404; (b) A. El-Faham and F. Albericio, *J. Pept. Sci.*, 2010, 16, 6.
- 123 R. Subirós-Funosas, A. El-Faham and F. Albericio, *Org. Biomol. Chem.*, 2010, 8, 3665.
- 124 Y. E. Jad, S. N. Khattab, B. G. de la Torre, T. Govender, H. G. Kruger, A. El-Faham and F. Albericio, *Org. Biomol. Chem.*, 2014, 12, 8379.
- 125 Y. E. Jad, S. N. Khattab, B. G. de la Torre, T. Govender, H. G. Kruger, A. El-Faham and F. Albericio, *Molecules*, 2014, 19, 18953.
- 126 Y. E. Jad, B. G. de la Torre, T. Govender, H. G. Kruger, A. El-Faham and F. Albericio, *Tetrahedron Lett.*, 2016, 57, 3523.
- 127 D. S. MacMillan, J. Murray, H. F. Sneddon, C. Jamieson and A. J. B. Watson, *Green Chem.*, 2013, 15, 596.
- 128 R. Subirós-Funosas, L. Nieto-Rodriguez, K. J. Jensen and F. Albericio, *J. Pept. Sci.*, 2013, 19, 408.
- 129 A. Kumar, Y. E. Jad, B. G. de la Torre, A. El-Faham and F. Albericio, *J. Pept. Sci.*, 2017, 23, 763.
- 130 A. D. McFarland, J. Y. Buser, M. C. Embry, C. B. Held and S. P. Kolis, *Org. Process Res. Dev.*, 2019, 23, 2099.
- 131 S. R. Manne, A. El-Faham, B. G. de la Torre and F. Albericio, *Tetrahedron*, 2021, 52, 3189.
- 132 M. Erny, M. Lundqvist, J. H. Rasmussen, O. Ludemann-Hombourger, F. Bihel and J. Pawlas, *Org. Process Res. Dev.*, 2020, 24, 1341.
- 133 G. A. Rockwood, D. E. Thompson and I. Petrikovics, *Toxicol. Ind. Health*, 2016, 32, 2009.
- 134 S. R. Manne, O. Luna, G. A. Acosta, M. Royo, A. El-Faham, G. Orosz, B. G. de la Torre and F. Albericio, *Org. Lett.*, 2021, 23, 6900.
- 135 (a) R. Dunetz, Y. Xiang, A. Baldwin and J. Ringling, *Org. Lett.*, 2011, 13, 5048; (b) S. Zhang, L. M. De Leon Rodriguez, E. Lacey, A. M. Piggott, I. K. H. Leung and M. A. Brimble, *Eur. J. Org. Chem.*, 2017, 149; (c) E. K. Davison, A. J. Cameron, P. W. R. Harris and M. A. Brimble, *MedChemComm*, 2019, 10, 693.
- 136 O. Al Musaimi, R. Wisdom, P. Talbiersky, B. G. de la Torre and F. Albericio, *ChemistrySelect*, 2021, 6, 2649.
- 137 J. B. Sperry, J. B. Minter, J. Tao, R. Johnson, R. Duzguner, M. Hawksorth, S. Oke, P. F. Richardson, R. Barnhart, D. R. Bill, R. A. Giusto and J. D. Weaver, *Org. Process Res. Dev.*, 2018, 22, 1262.
- 138 (a) Handoko, S. Satishkumar, N. R. Panigrahi and P. S. Arora, *J. Am. Chem. Soc.*, 2019, 141, 15977; (b) H. Bukya, K. Nayani, P. Gangireddy and P. S. Mainkar, *Eur. J. Org. Chem.*, 2020, 5358.
- 139 A. K. Mishra, S. K. Santra, A. Bazylevich, O. Dorfman, J. Rahamim and A. M. Szpilman, *Angew. Chem., Int. Ed.*, 2021, 60, 2.
- 140 J. Li, Y. Zhu, B. Liu, F. Tang, X. Zheng and W. Huang, *Org. Lett.*, 2021, 23, 7571.
- 141 (a) A. A. Zompra, A. S. Galanis, O. Werbitzky and F. Albericio, *Future Med. Chem.*, 2009, 1, 361; (b) C. Meneses, S. L. Nicoll and L. Trembleau, *J. Org. Chem.*, 2010, 75, 564.
- 142 (a) C. M. Gabriel, M. Keener, F. Gallou and B. H. Lipshutz, *Org. Lett.*, 2015, 17, 3968; (b) M. Cortes-Clerget, J.-Y. Berthon, I. Krolikiewicz-Renimel, L. Chaisemartin and B. H. Lipshutz, *Green Chem.*, 2017, 19, 2463; (c) M. Cortes-Clerget, S. E. Spink, G. P. Gallagher, L. Chaisemartin, E. Filaire, J.-Y. Berthon and B. H. Lipshutz, *Green Chem.*, 2019, 21, 2610.
- 143 T. Bruckdorfer, O. Marder and F. Albericio, *Curr. Pharm. Biotechnol.*, 2004, 5, 29.
- 144 (a) PEG: V. N. R. Pillai, M. Mutter, E. Bayer and I. Gatfield, *J. Org. Chem.*, 1980, 45, 5364; (b) Soluble Styrene: M. Narita, *Bull. Chem. Soc. Jpn.*, 1978, 51, 1477; (c) Fluorinated compounds: M. Mizuno, K. Goto, T. Miura, D. Hosaka and T. Inazu, *Chem. Commun.*, 2003, 972; (d) Aromatic phenol derivatives: H. Tamiaki, T. Obata, Y. Azefu and K. Toma, *Bull. Chem. Soc. Jpn.*, 2001, 74, 733.
- 145 (a) K. Chiba, S. Kim and Y. Kono, *US Patent* 8633298B2, 2014; (b) K. Chiba, S. Kim and Y. Kono, *US Patent* 8293948B2, 2012.
- 146 (a) D. Takahashi, *US Patent* 9353148B2, 2016; (b) D. Takahashi, *US Patent* 9334302B2, 2016; (c) D. Takahashi, *US Patent* 2016060198A1, 2016; (d) D. Takahashi, *US Patent* 9206230B2, 2015; (e) D. Takahashi, *US Patent* 9029504B2, 2015.
- 147 (a) Technology – Exactmer, <https://exactmer.com/technology/>, (accessed on November 10th, 2021); (b) C. Noti, M. Cristau, J. Riegler, V. d. I. P. d. M. Castro Pinzon, H. M. Rodriguez Cabrera, F. Albericio Palomera, W. Chen and A. G. Livingston, *WO Patent* 2016188835A1, 2016; (c) A. G. Livingston, J. Kim, I. B. Valtcheva, P. R. J. Gaffney and M. Schaeperstoens, *WO Patent* 2016020708A1, 2016; (d) A. G. Livingston, J. Kim, I. B. Valtcheva and P. R. J. Gaffney, *WO Patent* 2016 024105A1, 2016; (e) A. G. Livingston, S. Kumbharkar, L. Peeva and J. Da Silva Bural, *US Patent* 20170007963A1, 2017; (f) M. Mechelhoff, P. Marchetti, A. Livingston and Z. Karina, *US Patent* 10239024B2, 2019; (g) M. Schaeperstoens, P. R. J. Gaffney, G. Szekely and A. G. Livingston, *US Patent* 10239996B2, 2019; (h) M. Cook and A. Livingston, *US Pat.*, 20200122094A1, 2020; (i) A. G. Livingston, P. Marchetti, P. Gaffney and R. Liu, *US Patent* 10913033B2, 2021; (j) A. G. Livingston and M. F. Jimenez Solomon, *US Patent* 11117104B2, 2021; (k) A. G. Livingston, Z. Jiang, R. Dong, J. Xu and S. Li, *WO Patent* 2021205141A1, 2021.
- 148 (a) C. Seifert, *US Patent* 20210079036A1, 2021; (b) C. Seifert, *WO Patent* 2020159837A1, 2020; (c) C. Seifert, *WO Patent* 2019217116A1, 2019; (d) C. Seifert, *WO Patent* 2019231760A1, 2019; (e) C. Seifert and G. Li, *US Patent* 10947267B2, 2021.
- 149 (a) G. Tana, S. Kitada, S. Fujita, Y. Okada, S. Kim and K. Chiba, *Chem. Commun.*, 2010, 46, 8219; (b) Y. Okada,



- H. Suzuki, T. Nakae, S. Fujita, H. Abe, K. Nagano, T. Yamada, N. Ebata, S. Kim and K. Chiba, *J. Org. Chem.*, 2013, **78**, 320; (c) H. Wakamatsu, Y. Okada, M. Sugai, S. R. Hussaini and K. Chiba, *Asian J. Org. Chem.*, 2017, **6**, 1584.
- 150 (a) K. Chiba, M. Sugihara, K. Yoshida, Y. Mikami and S. Kim, *Tetrahedron*, 2009, **65**, 8014; (b) S. Kitada, S. Fujita, Y. Okada, S. Kim and K. Chiba, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 4476; (c) S. Kitada, M. Takahashi, Y. Yamaguchi, Y. Okada and K. Chiba, *Org. Lett.*, 2012, **14**, 5960; (d) Y. Fujita, S. Fujita, Y. Okada and K. Chiba, *Org. Lett.*, 2013, **15**, 1155; (e) S. Kitada, S. Fujita, Y. Okada, S. Kim and K. Chiba, *Tetrahedron*, 2013, **69**, 2555; (f) Y. Okada, S. Hosoya, H. Suzuki and K. Chiba, *Org. Lett.*, 2014, **16**, 6448; (g) E. Matsumoto, Y. Fujita, Y. Okada, E. I. Kauppinen, H. Kamiya and K. Chiba, *J. Pept. Sci.*, 2015, **21**, 691; (h) Y. Okada, H. Wakamatsu, M. Sugai, E. I. Kauppinen and K. Chiba, *Org. Lett.*, 2015, **17**, 4264; (i) Y. Okada, H. Asama, H. Wakamatsu, K. Chiba and H. Kamiya, *Eur. J. Org. Chem.*, 2017, 5961; (j) K. Ogami, Y. Okada and K. Chiba, *Chem. Lett.*, 2018, **47**, 138; (k) S. Yamagami, Y. Okada, Y. Kitano and K. Chiba, *Eur. J. Org. Chem.*, 2021, 31338.
- 151 Y. Okada, R. Takasawa, D. Kubo, N. Iwanaga, S. Fujita, K. Suzuki, H. Suzuki, H. Kamiya and K. Chiba, *Org. Process Res. Dev.*, 2019, **23**, 2576.
- 152 (a) BACHEM and JITSUBO enter into exclusive licensing agreement, <https://www.bachem.com/news/bachem-and-jitsubo-enter-into-exclusive-licensing-agreement/>, (accessed on November 2021); (b) Cost-efficient and green manufacturing of peptides thanks to Molecular Hiving™ technology, <https://www.smi-online.co.uk/pharmaceuticals/webinar/molecular-hiving-technology>, (accessed on November 10th, 2021).
- 153 <https://www.ajibio-pharma.com/cdmo-services/oligo-peptide-synthesis/ajiphase-synthesis/> (accessed on November 10th, 2021).
- 154 D. Takahashi and T. Yamamoto, *Tetrahedron Lett.*, 2012, **53**, 1936.
- 155 D. Takahashi, T. Yano and T. Fukui, *Org. Lett.*, 2012, **14**, 4514.
- 156 D. Takahashi, T. Inomata and T. Fukui, *Angew. Chem.*, 2017, **129**, 7911.
- 157 (a) S. So, L. G. Peeva, E. W. Tate, R. J. Leatherbarrow and A. G. Livingston, *Chem. Commun.*, 2010, **46**, 2808; (b) S. So, L. G. Peeva, E. W. Tate, R. J. Leatherbarrow and A. G. Livingston, *Org. Process Res. Dev.*, 2010, **14**, 1313; (c) V. Castro, C. Noti, W. Chen, M. Cristau, A. Livingston, H. Rodriguez and F. Albericio, *Macromolecules*, 2017, **50**, 1626.
- 158 I. B. Valtcheva, P. Marchetti and A. G. Livingston, *J. Membr. Sci.*, 2015, **493**, 568.
- 159 C. W. Seifert, A. Paniagua, G. A. White, L. Cai and G. Li, *Eur. J. Org. Chem.*, 2016, 1714.
- 160 <https://gappeptides.com/publications/> (accessed on November 10th, 2021).
- 161 (a) H. Li, J. Chao, J. Hasan, G. Tian, Y. Jin, Z. Zhang and C. Qin, *J. Org. Chem.*, 2020, **85**, 6271; (b) H. Li, J. Chao, J. Hasan, G. Tian, Y. Jin, N. Chang and C. Qin, *Org. Lett.*, 2020, **22**, 3323; (c) H. Li, J. Chao, G. Tian, J. Hasan, Y. Jin, Z. Zhang and C. Qin, *Org. Chem. Front.*, 2020, **7**, 689; (d) H. Li, J. Ren, J. Li, Z. Zhang, M. Chang and C. Qin, *Org. Biomol. Chem.*, 2020, **18**, 8433.
- 162 (a) I. F. Eggen, P. B. W. Ten Kortenaar and C. A. G. Haasnoot, *US Patent* 20030018164A1, 2003; (b) <https://sb3000.tech/> (accessed on November 10th, 2021).
- 163 I. F. Eggen and P. B. W. Ten Kortenaar, *US Patent* 6864357B2, 2005.
- 164 I. F. Eggen, F. T. Bakelaar, A. Petersen, P. B. W. Ten Kortenaar, N. H. S. Ankone, H. E. J. M. Bijsterveld, G. H. L. Bours, F. El Bellaj, M. J. Hartsuiker, G. J. Kuiper and E. J. M. Ter Voert, *J. Pept. Sci.*, 2005, **11**, 633.
- 165 I. F. Eggen, F. T. Bakelaar, A. Petersen and P. B. W. Ten Kortenaar, *Org. Process Res. Dev.*, 2005, **9**, 98.
- 166 I. F. Eggen, F. T. Bakelaar, P. B. W. Ten Kortenaar, K. Adermann, W. G. Forssmann and A. Schulz, Rapid Solution-phase Synthesis of a 20-mer Peptide According to the DioRaSSP® Method, *Understanding Biology Using Peptides. America Peptide Symposia*, ed. S. E. Blondelle, Springer, New York, 2005.
- 167 <https://www.aspenapi.com/api-catalogue/> (accessed on November 10th, 2021).
- 168 R. A. Houghton, *Proc. Natl. Acad. Sci. U. S. A.*, 1985, **82**, 5131.
- 169 J. Rantanen, S. Mulvany, W. Lennard, R. G. Petersen, Y. Ermolovich and J. Bukrinski, *Innovative Chemistry for Peptide Manufacturing and Analysis Meeting*, March 2021, oral presentation essentially focused on the DOE of the piperidine deprotection.
- 170 S. Wu, R. Snajdrova, J. C. Moore, K. Baldenius and U. T. Bornscheuer, *Angew. Chem., Int. Ed.*, 2021, **60**, 88.
- 171 (a) A. M. Weeks and J. A. Wells, *Chem. Rev.*, 2020, **120**, 3127; (b) T. Nuijens, A. Toplak, M. Schmidt, A. Ricci and W. Cabri, *Front. Chem.*, 2019, **7**, 829.
- 172 (a) S. K. Mazmanian, G. Liu, H. Ton-That and O. Schneewind, *Science*, 1999, **285**, 760; (b) H. Ton-Taht, G. Liu, S. K. Mazmanian, K. F. Faull and O. Schneewind, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 12424; (c) U. Ilangovan, H. Ton-Tht, J. Iwahara, O. Scheewind and R. T. Clubb, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 6056; (d) H. Ton-That, S. K. Mazmanian, K. F. Faull and O. Schneewind, *J. Biol. Chem.*, 2000, **13**, 9876.
- 173 R. L. Policarpo, H. Kang, X. Liao, A. E. Rabideau, M. D. Simon and B. L. Pentelute, *Angew. Chem., Int. Ed.*, 2014, **53**, 9203.
- 174 B. M. Dorr, H. O. Ham, C. An, E. L. Chaikof and D. R. Liu, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 13343.
- 175 I. Chen, B. M. Dorr and D. R. Liu, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **118**, 11399.
- 176 Z. Zou, D. M. Mate, M. Nöth, F. Jakob and U. Schwaneberg, *Chem. – Eur. J.*, 2020, **26**, 13568.



- 177 G. K. T. Nguyen, S. Wang, Y. Qiu, X. Hemu, Y. Lian and J. P. Tam, *Nat. Chem. Biol.*, 2014, **10**, 732.
- 178 D. J. Craik, N. L. Daly, T. Bond and C. Waine, *J. Mol. Biol.*, 1999, **294**, 1327.
- 179 G. K. T. Nguyen, Y. Cao, W. Wang, C. F. Liu and J. P. Tam, *Angew. Chem., Int. Ed.*, 2015, **54**, 15694.
- 180 X. Hemu, X. Zhang, G. K. T. Nguyen, J. To, A. Serra, S. Loo, S. Kwan Sze, C.-F. Liu and J. P. Tam, *RSC Adv.*, 2021, **11**, 23105.
- 181 A. M. James, J. Haywood, J. Leroux, K. Ignasiak, A. G. Elliott, J. W. Schmidberger, M. F. Fisher, S. G. Nonis, R. Fenske, C. S. Bond and J. S. Mylne, *Plant J.*, 2019, **98**, 988.
- 182 X. Hemu, A. El Sahili, S. Hu, X. Zhang, A. Serra, B. C. Goh, D. A. Darwis, M. W. Chen, S. K. Sze, C. Liu, J. Lescar and J. P. Tam, *ACS Catal.*, 2020, **10**, 8825.
- 183 (a) K. S. Harris, T. Durek, Q. Kaas, A. G. Poth, E. K. Gilding, B. F. Conlan, I. Saska, N. L. Daly, N. L. van der Weerden, D. J. Craik and M. A. Anderson, *Nat. Commun.*, 2015, **6**, 10199; (b) K. S. Harris, R. F. Guarino, R. S. Dissanayake, P. Quimbar, O. C. McCorkelle, S. Poon, Q. Kaas, T. Durek, E. K. Gilding, M. A. Jackson, D. J. Craik, N. L. van der Weerden, R. F. Anders and M. A. Anderson, *Sci. Rep.*, 2019, **9**, 10820.
- 184 M. A. Jackson, E. K. Gilding, T. Shafee, K. S. Harris, Q. Kaas, S. Poon, K. Yap, H. Jia, R. Guarino, L. Y. Chan, T. Durek, M. A. Anderson and D. J. Craik, *Nat. Commun.*, 2018, **9**, 2411.
- 185 X. Hemu, A. El Sahili, S. Hu, K. Wong, Y. Chen, Y. H. Wong, X. Zhang, A. Serra, B. C. Goh, D. A. Darwis, M. W. Chen, S. K. Sze, C.-F. Liu, J. Lescar and J. P. Tam, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 11737.
- 186 (a) R. Yang, Y. H. Wong, G. K. T. Nguyen, J. P. Tam, J. Lescar and B. Wu, *J. Am. Chem. Soc.*, 2017, **139**, 5351; (b) J. Du, K. Yap, L. Y. Chan, F. B. H. Rehm, F. Y. Looi, A. G. Poth, E. K. Gilding, Q. Kaas, T. Durek and D. J. Craik, *Nat. Commun.*, 2020, **11**, 1575.
- 187 X. Hemu, J. To, X. Zhang and J. P. Tam, *J. Org. Chem.*, 2020, **85**, 1504.
- 188 F. B. H. Rehm, T. J. Tyler, J. Xie, K. Yap, T. Durek and D. J. Craik, *ChemBioChem*, 2021, **22**, 2079.
- 189 (a) K. E. Neet and D. E. Koshland, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **56**(5), 1606; (b) L. Polgár and M. L. Beder, *Biochemistry*, 1967, **6**, 610.
- 190 (a) A. C. Braisted, J. K. Judice and J. A. Wells, *Methods Enzymol.*, 1997, **289**, 298; (b) L. Abrahmsen, J. Tom, J. Burnier, K. A. Butcher, A. Kossiakoff and J. A. Wells, *Biochemistry*, 1991, **30**, 4151.
- 191 A. Toplak, T. Nuijens, P. J. L. M. Quaedflieg, B. Wu and D. B. Janssen, *Adv. Synth. Catal.*, 2016, **358**, 2140.
- 192 A. Toplak, E. F. T. de Oliveira, M. Schmidt, H. J. Rozeboom, H. J. Wijma, L. K. M. Meekels, R. de Visser, D. B. Janssen and T. Nuijens, *Comput. Struct. Biotechnol. J.*, 2021, **19**, 1277.
- 193 (a) J. Pawlas, T. Nuijens, J. Persson, T. Svensson, M. Schmidt, A. Toplak, M. Nilsson and J. H. Rasmussen, *Green Chem.*, 2019, **21**, 6451; (b) M. Schmidt and T. Nuijens, Chapter 4 - Chemoenzymatic Synthesis of Linear and Head-to-Tail Cyclic Peptides Using Omniligase-1, *Enzyme-Mediated Ligation Methods*, Humana, New York, 2019, vol. 2012.
- 194 M. Schmidt, A. Toplak, H. J. Rozeboom, H. J. Wijma, P. J. L. M. Quaedflieg, J. H. van Maarseveen, D. B. Janssen and T. Nuijens, *Org. Biomol. Chem.*, 2018, **16**, 609.
- 195 M. Schmidt, A. Toplak, P. J. L. M. Quaedflieg, H. Ippel, G. J. J. Richelle, T. M. Hackeng, J. H. van Maarseveen and T. Nuijens, *Adv. Synth. Catal.*, 2017, **359**, 2050.
- 196 S. Liebscher, M. Schöpfel, T. Aumüller, A. Sharkhuukhen, A. Pech, E. Höss, C. Parthier, G. Jahreis, M. T. Stubbs and F. Bordusa, *Angew. Chem., Int. Ed.*, 2014, **53**, 3024.
- 197 S. Liebscher, S. Mathea, T. Aumüller, A. Pech and F. Bordusa, *ChemBioChem*, 2021, **22**, 1201.
- 198 (a) J.-L. Do and T. Friscic, *ACS Cent. Sci.*, 2017, **3**, 13; (b) S. L. James, C. J. Adams, C. Bolm, D. Braga, P. Collier, T. Friscic, F. Grepioni, K. D. M. Harris, G. Hyett, W. Jones, A. Krebs, J. Mack, L. Maini, A. G. Orpen, I. P. Parkin, W. C. Shearouse, J. W. Steed and D. C. Waddell, *Chem. Soc. Rev.*, 2012, **41**, 413; (c) J. L. Howard, Q. Cao and D. L. Browne, *Chem. Sci.*, 2018, **9**, 3080.
- 199 L. Takacs, *Chem. Soc. Rev.*, 2013, **42**, 7649.
- 200 G. A. Bowmaker, *Chem. Commun.*, 2013, **49**, 334.
- 201 A. Dicks and A. Hent, *Green Chem. Metrics*, 2015, 45.
- 202 J. G. Hernandez and C. Bolm, *J. Org. Chem.*, 2017, **82**, 4007.
- 203 D. Tan, L. Loots and T. Friscic, *Chem. Commun.*, 2016, **52**, 7760.
- 204 V. Declerck, P. Nun, J. Martinez and F. Lamaty, *Angew. Chem., Int. Ed.*, 2009, **48**, 9318.
- 205 J. Bonnamour, T.-X. Métro, J. Martinez and F. Lamaty, *Green Chem.*, 2013, **15**, 1116.
- 206 J. G. Herneandez and E. Juaristi, *J. Org. Chem.*, 2010, **75**, 7107.
- 207 (a) V. Strukil, B. Bartolec, T. Portada, I. Dilovic, I. Halasz and D. Margetic, *Chem. Commun.*, 2012, **48**, 12100; (b) C. Duangkamol, S. Jaita, S. Wangngae, W. Phakhodee and M. Pattarawarapan, *RSC Adv.*, 2015, **5**, 52624; (c) J. M. Landeros and E. Juaristi, *Eur. J. Org. Chem.*, 2017, 687; (d) Y. Yeboue, M. Jean, G. Subra, J. Martinez, F. Lamaty and T.-X. Métro, *Org. Lett.*, 2021, **23**, 631.
- 208 V. Porte, M. Thioly, T. Pigoux, T.-X. Métro, J. Martinez and F. Lamaty, *Eur. J. Org. Chem.*, 2016, 3505.
- 209 O. Maurin, P. Verdié, G. Subra, F. Lamaty, J. Martinez and T.-X. Métro, *Beilstein J. Org. Chem.*, 2017, **13**, 208.
- 210 L. Gonnet, T. Tintillier, N. Venturini, L. Konnert, J.-F. Hernandez, F. Lamaty, G. Laconde, J. Martinez and E. Colacino, *ACS Sustainable Chem. Eng.*, 2017, **5**, 2936.
- 211 M. Anselmi, P. Stavole, E. Boanini, A. Bigi, E. Juaristi and L. Gentilucci, *Future Med. Chem.*, 2020, **12**, 479.
- 212 K. Yazawa and K. Numata, *Molecules*, 2014, **19**, 13755.
- 213 J. G. Hernández, K. J. Ardila-Fierro, D. Crawford, S. L. James and C. Bolm, *Green Chem.*, 2017, **19**, 2620.
- 214 M. O. Frederick, R. A. Boyse, T. M. Braden, J. R. Calvin, B. M. Campbell, S. M. Changi, S. R. Coffin, C. Condon, O. Gowran, J. McClary Groh, S. R. Groskreutz,



- Z. D. Harms, A. A. Humenik, N. J. Kallman, N. D. Klitzing, M. E. Kopach, J. K. Kretsinger, G. R. Lambertus, J. T. Lampert, L. M. Maguire, H. A. Moynihan, N. S. Mullane, J. D. Murphy, M. E. O'Mahony, R. N. Richey, K. D. Seibert, R. D. Spencer, M. A. Strege, N. Tandogan, F. L. Torres Torres, S. V. Tsukanov and H. Xia, *Org. Process Res. Dev.*, 2021, **25**, 1628.
- 215 C. de Luca, G. Lievore, D. Bozza, A. Buratti, A. Cavazzini, A. Ricci, M. Macis, W. Cabri, S. Felletti and M. Catani, *Molecules*, 2021, **26**, 1.
- 216 W. Zhang and B. W. Cue, *Green Techniques for Organic Synthesis and Medicinal Chemistry*, Wiley-VCH, 2012.
- 217 (a) H. Schmidt-Traub, *Preparative chromatography of fine chemicals and pharmaceutical agents*, Wiley-VCH, 2005; (b) P. J. Dunn, A. S. Wells and M. T. Williams, *Green Chemistry in the Pharmaceutical Industry*, Wiley-VCH, 2010; (c) C. J. Welch, N. Wu, M. Biba, R. Hartman, T. Brkovic, X. Gong, R. Helmy, W. Schafer, J. Cuff, Z. Pirzada and L. Zhou, *Trends Anal. Chem.*, 2010, **29**, 667; (d) M. I. Shaik and N. M. Sarbon, *Food Rev. Int.*, 2020, 1–21; (e) C. M. Grill and L. Miller, *J. Chromatogr. A*, 1998, **827**, 359.
- 218 C. de Luca, S. Felletti, G. Lievore, A. Buratti, S. Vogg, M. Morbidelli, A. Cavazzini, M. Catani, M. Macis, A. Ricci and W. Cabri, *J. Chromatogr. A*, 2020, **1625**, 461304.
- 219 Y. Shen, B. Chen and T. A. van Beek, *Green Chem.*, 2015, **17**, 4073.
- 220 A. Kremser and C. A. White, *Chem. Today*, 2019, **37**, 12.
- 221 B. Vanholme, T. Desmet, F. Ronsse, K. Rabaey, F. van Breusegem, M. de Mey, W. Soetaert and W. Boerjan, *Front. Plant Sci.*, 2013, **4**, 174.
- 222 D. Guo, C. T. Mant and R. S. Hodges, *J. Chromatogr. A*, 1987, **386**, 205–222.
- 223 K. R. Solomon, G. J. M. Velders, S. R. Wilson, S. Madronich, J. Longstreth, P. J. Aucamp and J. F. Bornman, *J. Toxicol. Environ. Health*, 2016, **19**, 289.
- 224 J. Cornish, K. E. Callon, C. Q.-X. Lin, C. L. Xiao, T. B. Mulvey, G. J. S. Cooper and I. R. Reid, *Am. J. Physiol.*, 1999, **277**, E779.
- 225 K. Sikora, M. Jaśkiewicz, D. Neubauer, D. Migoń and W. Kamysz, *Pharmaceuticals*, 2020, **13**, 442.
- 226 (a) J. E. Rivier, *J. Liq. Chromatogr.*, 1978, **1**, 1; (b) C. T. Mant, Y. Chen, Z. Yan, T. V. Popa, J. M. Kovacs, J. B. Mills, B. P. Tripet and R. S. Hodges, *Methods Mol. Biol.*, 2007, **386**, 3.
- 227 O. Reimann, O. Seitz, D. Sarma and R. Zitterbart, *J. Pept. Sci.*, 2019, **25**, e3136.
- 228 The only commercial c&r method has been reported by D. W. Anderson, G. J. Cotton, M. H. Alastair, W. A. Paul and W. Ian, US20130211047, 2011.
- 229 T. Müller-Späth, G. Ströhlein, O. Lyngberg and D. Maclean, *Chem. Today*, 2013, **31**, 56.
- 230 S. Vogg, N. Ulmer, J. Souquet, H. Broly and M. Morbidelli, *Biotechnol. J.*, 2019, **14**, 1800732.
- 231 (a) C. de Luca, S. Felletti, D. Bozza, G. Lievore, M. Morbidelli, M. Sponchioni, A. Cavazzini, M. Catani, W. Cabri, M. Macis and A. Ricci, *Ind. Eng. Chem. Res.*, 2021, **60**, 6826; (b) D. Gétaz, G. Stroehlein, A. Butté and M. Morbidelli, *J. Chromatogr. A*, 2013, **1284**, 69; (c) F. Steinebach, T. Müller-Späth and M. Morbidelli, *Biotechnol. J.*, 2016, **11**, 1126.
- 232 (a) C. M. Grill, *J. Chromatogr. A*, 1998, **796**, 101; (b) C. Grill, L. Miller and T. Yan, *J. Chromatogr. A*, 2004, **1026**, 101; (c) I. Quiñones, C. M. Grill, L. Miller and G. Guiochon, *J. Chromatogr. A*, 2000, **867**, 1; (d) J. Dingenen and J. N. Kinkel, *J. Chromatogr. A*, 1994, **666**, 627.
- 233 (a) D. W. Guest, *J. Chromatogr. A*, 1997, **760**, 159; (b) D. Broughton and C. Gerhold, *Patent US2985589A*, 1961.
- 234 Y. Xie, S. Mun, J. Kim and N.-H. L. Wang, *Biotechnol. Prog.*, 2002, **18**, 1332.
- 235 D. Pfister, L. Nicoud and M. Morbidelli, *Continuous Biopharmaceutical Processes: Chromatography, Bioconjugation, and Protein Stability*, Cambridge University Press, 2018.
- 236 (a) E. R. Francotte and P. Richert, *J. Chromatogr. A*, 1997, **769**, 101; (b) V. P. Chernev, A. v. Wouwer and A. Kienle, *Processes*, 2016, **8**, 1316.
- 237 S. Imamoglu, *Adv. Biochem. Eng./Biotechnol.*, 2002, **76**, 211.
- 238 D. Pfister, L. Nicoud and M. Morbidelli, *Continuous Biopharmaceutical Processes: Chromatography, Bioconjugation, and Protein Stability*, Cambridge University Press, 2018. DOI: 10.1017/9781108332897.
- 239 (a) C. de Luca, S. Felletti, M. Macis, W. Cabri, G. Lievore, T. Chenet, L. Pasti, M. Morbidelli, A. Cavazzini, M. Catani and A. Ricci, *J. Chromatogr. A*, 2020, **1616**, 460789; (b) N. Marchetti, F. Dondi, A. Felinger, R. Guerrini, S. Salvadori and A. Cavazzini, *J. Chromatogr. A*, 2005, **1079**, 162; (c) L. Aumann and M. Morbidelli, *Biotechnol. Bioeng.*, 2007, **98**, 1043.
- 240 A. L. Zydney, *Biotechnol. Bioeng.*, 2016, **113**, 465.
- 241 Y. Xie, S. Mun, C. Y. Chin and N.-H. L. Wang, *Front. Biomed. Eng.*, 2003, 507.
- 242 (a) L. Aumann and M. Morbidelli, *Patent EP1877769B1*, 2006; (b) L. Aumann and M. Morbidelli, *Biotechnol. Bioeng.*, 2008, **99**, 728; (c) G. Ströhlein, L. Aumann, M. Mazzotti and M. Morbidelli, *J. Chromatogr. A*, 2006, **1126**, 338.
- 243 (a) T. Müller-Späth, L. Aumann, L. Melter, G. Ströhlein and M. Morbidelli, *Biotechnol. Bioeng.*, 2008, **100**, 1166; (b) B. Schenkel, L. Aumann, G. Stroehlein and M. Morbidelli, *BioPharm Int.*, 2009, **22**, 46; (c) C. de Luca, S. Felletti, G. Lievore, T. Chenet, M. Morbidelli, M. Sponchioni, A. Cavazzini and M. Catani, *TrAC, Trends Anal. Chem.*, 2020, **132**, 116051; (d) G. Stroehlein, L. Aumann, T. Müller-Späth, A. Tarafder and M. Morbidelli, *BioPharm Int.*, 2007, **22**, 42; (e) F. Steinebach, M. Krättli, G. Storti and M. Morbidelli, *Ind. Eng. Chem. Res.*, 2017, **56**, 13482; (f) G. Subramanian, *Continuous processing in pharmaceutical manufacturing*, Wiley-VHC, 2005.



- 244 L. Aumann, G. Stroehlein and M. Morbidelli, *Biotechnol. Bioeng.*, 2007, **98**, 1029.
- 245 F. Steinebach, N. Ulmer, L. Decker, L. Aumann and M. Morbidelli, *J. Chromatogr. A*, 2017, **1492**, 19.
- 246 M. Catani, C. de Luca, J. Medeiros Garcia Alcântara, N. Manfredini, D. Perrone, E. Marchesi, R. Weldon, T. Müller-Späth, A. Cavazzini, M. Morbidelli and M. Sponchioni, *Biotechnol. J.*, 2020, **15**, 1900226.
- 247 A. Tarafder, G. Ströhlein, L. Aumann and M. Morbidelli, *J. Chromatogr. A*, 2008, **1183**, 87.
- 248 T. Müller-Späth and M. Bavand, *Pharm. Eng.*, 2019, **39**, 68.
- 249 <https://www.bachem.com/event/continuous-chromatography-of-peptides/>.
- 250 (a) G. Guiochon and A. Tarafder, *J. Chromatogr. A*, 2011, **1218**, 1037; (b) C. West, *Anal. Bioanal. Chem.*, 2018, **410**, 6441.
- 251 (a) K. Govender, T. Naicker, S. Baijnath, H. G. Kruger and T. Govender, *J. Pharm. Biomed. Anal.*, 2020, **190**, 113539; (b) M. Saito, *J. Biosci. Bioeng.*, 2015, **115**, 590.
- 252 M. Perrut, *Patent* US4478720A, 1983.
- 253 S. Felletti, O. H. Ismail, C. de Luca, V. Costa, F. Gasparrini, L. Pasti, N. Marchetti, A. Cavazzini and M. Catani, *Chromatographia*, 2019, **82**, 65.
- 254 <https://www.americanpharmaceuticalreview.com/Featured-Articles/185891-A-Perspective-on-the-Application-of-Preparative-Supercritical-Fluid-Chromatography-Using-Achiral-Stationary-Phases-in-Pharmaceutical-Drug-Discovery-and-Development/> (accessed November 4, 2021).
- 255 (a) O. H. Ismail, S. Felletti, C. de Luca, L. Pasti, N. Marchetti, V. Costa, F. Gasparrini, A. Cavazzini and M. Catani, *Molecules*, 2018, **23**, 2709; (b) C. West, *TrAC, Trends Anal. Chem.*, 2019, **120**, 115648; (c) J. Molineau, M. Hideux and C. West, *J. Pharm. Biomed. Anal.*, 2021, **193**, 113736.
- 256 (a) K. B. Thurbide and J. Zhang, *Anal. Bioanal. Chem.*, 2005, **382**, 1227; (b) J. Zhang and K. B. Thurbide, *J. Chromatogr. A*, 2006, **1101**, 286; (c) J. Zheng, J. D. Pinkston, P. H. Zoutendam and L. T. Taylor, *Anal. Chem.*, 2006, **78**, 1535; (d) Y. Shao, C. Wang, A. Apedo, O. Mcconnell, Y. Shao, C. Wang, A. Apedo and O. Mcconnell, *J. Anal. Sci., Methods Instrum.*, 2016, **6**, 23; (e) M. Enmark, E. Glenne, M. Leško, A. Langborg Weinmann, T. Leek, K. Kaczmariski, M. Klarqvist, J. Samuelsson and T. Fornstedt, *J. Chromatogr. A*, 2018, **1568**, 177; (f) V. Spelling and M. Stefansson, *J. Chromatogr. A*, 2020, **1633**, 461646.
- 257 N. M. Schiavone, R. Bennett, M. B. Hicks, G. F. Pirrone, E. L. Regalado, I. Mangion and A. A. Makarov, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2019, **1110–1111**, 94.
- 258 M. Ventura, *J. Pharm. Biomed. Anal.*, 2020, **185**, 113227.
- 259 V. Kasche, R. Schlothauer and G. Brunner, *Biotechnol. Lett.*, 1988, **10**, 569.
- 260 J. Zagrobelny and F. V. Bright, *Biotechnol. Prog.*, 1992, **8**, 421.
- 261 M. Ventura, *J. Pharm. Biomed. Anal.*, 2020, **185**, 113227.

